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Summary  
 
Influenza is a highly contagious respiratory disease that poses significant threat to human 
health worldwide and exacts considerable economic burden. Lung pathology observed during 
influenza infection is due to direct damage resulting from viral replication and bystander 
damage caused by overly exuberant antiviral immune mechanisms. Virus-induced pro-
inflammatory interleukin-1β (IL-1β) and IL-18 are processed via caspase-1 in the 
inflammasome.  
This study investigated the role of caspase-1 in influenza virus-associated pulmonary 
pathology and inflammation using a mouse model of influenza pneumonitis. Caspase-1-
deficient (Casp1-/-) and wild-type C57BL/6 mice were infected with 500 plaque-forming units 
of influenza A/Puerto Rico/8/34 (H1N1) virus. Increased virus titres were observed in the lungs 
of Casp1-/- mice at day 7 post-infection compared to wild-type animals, suggesting that Casp1-
/- mice are more susceptible to infection. Histopathologic analysis, based on lung injury scores, 
of Casp1-/- mice at day 7 post-infection exhibited increased intra-alveolar fibrin deposition, 
implying augmented alveolar damage. Casp1-/- mice also displayed increased cellular 
recruitment in the lungs. The pulmonary infiltration was predominantly neutrophilic in the 
bronchoalveolar lavage fluid (BALF) of Casp1-/- mice at days 3 and 6 post-infection. Lower 
levels of IL-1β protein were detected in the lungs of Casp1-/- mice, but higher levels of IFN-γ, 
MCP-1, MIP-1α, MIP-1β, RANTES were found in the lung airways that correlated with the 
increased inflammation. A higher average number of TUNEL-positive lung cells per field and 
elevated protein concentration were observed in BALF of Casp1-/- mice, indicating a greater 
degree of lung damage in the caspase-1-deficient mice.  
Interestingly, 2 of the 10 infected Casp1-/- mice exhibited brain inflammation that was absent 
in wild-type counterparts. Up-regulation of caspase-1 expression by RT-PCR and Western blot 
 x  
analyses was also observed in infected wild-type mice and in infected RAW264.7 murine 
macrophages. Transcriptomic analysis of infected lungs revealed that caspase-4 gene 
expression increased to a lower extent in infected Casp1-/- mice than the wild-type group. The 
gene expression microarray also revealed that genes differentially expressed in the infected 
Casp1-/- mice suggest a greater severity of influenza pathogenesis in the lungs of these mice.  
This study provided a thorough histopathological analysis of the lung with quantitative scoring 
as well as analysis of other organs, namely the brain and heart. Cell death assays were 
performed on the lung section and BALF cells which substantiated the increased lung damage 
observed in Casp1-/- mice. The microarray analysis unveiled genes with differential expression 
which may influence the outcome of influenza A pathogenesis in caspase-1-deficiency.  
Our study suggests a protective role of caspase-1 in the regulation of inflammatory host 
response in combating influenza infection and reveals the molecular pathways that underpin 
its functional mechanisms.  
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Influenza, commonly known as the flu, is a highly contagious acute respiratory disease of 
global significance as it presents with considerable morbidity and mortality. Influenza affects 
people of all ages and all individuals are susceptible to repeated infections. In yearly 
epidemics, the influenza virus causes 3 to 5 million cases of severe illness and 250,000 to 
500,000 deaths worldwide (WHO 2010). Influenza is of public health concern because 
influenza epidemics evolve quickly causing widespread morbidity and severe complications 
such as viral pneumonia. The vulnerability of the world’s population to novel influenza 
subtypes can give rise to pandemics such as the swine-origin influenza virus A (H1N1) which 
emerged in April 2009. Pandemics spread fear and inflict substantial economic burden in 
health care costs of prevention and treatment, hospitalizations and losses in labour 
productivity.  
Influenza is one of the most common causative agents of human respiratory and viral 
pneumonitis can lead to post-infection sequelae such as acute lung injury (ALI) and acute 
respiratory distress syndrome (ARDS) (Yokoyama, Tsushima et al. 2010). Lung pathology 
observed during influenza infection is due to direct damage resulting from viral replication 
and bystander damage caused by overly exuberant antiviral immune mechanisms. Caspase-1 
plays a key role in innate immunity and host resistance to pathogens by processing pro-forms 
of members of the interleukin (IL)-1 family such as IL-1β and IL-18 (Dinarello 2009). These 
cytokines are potent mediators of inflammation that stimulate fever, recruitment and 
activation of immune cells which are features of influenza pneumonitis.  
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In this study, we investigate the role of caspase-1 pulmonary inflammation and cell death and 
its contribution to immunopathology of influenza infection of the lung in an in vivo murine 
model. A detailed understanding of the mechanisms that undermine pathogenicity and the 
host-virus interactions that influence the outcome of the illness are critical for the control of 
influenza. 
 
1.2 Influenza viruses 
 
The influenza virus belongs to the Orthomyxoviridae family of negative single-stranded, 
envelope ribonucleic acid (RNA) viruses with a segmented genome. There are 3 genera of 
influenza viruses, namely influenza A, B and C, and they are distinguished based on antigenic 
differences in the matrix (M) and nucleocaspid (NP) proteins. All of these viruses can infect 
humans but of the 3, influenza A virus is of the greatest concern as it has been responsible for 
all influenza pandemics and has claimed the lives of millions each time (Zambon 1999). 
Influenza A viruses are further subdivided into different subtypes based on the antigenic 
variation of the hemagglutinin (HA) and neuraminidase (NA) surface glycoproteins.  
Influenza A are spherical or filamentous in shape, with the spherical forms ranging from 80 to 
120 nm in diameter and the filamentous forms about 300 nm in length. Glycoprotein spikes of 
HA and NA are embedded in and projects from a host cell-derived lipid membrane during viral 
budding (Figure 1-1). The HA homotrimer is responsible for binding virus to sialic acid–
containing cell-surface receptors and for membrane fusion during virus entry into host cells. It 
is also the principal target antigen for neutralizing antibodies. The NA homotetramer 
hydrolyzes sialic acid groups from glycoproteins and to release the viral progeny from infected 
cells. The M2 protein also anchored in the envelope, functions as an ion channel between the 
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interior of virus and its environment and maintains a low pH during virion uncoating during 
initial stages of infection (Pinto, Holsinger et al. 1992; Wang, Lamb et al. 1994). 
Beneath the envelope and its 3 integral membrane proteins HA, NA, and M2, there is the 
matrix protein M1 which encloses the virion core. M1 interacts with the virus genome and 
nuclear export factor and aids viral assembly (Ruigrok, Calder et al. 1989). Inside the virion, 
the 8 viral RNA segments are bound to nucleoprotein (NP) and virally encoded RNA 
polymerases to form the ribonucleoprotein (RNP) complex. The heterotrimeric RNA-
dependent RNA polymerase is composed of 2 "polymerase basic" (PB1 and PB2) and 1 
"polymerase acidic" (PA) subunits. These are responsible for transcribing messenger RNAs 
(mRNAs), synthesizing positive-sense complementary template RNAs (cRNAs), and for 
transcribing the cRNAs into the gene segments (vRNAs) that are incorporated into progeny 
virions (Lamb and Choppin 1983).  
 
 
Figure 1-1: Diagramatic representation of an influenza virion. 
(Source: www.influenzareport.com/ir/images/virus.jpg; accessed September 2008) 
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1.3 Epidemiology of influenza A viruses  
 
Influenza viruses are among the most common causative agents of human respiratory 
infections (Wright, Neumann et al. 2007). Influenza viruses can be transmitted through large 
droplet spread, direct or indirect contact with respiratory secretions and through airborne 
spread. A cough or sneeze of an infected person can generate droplets of various sizes that 
mediate transmission. The incubation period is usually 2 days and an infected person is 
contagious 1 day before the onset of any symptoms. 
Influenza A was the causative agent of all 4 major pandemics which occurred during the 20th 
century, namely, the 1918 H1N1 “Spanish Flu”, the 1957 H2N2 Asian Flu, the 1968 H3N2 Hong 
Kong Flu and the most recent Mexico swine-origin influenza A/H1N1 (2009). Of these 4, the 
infamous 1918 “Spanish Flu” pandemic was one of the most destructive events in medical 
history and it killed 20 to 40 million people globally (Taubenberger, Reid et al. 2000).  
The segmented genome of influenza A viruses enables antigenic shift, in which a virus strain 
acquires the HA and/or NA segment from a virus of a different subtype. This segment 
reassortment may occur in cells infected with different human and animal viruses. Pandemic 
influenza arises when antigenic shift generates a virus to which the human population are 
susceptible and has no pre-existing immunity against (Ahmed, Oldstone et al. 2007), as seen in 
the latest pandemic of the swine-origin influenza A/H1N1 (2009) strain. It is a triple 
reassortant with 5 genome segments (HA, NP, NA, M and NS2) of porcine influenza, 2 from 
avian (PA and PB2) and the PB2 gene segment from human influenza (Garten, Davis et al. 
2009; Shinde, Bridges et al. 2009). The influenza virus mutates frequently to escape host's 
neutralizing antibodies. Antigenic drift occurs when amino acid changes at the antigenic sites 
of HA accumulate and result in a virus strain that is no longer neutralized by host antibodies. 
The host thus becomes susceptible again to infection. 
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In recent years, the avian influenza A subtype H5N1 was directly transmitted from birds to 
humans in Hong Kong in 1997 and 2003. Outbreaks have also been reported in China, 
Cambodia, Vietnam, Thailand and Indonesia. The avian H5N1 virus resulted in a mortality rate 
of more than 60% (WHO 2010) and with each case of human infection, the virus has yet 
another chance to acquire the ability to transmit efficiently between humans, thus increasing 
the likelihood of a pandemic. 
 
1.4 Clinical manifestations and pathology of influenza infection  
 
Influenza viruses can infect people of all age groups. In addition, infants, the aged and people 
with underlying chronic illnesses such as pulmonary or cardiac diseases are at high-risk of 
complications such as haemorrhagic bronchitis, primary viral or secondary bacterial 
pneumonia, and even death (Taubenberger and Morens 2008). Patients tend to manifest a 
sudden onset, high fever and chills, myalgia, arthralgia, malaise and a dry, non-productive 
cough and diarrhorea. Physical signs include the appearance of being unwell, hot and moist 
skin, flushed face, injected eyes, hyperaemic mucous membranes, and a clear nasal discharge 
(Cox and Subbarao 1999). Acute symptoms and fever may last for 7 to 10 days.  
Acute infections of influenza viruses lead to acute illness with destruction and desquamation 
of the pseudostratified columnar epithelium of the trachea and bronchi. In the submucosal 
spaces of the trachea and bronchi, there is significant edema and congestion, with edematous 
and swollen surfaces. In the bronchiole-alveolar junctions, there is massive necrotic cell death 
of the epithelial cells, sometimes accompanied by formation of hyaline membranes. The 
interstitium may display congestion and inflammatory infiltrates such as neutrophils in the 
bronchiolar lumen (Taubenberger and Morens 2008). There are also prominent diffused 
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alveolar damage and edema and fibrin exudates inside the alveoli, leading to possible Acute 
Respiratory Distress Syndrome (ARDS) where infected subjects face difficulty in breathing due 
to the destruction of the alveolar architecture and highly inefficient or complete loss of 
gaseous exchange at the air-fluid interface of the alveoli (Takiyama, Wang et al. 2010). 
In human infections of H5N1, a high mortality rate of 60% occurs. Patients that do not 
succumb to the viral infection experience long-term problems due to the damage sustained by 
the lung during the course of infection. This damage is caused by pulmonary fibrosis of the 
lungs, causing patients to experience similar symptoms as emphysema, with pronounced 
difficulty in breathing. Pulmonary fibrosis is characterized by intense interstitial and intra-
alveolar fibrosis, with thickening of alveolar walls, collapsed alveoli and multifocal fibrosis in 
the lungs. There is also increased deposition of collagen in the lungs of fibrotic lungs of 
subjects infected with highly virulent influenza strains. 
 
1.5 Innate immunity in the lungs in response to influenza  
 
1.5.1 Pattern-recognition receptors and innate recognition of viral infection 
 
The innate immune system acts as a first line of defense against microorganisms and is 
characterized by its ability to recognize a wide range of pathogens including bacteria, fungi 
and viruses through a relatively small number of germ-line encoded receptors termed as 
pattern-recognition receptors (PRRs) (Medzhitov and Janeway 2002) which target pathogen-
associated molecular patterns (PAMPs). PAMPs are unique to microbes (and are not produced 
by the host), and common among microorganisms within the same class (Medzhitov and 
Janeway 1997).  
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In an influenza infection, viruses first target the epithelial cells along the respiratory mucosa. 
The presence of invading viruses is detected through pattern-recognition PRRs in epithelial 
cells, alveolar macrophages and dendritic cells. The recognition of PAMPs by PRRs initiates 
signalling cascades that lead to the production and release of inflammatory cytokines and 
chemokines, which in turn trigger the innate immune system to establish a localized antiviral 
state. Chemokines recruit circulating leukocytes to the site of infection. The inflammatory 
response stimulates dendritic cells (DC) maturation and trafficking required for the induction 
of adaptive immune responses.  
PAMPs present generated by the influenza A virus during infection are recognized by 3 major 
classes of pattern-recognition receptors (PRRs), namely, the Toll-like receptors (TLRs), retinoic 
acid inducible gene-I (RIG-I)-like receptors (RLRs), and the nucleotide-binding domain-leucine-
rich repeat-containing molecules (NLRs). TLRs are transmembrane proteins with an 
extramembranous domain comprising leucine-rich repeats involved in ligand recognition 
either in the extracellular environment or within endosomes and the cytoplasmic domain 
involved in signal transduction. TLR-7 interacts with influenza ssRNA which is exposed after 
virus capsid degradation in the acidified endosomes (Diebold, Kaisho et al. 2004; Lund, 
Alexopoulou et al. 2004). RLRs are intracellular RNA helicases include the retinoic acid-
inducible gene I (RIG-I) which sense single-stranded viral RNA containing 5’triphosphate, 
which is exposed after viral fusion and replication (Hornung, Ellegast et al. 2006). Detection of 
influenza A virus by TLRs or RLRs lead to the transcription of interferon (IFN)-inducible genes 
and nuclear factor-κB (NF-κB) activation, and induce anti-viral states or viral resistance in 
neighbouring uninfected cells. (Wang, Kurt-Jones et al. 2007). 
More recently, studies have discovered that cytosolic complexes termed as the 
inflammasomes participate in influenza viral recognition and host immunity (Allen, Scull et al. 
2009; Ichinohe, Lee et al. 2009; Thomas, Dash et al. 2009). The inflammasomes are 
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multiprotein platform for the activation of caspase-1, which in turn cleaves immature forms of 
cytokines such as pro-interleukin (IL)-1β and pro-IL-18, resulting in their secretion into the 
extracellular space (Dinarello 2009). The PRRs contained in the inflammasomes are the NLRs, 
which are comprised of a central nucleotide-binding oligomerization domain (NOD), which 
undergoes self-oligomerization during activation, with a carboxy terminus leucine-rich repeat 
(LRR) that detects PAMPs. At the amino terminus, NLRs have a variable N-terminal protein-
protein interaction domain. One of the best characterized NLRs in viral recognition is the 
NLRP3 (NALP3 or Cryopyrin). NLRP3 recruits the adaptor apoptosis-associated speck-like 
protein containing a caspase recruitment domain (ASC), also known as PYCARD, which 
consists of an N-terminal PYD domain and a C-terminal caspase activation and recruitment 
domain (CARD) that is necessary for the binding of caspase-1 to the inflammasome (Martinon 
and Tschopp 2007). 
 
1.5.2 Early inflammatory response 
 
The pleiotropic antiviral cytokines of the type I interferon family are among the first cytokines 
produced, of which IFN-α and IFN-β are most commonly associated with early antiviral 
responses in the lung. Type I IFNs produced upon infection form a feedback loop by signalling 
through the IFN-α/β receptor and act together with PRR signalling to promote sustained 
production of pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 from lung-resident 
innate immune cells (Pirhonen, Sareneva et al. 1999; Chan, Cheung et al. 2005). These pro-
inflammatory cytokines also prompt alveolar macrophages, DCs and epithelial cells to trigger a 
programme of chemokine production following virus infection. Epithelial cells and alveolar 
macrophages, in particular chemokines capable of recruiting monocytes and memory T cells, 
also contribute to early chemokine production following infection and/or inflammation 
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(Herold, von Wulffen et al. 2006; Wareing, Lyon et al. 2007). During a primary influenza virus 
infection, the innate immune cells recruited to the lung are predominantly neutrophils and 
natural killer cells. Upon influenza virus infection, neutrophil effector systems are mobilized 
and the virus or virus-infected cells are engulfed and phagocytosed to form a lysosome within 
the neutrophil (Witko-Sarsat, Rieu et al. 2000). This engulfment activates the neutrophil and it 
undergoes respiratory burst, which involves the rapid increase in oxygen consumption to 
generate reactive oxygen species. The neutrophils also release the contents from their 
cytosolic primary and secondary granules into the phagolysosome, creating a highly toxic 
microenvironment which kills the virus or infected host cells. These short-lived leukocytes 
eventually undergo apoptosis and are engulfed by macrophages, in which their contents are 
degraded (Appelberg 2007). 
 
1.6 Inflammasome and NLR signalling 
 
NLRs that participate in caspase-1 activation include NLRP1, NLRP3, and NLRC4. An example of 
the steps of inflammasome activation is shown on Figure 1-2. Caspase-1 activation is required 
for the cleavage of pro-IL-1β and pro-IL-18 into their mature, biologically active forms. 
Adaptor apoptosis-associated speck-like protein containing a caspase recruitment domain 
(ASC) is recruited to NLRs through homophilic pyrin domain (PYD)-PYD interactions and via its 
CARD domain. ASC, in turn, interacts with caspase-1. These protein-protein interactions 
promote oligomerization and recruitment of effector proteins for the auto-catalysis and 
activation of caspase-1 (Martinon, Burns et al. 2002; Masumoto, Dowds et al. 2003). This 
caspase-1-dependent pathway is defined by the assembly of large macromolecular complexes 
through CARD-CARD and PYD-PYD protein-protein interactions into a scaffold for pro-caspase-
1 recruitment and activation. This molecular platform has been termed the inflammasome 
 11  
(Martinon, Burns et al. 2002) as an analogy to the apoptosome, an activator of caspase-9 
during apoptosis (Pop, Timmer et al. 2006). 
 
Figure 1-2: The activation of the NALP3 inflammasome induced by IL-1β.  
Primary blood monocytes or tissue macrophages are activated by IL-1β (step 1). The IL-1 receptor 
complex heterodimer leads to the association of the Toll IL-1 receptor (TIR) domains (red) and the 
recruitment of MyD88. IL-1β mRNA is transcribed (step 2) and translation into the IL-1β precursor 
occurs in the cytosol (step 3). The activated monocyte/macrophage releases ATP into the extracellular 
space. Upon activation of the P2X7 receptor by ATP (step 4), there is a rapid efflux of potassium from 
the cell (step 5a) resulting in a fall in intracellular levels of potassium (step 5b). The fall in intracellular 
potassium levels triggers the assembly of the components of the NALP3 inflammasome (step 6). Given 
that NALP3 (cryopyrin) does not contain a caspase-activating recruiting domain (CARD), the adaptor 
protein termed apoptosis-associated speck-like protein containing a C-terminal CARD (ASC) is required 
together with CARDINAL for oligomerization. The assembled components of the inflammasome initiate 
the processing of procaspase-1, resulting in the formation of the active caspase-1. Active caspase-1 
processes the IL-1β precursor (step 7) in the cytosol results in the generation of the mature IL-1β. An 
influx of calcium into the cell (step 8) with an increase in intracellular calcium levels provides a 
mechanism by which mature IL-1β is secreted (step 9). (Adapted from (Dinarello 2009)) 
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1.7 Caspases  
 
Caspases are an evolutionarily conserved family of cysteine-dependent aspartate-specific 
proteases and were first implicated in programmed cell death in genetic studies of the 
nematode worm Caenorhabditis elegans. The product of the ced-3 gene was found to be 
required for all developmental programmed cell deaths in the worm. In 1993, Yuan et al. 
described that CED-3 showed homology with a human protease, interleukin-1β-converting 
enzyme (ICE) (now termed as caspase-1) (Yuan, Shaham et al. 1993). Originally, caspase-1 was 
identified as a protease that proteolytically activates the pro-forms of pro-inflammatory 
cytokines such as IL-1β and IL-18 in monocytes and macrophages (Thornberry, Bull et al. 
1992). Subsequent studies established that caspase-1 does not play a central role in 
mammalian apoptosis. Nonetheless, the discovery of the homology between CED-3 and ICE 
led to the identification of a large family of mammalian CED-3/ICE-like proteases (now termed 
as caspases), which initiate or execute cellular pathways which lead to inflammation or cell 
death. 
Caspases share similarities in amino acid sequence, structure and substrate specificity. 
Caspases are expressed as single-chain, inactive pro-enzymes (zymogens) which are composed 
of three domains: an N-terminal pro-peptide, a large subunit and a small subunit. Caspases 
are cysteine proteases that exhibit specificity for aspartic acid (Asp) and cleave their 
substrates after tetrapeptide motifs that contain Asp in the P1 position (Cohen 1997; 
Earnshaw, Martins et al. 1999). They are regulated by this proteolytic cleavage into active 
forms.  
Mammalian CED-3 homologues (caspase-3, caspase-6 and caspase-7) are effectors of 
apoptosis. Caspase-2, caspase-8, caspase-9 and caspase-10, function upstream of the effector 
caspases in apoptosis and are known as initiator caspases. A phylogenetically distinct group of 
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caspases (caspase-1, caspase-4, caspase-5, caspase-11 and caspase-12) activates crucial 
mediators of innate immunity and inflammation through the proteolytic processing of the 
precursors of the inflammatory cytokines such as interleukin-1β (IL-1β) and IL-18 (Martinon 
and Tschopp 2007). They are, hence, termed as ‘inflammatory’ caspases. 
 
1.8 Caspase-1  
 
Caspase-1 is important in innate immunity and host resistance to pathogens because it 
cleaves pro-forms of members of the IL-1 family such as IL-1β, IL-18, IL-33. These cytokines are 
potent mediators of inflammation that stimulate fever, recruitment and activation of immune 
cells and the production of secondary cytokines (Dinarello 1998). The activation of caspase-1 
not only leads to inflammation but also causes an inflammatory form of cell death termed as 
‘pyroptosis’ (Cookson and Brennan 2001). Pyroptosis occurs in response to infection by a 
number of intracellular bacterial pathogens and in macrophages treated with 
lipopolysaccharide (LPS) (Fernandes-Alnemri, Wu et al. 2007). Like apoptosis, pyroptosis 
requires the proteolytic activation of specific caspases: caspase-3 and caspase-7 for apoptosis, 
and caspase-1 for pyroptosis. In contrast to apoptosis, which is often anti-inflammatory, 
pyroptosis is pro-inflammatory because of the rapid loss of cell membrane integrity and 
release of cytosolic contents.  
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1.8.1 Biochemistry of caspase-1 
 
The active form of caspase-1 is a heterotetramer composed of two large (20 kDa) and two 
small (10 kDa) subunits derived from a 45 kDa precursor. The active enzymatic site spans 
residues from both subunits, with the p20 containing the catalytic cysteine (Cys285) at its C-
terminus and the p10 containing residues involved in substrate specificity (Thornberry, Bull et 
al. 1992). Caspase-1 absolutely requires an Asp at P1 and a small hydrophobic residue at P1’ 
(either Gly or Ala), conservative substitutions are tolerated in the P2 and P3 positions but a 
large hydrophobic residue such as tryptophan or tyrosine is preferred at P4. Caspase-1 is able 
to cleave substrates with the sequence WEHD or YVAD (Garcia-Calvo, Peterson et al. 1998). 
Caspase-1 is activated through oligomerization and then autocatalysis between its small and 
large subunits and the cleavage of its pro-domain (Wilson, Black et al. 1994; Gu, Wu et al. 
1995). 
 
1.8.2 Substrates of caspase-1 
 
IL-1β is considered to be a master cytokine in that it mediates several innate and adaptive 
immune responses directly or through the induction of other cytokines such as IL-6 and TNF-α. 
In addition, IL-1β is a potent pyrogen that is involved in the development of fever in response 
to pathogen infection (Dinarello and Wolff 1993). IL-1β is normally produced in response to 
infection, injury, or immunologic challenge. However, at high systemic concentrations, its 
effects become potentially lethal. Dysregulated production of IL-1β is associated with severe 
pathological conditions, including rheumatoid arthritis, inflammatory bowel disease, sleep 
sickness, acute and chronic myelogenous leukemia, insulin-dependent diabetes mellitus, 
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atherosclerosis, asthma, and septic shock (Dinarello and Wolff 1993). IL-18 induces interferon-
γ production and promotes the differentiation of type 1 helper T cells (Th1) (Dinarello 2002). 
 
1.8.3 Synthetic caspase inhibitors 
 
Caspases have been implicated in the pathogenesis of many inflammatory diseases (Cohen 
1997; Künstle, Leist et al. 1997). As inappropriate apoptosis has been implicated in many 
diseases including ischemic vascular diseases such as heart attacks, stroke as well as 
degenerative diseases such as Alzheimer's disease, motor neurone disease (Talanian, Brady et 
al. 2000), there has been an active engagement in developing synthetic caspase both as 
research tools, and with the hope that they may eventually be used to prevent cell death in 
the clinic. Accordingly, if caspases act as potential therapeutic targets, pharmacological 
intervention can minimize cell death and tissue damages. 
Caspase inhibitors have been designed based upon the substrate cleavage sites of specific 
caspases. These peptides behave as pseudo-substrates for active caspases thereby acting as 
competitive inhibitors. Peptides have been linked to chemical groups that serve to block the 
amino acids and to improve cell permeability, stability and efficacy. Those linked to aldehydes 
(or nitriles or ketones) are reversible inhibitors which bind to the catalytic site, but do not 
irreversibly chemically alter the enzyme. Examples include Ac-DEVD-CHO and Ac-YVAD-CHO. 
Peptides linked to leaving groups such as halomethylketones (chloro or fluoro), acylomethyl 
ketones and methyl ketones are irreversible inhibitors inactivates the caspase via a covalent 
thioester bond to an adjacent cysteine residue in the transition state (Walker, Talanian et al. 
1994). An example is Ac-DVAD-FMK. 
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In mice models, the pan-caspase inhibitor, z-VAD-FMK protects mice from lipopolysaccharide-
induced acute lung injury (Kawasaki, Kuwano et al. 2000) and bleomycin-induced 
pneumopathy (Kuwano, Kunitake et al. 2001). Kawasaki et al. (2000) described that 
intravenous injection of the pan-caspase inhibitor z-VAD-FMK suppressed the caspase-3 
activity in lung tissues, and significantly decreased the number of apoptotic cells as well as 
prolonged the survival rate of mice. Kuwano et al. (2000) reported that inhalation of z-VAD-
FMK decreased the activity of caspase-1 and caspase-3 and decreased the number of 
apoptotic cells and lung pathology of bleomycin-induced pulmonary fibrosis. These results 
indicate that apoptosis may play an important role in acute lung injury, and that the inhibition 
of caspase activity could be a therapeutic approach against lung injury. 
 
1.9 Animal models in influenza pneumonia 
 
Animal models for lung infections are necessary to facilitate the study of host pathogen 
interactions to pulmonary infection and to develop therapeutics and vaccines before testing in 
humans. The human upper respiratory tract consists of the nasal passages, pharynx, larynx, 
trachea as well as the bronchi and bronchioles. The lower respiratory tract begins in the 
bronchio-alveolar junction, alveolar ducts and sacs, and alveoli. The air spaces in the lungs and 
septa in the lower respiratory tract are affected in pneumonia. Acute infections in the lower 
respiratory tract are major causes of morbidity and mortality worldwide (Mizgerd 2008). 
Several mammalian models have been used in the study of pathology of influenza. They 
include ferrets, mice, guinea pigs, non-human primates, cats and dogs. For instance, the 
influenza virus was first isolated from ferrets in 1933 and ferrets remain a useful model that 
manifests symptoms of influenza which closely mirrors that of humans (Smith, Andrewes et al. 
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1995). Ferrets can be naturally infected with human influenza isolates, develop a fever and 
exhibit infection primarily of nasal turbinates with lesser amounts of infection of the trachea, 
bronchi and lungs.  
Nonetheless, mice are the most frequently used animal in pneumonia studies due to its easy-
husbandry, low cost and the ability to manipulate their genome. Mouse-adapted strains of the 
virus, in particular the A/Puerto Rico/8/1934 (H1N1) virus have been widely used in 
pathogenesis studies in mice. Mice develop a lower respiratory tract infection with similarities 
in lung pathology comparing pneumonia in humans and in mice. Clinical signs include 
anorexia, sleepiness and lethargy. Viral burden in the lungs can be measured by enumeration 
of plaque-forming units by culturing lung homogenates. The inflammatory response to 
influenza can be measured in lungs of mice models. Determinants of pneumonia include 
neutrophil recruitment and pulmonary edema which occur both in humans as well as mice. 
Neutrophil recruitment in the lungs can be enumerated in bronchoalveolar lavage. Pulmonary 
edema could be measured from protein-rich plasma exudates by quantifying concentrations 
of total protein in bronchoalveolar lavage fluid (Mizgerd and Skerrett 2008). Studies have also 
documented an early rise of cytokines such as interferon (IFN)-α, tumor necrosis factor (TNF)-
α, IL-1α and IL-β and IL-6 in bronchoalveolar lavage fluids or lung homogenates of mice (Conn, 
McClellan et al. 1995; Kurokawa, Imakita et al. 1996). However, a major drawback of mice 
studies is that the clinical picture in mice differs somewhat from that seen in the natural 
hosts. For instance, mice usually manifest a drop in body temperature instead of fever, and 
the infection is usually lethal. 
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1.10 Caspase-1 and host response to infection in vivo 
 
Caspase-1-deficient mice are highly susceptible to bacterial infections with Escherichia coli, 
Salmonella typhimurium, Francisella tularensis and Burkholderia pseudomallei, among others. 
Caspase-1-deficient mice infected with F. tularensis showed increased bacterial burdens and 
mortality compared to wild-type mice (Mariathasan, Weiss et al. 2005). Caspase-1 knock-out 
mice challenged with B. pseudomallei maintained a significantly higher bacterial burden two 
days after infection (Breitbach, Sun et al. 2009). Miao et al. (2010) demonstrates that 
activation of caspase-1 clears intracellular bacteria, Legionella pneumophila and Burkholderia 
thailandensis, independently of IL-1β and IL-18 and suggests a role for pyroptosis in bacterial 
clearance by the innate immune system. Caspase-1 knock-out mice succumbed to a sepsis-
induced model of infection by E. coli, with a 3- to 4-fold lower LD50 as compared to wild-type 
mice. Wild-type mice treated with the caspase-1 inhibitor Ac-YVAD-CHO are more susceptible 
to E. coli infection than untreated mice (Joshi, Kalvakolanu et al. 2002). Caspase-1-deficient 
mice are also more susceptible to oral infection with S. typhimurium. As compared to controls, 
caspase-1 knock-out mice died faster and higher bacterial loads were found in the spleens. 
The cecum histopathology of caspase-1 knock-out mice revealed more pronounced 
inflammation; lesions showed more neturophil infiltration and disrupted epithelium than its 
wild-type counterparts (Lara-Tejero, Sutterwala et al. 2006). In all, caspase-1 plays a 
protective role in these systems of infection. 
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1.11 Generation of caspase-1 knock-out mice by germ line gene-
targeting 
 
The laboratory mouse has become an important tool for facilitating functional in vivo data on 
gene function. Conventional knock-out mice are generated by homologous DNA 
recombination in murine embryonic stem cells (ES) (Doetschman, Gregg et al. 1987; Thomas 
and Capecchi 1987). A general outline is depicted in Figure 1-3. 
 
Figure 1-3: Generation of knock-out mice using homologous recombination in embryonic stem (ES) 
cells. 
(A) The wild-type locus with 5 exons (E1–E5) will recombine with the targeting construct thereby 
introducing a selection marker and deleting E3. P, promoter driving expression of the selectable 
marker; pA, polyadenylation signal. (B) Homologous recombined ES cells are injected into a blastocyst, 
which is transferred into a pseudo-pregnant recipient mother. As the injected ES cells contribute to all 
tissues, chimeric mice can be generated. The previously introduced recombination is then transmitted 
to the germ line resulting in homozygous knockout mice. (adapted from (Bockamp, Maringer et al. 
2002)). 
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A gene targeting construct (Figure 1-3A) consists of a core region containing the desired 
genetic modification together with a positive selection cassette conferring antibiotic 
resistance such as neomycin. This is flanked by two regions of absolute sequence identity to 
the targeted region so that homologous recombination can occur. Given that homologous 
recombination in ES cells is a relatively rare event as compared to random integration of DNA, 
recombined ES cell clones are enriched by employing negative selection markers such as the 
herpes simplex virus type-1 thymidine kinase (tk) gene, located outside the homology region 
of the targeting construct (Dzierzak, Daly et al. 1993). In a successful homologous 
recombination, the negative selection marker, tk gene, is not integrated into the genome 
while most randomly integrated targeting constructs still retain the negative selection marker. 
Gancyclovir drug selection kills cells in which thymidine kinase gene is integrated in the 
genome. Hence, successful clones are resistant to neomycin G418 and gancyclovir. 
Homologous recombined ES cells are injected into a blastocyst, which is then transferred into 
a pseudo-pregnant recipient mother. Chimeric mice are generated and heterozygous mice are 
interbred to obtain the homozygous knock-out mice. 
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Figure 1-4: Disruption of the murine ICE gene by homologous recombination.  
Restriction maps of the murine ICE locus (10 exons), the targeting vector, and the mutant ICE locus. neo 
and tk indicate the minigenes consisting of promoters, coding sequences and polyadenylation signals 
for the neomycin resistance and HSV thymidine kinase genes respectively. Each white box represents 
an exon (adapted from (Kuida, Lippke et al. 1995)). 
 
To investigate the physiological functions of ICE, Kuida et al. (1995) disrupted the murine ICE 
gene in D3 embryonic stem (ES) cells by replacing part of exons 6 and 7 (Figure 1-4) with a 
neomycin resistance gene cassette (Thomas and Capecchi 1987). Chimeric mice were 
obtained by injection of mutant ES cells into C57BL/6 blastocysts, and the chimeric males 
were mated with C57BL/6 mice. Interbreeding of the heterozygous mice generated the 
expected Mendelian 1:2:1 ratio of wild-type (ICE+/+), heterozygous (ICE+/-), and homozygous 
(ICE-/-) mutant mice. Homozygous knock-out mice are mice with 2 copies of the disrupted ICE 
gene, now known as Caspase-1 gene. 
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1.12 Objectives of study 
 
The scope of this project covers the following: 
1. To examine the response of host caspase-1 to an influenza A/Puerto Rico/8/34 (H1N1) 
virus infection of RAW264.7 murine macrophages, in vitro. 
2. To investigate the role of caspase-1 in pulmonary inflammation and cell death and its 
contribution to lung pathology following influenza virus infection in mice. To this end, 
caspase-1 knock-out were infected with influenza A/Puerto Rico/8/34 (H1N1) and 
compared to wild-type controls. 
3. To explore the roles of caspase-1 and other mediators of cell death by means of 
inhibitors in vitro, to complement the in vivo studies.  Inhibitory studies with a pan-
caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone (z-VAD-FMK), a caspase-1 
inhibitor Z-Leu-Glu(OMe)-Val-Asp(OMe)-fluoromethylketone (z-LEVD-FMK) and 
reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription, 
2-(2-Imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone hydrobromide 
(pifithrin-α) were conducted in vitro. 
 
  










Methods and Materials 
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2 METHODS AND MATERIALS 
 
2.1 Cell lines 
 
Madin-Darby Canine Kidney (MDCK) (CCL-34TM, American Type Culture Collection, Virgina, 
USA) were cultured in a complete growth medium composed of Eagle’s Minimum Essential 
Medium and RAW264.7 murine macrophage cell (TIB-71TM, American Type Culture Collection, 
Virgina, USA) in Dulbecco’s Modified Eagle’s Medium (American Type Culture Collection, 
Virgina, USA) with 10% heat-inactivated foetal bovine serum (FBS) (Biowest S.A.S, France) and 
incubated in a humidified atmosphere containing 5% carbon dioxide (CO2) at 37°C.  
Procedures for sub-culturing, cyro-preservation and recovery of frozen cells are found on 
Appendix I. 
 
2.2 Viable cell counting by trypan-blue cell exclusion  
 
Trypan blue is a vital dye and the negatively charged chromophore does not interact with 
viable cells and the dye is thus excluded. Cell suspension, detached from culture flasks and 
resuspended in medium, was mixed with 10 μl of 0.4% trypan blue solution (Sigma-Aldrich®, 
St. Louis, USA) in a 1:1 ratio then loaded onto an improved Neubauer haemocytometer.  
Clear, opalescent viable cells were observed under the 10x microscope objective. Cells within 
the four corner 1-mm2 squares of 0.1 mm3 volume each were enumerated and the average 
counts obtained. The total number of viable cells per ml of suspension was calculated as 
follows: Average number of cells x 104 x dilution factor  
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2.3 Mice  
 
2.3.1 Animal husbandry 
 
Heterozygous (Casp1+/-) mice were generated by back-crossing male and female homozygous 
caspase-1 knock-out (Casp1-/-) mice with wild-type C57BL/6 mice and were mated to start the 
colony. Subsequently, heterozygous (Casp1+/-) male and female mice were mated. Mice were 
housed under specific pathogen-free conditions in a light- (12 hours on / 12 hours off) and 
temperature-controlled environment with food and water ad libitum. The colony was 
maintained for at least 6 generations before the mice were used for experiments. Eight to 10 
week-old male and female littermates of homozygous knock-outs (Casp1-/-) and wild-type 
(Casp1+/+) were employed in the study. All animal experiments were performed in the Animal 
Bio-Safety Level 2 containment facility and according to approved guidelines of the 
Institutional Animal Care and Use Committee, National University of Singapore. 
  
2.3.2 Ear punching for identification and tail biopsy for genotyping 
 
Pups were weaned at 21 days and separated by gender. Mice were identified by ear punching 
(Figure 2-1). The animal was manually restrained and an alcohol-sterilized ear punch device 
was placed on the external ear in a location to be marked and punched through the ear. 
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Figure 2-1: Standard animal identification ear punch pattern.  
(Figure adapted from 
http://www.research.uky.edu/dlar/TissueCollectionForGeneticIdentificationofRodents.mht;  
Date assessed 22 August 2010) 
 
Tail biopsy, for DNA extraction, was also performed. The animal was manually restrained and 
one clean cut was made through the tail using an alcohol-sterilized scissors. Care was taken to 
ensure that tissue taken did not exceed 0.5 cm. Bleeding was controlled by applying local 
pressure and SuperClotTM styptic gel (Synergy Labs, Florida, USA).  
 
2.3.3 Genomic DNA extraction from tail snips 
 
Tail snip was minced in 0.5 ml of tail lysis buffer (Appendix II). Minced tail snips were digested 
with 400 μg of Proteinase K (InvitrogenTM, California, USA) and incubated overnight in a 56°C 
water bath. To the lysed tail mixture, 0.5 ml of 1:1 phenol-chloroform mixture was added 
[Phenol solution equilibrated with 10 mM Tris-HCl, pH 8.0, 1 mM EDTA (Sigma-Aldrich®, 
Missouri, USA); Chloroform (Sigma-Aldrich®, Missouri, USA)]. This mixture was mixed by 
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vortexing for 30 seconds before centrifugation at 10,000 r.p.m for 10 minutes at 4°C. The top 
aqueous layer was carefully aspirated to a new 1.5 ml micro-centrifuge tube and 1 ml of ice-
cold absolute ethanol was added. DNA was precipitated by inverting the tube several times. 
DNA was transferred to another new tube and washed with 0.5 ml of 70% ethanol. After the 
removal of ethanol by pipetting, the precipitated DNA was air-dried before resuspending in 80 
μl of nuclease-free water. 
DNA concentration and purity were measured using the NanoDrop ND-1000 
Spectrophotometer (Thermo Fisher Scientific Inc., Delaware, USA). DNA was used in the 
subsequent genotyping polymerase chain reaction (PCR) or stored at -20°C.  
 
2.3.4 Genotyping by polymerase chain reaction (PCR) 
 
The expression of Casp1 in Casp1+/+, Casp1+/- and Casp1-/- mice were analysed by PCR using the 
following primers (1st BASE, Singapore):  
Exon6F       
5’-GAGATGGTGAAAGAGGTGAAAG-3’  
  
Exon7R       
5’-CTCTATATGGGCCTTCTTAATG-3’ 
 
Neom_R        
5’-GCCAGCTCATTCCTCCACT-3’ 
 
Primer pair Exon6F and Exon7R generates a product of 754 base-pairs (bp) on genomic DNA 
while Exon6F and NeomR generate a product of 380 bp in size on mutant DNA. Reagents used 
in the PCR are shown in Figure 2-2 and thermal cycling conditions on Figure 2-3.   
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For a 12.5 μl reaction Volume (μl) 
10 mM dNTPs (Promega Corporation) 0.25 
Exon6 Forward primer 0.5 
Exon7 Reverse primer 0.5 
Neomycin Reverse primer 0.25 
10x ThermoPol buffer 1.25 
Taq polymerase (New England BioLabs®) 0.25 
Nuclease-free water 9 
Genomic DNA 0.5 
Total 12.5 
Figure 2-2: Volume of reagents used for a PCR reaction 
 
The thermal cycling conditions were as follows (Mastercycler®, Eppendorf, Hamburg, 
Germany): 
Segment No. of cycles Temperature Hold Time 
Initial denaturation 1 94°C  2 min 
Amplification 35   
Denaturation  94°C 30 s 
Annealing  55°C 30 s 
Extension  72°C 1 min 
Final extension 1 72°C 5 min 
Hold  4°C ∞ 
Figure 2-3: Genotyping PCR Thermal Cycling conditions. 
 
Agarose gel electrophoresis of PCR products were performed on a 1x Tris-Acetate-EDTA (TAE) 
(40 mM Tris, 20 mM Acetic Acid, 1 mM EDTA; pH 7.6), 1.5% agarose gel pre-stained with 
ethidium bromide (0.5 μg/ml). DNA bands were visualised under ultra-violet. A 100 bp or 1 kb 




Influenza A/Puerto Rico/8/34 (H1N1) (American Type Culture Collection, VR-95TM) was 
propagated in 10 to 12-day old embryonated chicken eggs by intra-allantoic inoculation. Eggs 
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were incubated at 35°C for 2 days. Allantoic fluid was harvested and stored in 1 ml cryotubes 
at -80°C until use. 
Virus was diluted in 1x PBS for in vivo mice experiments to obtain 500 plaque forming units 
(PFU) in 50 μl or diluted in serum-free growth medium containing 1 μg/ml L-(tosylamido-2-
phenyl) ethyl chloromethyl ketone (TPCK)-trypsin (Sigma-Aldrich®, St. Louis, USA) for in vitro 
infection of cell lines. 
 
2.5 Virus titration by plaque assay 
 
In a 24-well, flat bottomed polystyrene cell culture plate (Greiner Bio-One GmbH, Cellstar®, 
Fickenhausen, Germany), 1 x 105 MDCK cells were seeded per well and grown to confluency 
overnight. Ten-fold serial dilution was performed with 50 μl of virus diluted in infection 
medium (1 μg/ml of TPCK-trypsin in serum-free Eagle’s Minimum Essential Medium). Cell 
monolayer was washed twice with 1x PBS prior infection. 100 μl virus diluents were 
inoculated to cells and incubated at 37°C for 1 hour for viral absorption. Plates were rocked 
every 15 minutes to prevent cells from drying. Negative control wells were inoculated with 
100 μl of infection medium.  
After the hour’s incubation, virus inoculums were discarded and 1 ml of Avicel® overlay 
medium (Appendix III) were added per well. Plates were incubated at 35°C in 5% CO2 for 3 
days. Care was taken not to disturb the plates during the incubation period in order to avoid 
the formation of uneven plaques. After 3 days of incubation, the overlay medium were 
removed and cells were washed with 1x PBS and immediately fixed with 20% formalin (Merck 
KgaA, Darmstadt, Germany) in PBS for 1 hour at room temperature. After the removal of 
formalin, cells were then stained with 1% crystal violet solution for 15 minutes. Crystal violet 
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was removed and the stained plates were washed with water and left to air dry before visible 
plaques were counted. 
 
2.6 Intra-tracheal infection of mice with influenza A virus 
 
Mice were anaesthetised intra-peritoneally with mice anaesthesia (Comparative Medicine 
Centre, National University of Singapore, Ketamine 7.5 mg/ml, Medetomidine 0.1 mg/ml) at 
50 μl per 10 g of body weight. The mouse was then propped cranial side up using a clean 
dental floss supporting the incisor teeth. With the ventral side of the mouse facing the 
worker, the tongue was scooped out, pressed down and secured laterally with a sterile 
pipette tip to restrict deglutition. 50 μl of diluted virus in PBS was then administrated with a 
pipette into the oropharynx. Nostrils were then immediately closed until all liquid was 
observed to be emptied from the oral cavity. Effects of the mice anaesthesia were reversed by 
administrating intra-peritoneally 1:1000 dilution of Anti-Sedan® (stock 5 mg/ml Atipamezole 
Hydrochloride, Pfizer, Australia) at 50 μl per 10 g body weight. Mice body weights were 
monitored daily. 
 
2.7 Mice euthanasia, harvesting of organs and serum from blood 
 
Mice were euthanized by CO2 inhalation in a top-opening chamber. A flow of 5 litres per 
minute of CO2 was introduced to establish a high concentration at the bottom of the chamber. 
After the animals appear unconscious and all movements ceased, the flow was increased to 
10 litres per minute for an additional 5 minutes. Blood was immediately collected for serum 
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preparation by intra-cardiac puncture using a 1 ml syringe and 23-gauge needle (Becton, 
Dickinson, USA). 
Blood (approximately 0.4 - 0.9 ml) was collected in a 1.5 ml micro-centrifuge tube and allowed 
to stand at room temperature to clot before centrifugation at 12,000 r.p.m., 10 minutes, 4°C 
(Eppendorf, Hamburg, Germany). The supernatant sera was then transferred to a fresh sterile 
micro-centrifuge tube and stored in -80°C until use in the micro-neutralisation assay. 
Lungs were harvested by 3 cross sections of roughly equal sizes of both sides of lungs. One-
third of the lungs, half of the brain and half of the heart were fixed in 10% formalin in PBS for 
histopathology analyses, whereas remaining lung slices were transferred to 2 separate sterile 
micro-centrifuge tubes, snap-frozen in liquid nitrogen and stored at -80°C until use. 
 
2.8 Bronchoalveolar lavage fluid (BALF) collection 
 
Mice were euthanized by CO2 inhalation. The upper trachea was exposed and a small incision 
was made. A 23-gauge needle fitted with a 1-cm long, thin polyethylene tubing (Becton 
Dickinson Intramedic PE50 Clay Adams®) was inserted into the trachea, above the bifurcation 
point of the bronchi. The entire lung was then lavaged twice with 0.7 ml of sterile 1X PBS each 
time. At least 1 ml of instilled PBS was recovered. The bronchoalveolar lavage fluid (BALF) was 
placed immediately on ice. BALF cells were pelleted by centrifugation at 800 r.p.m., 10 
minutes. Cell-free BALF supernatant was transferred to a sterile 1.5 ml tube and stored at -
80°C until further use. 
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2.9 Differential cell counts of bronchoalveolar lavage fluid cells 
 
Upon aspirating BALF supernatant, cell pellets from infected mice were resuspended in 400 μl 
of 1x PBS. Cytocentrifuged slides were prepared by loading a glass microscope slide onto a 
stainless steel slide clip (Shandon Cytoclip®, Thermo Scientific, USA), a filter paper card was 
sandwiched in between the glass slide and a plastic Cytofunnel® (Thermo Fisher Scientific Inc., 
USA). 40 μl of the cell suspension was loaded into the funnel and placed in a Shandon 
Cytospin III® cytocentrifuge (Thermo Fisher Scientific Inc., USA) and centrifuged at 600 r.p.m., 
6 minutes.  
Cytocentrifuge slides were stained with Giemsa stain for 2 to 4 minutes and rinsed with 1x 
PBS. Stained slides were viewed under a light microscope at 400x magnification and cells were 
enumerated based on morphological differences. Resuspended cells were enumerated by 
trypan blue cell exclusion count. Total cell counts were calculated by taking into account the 
volume in which BALF cells were resuspended in. 
 
2.10 Homogenization of mice lungs and brains 
 
Frozen lung or brain pieces were transferred to gentleMACS™ M tubes (Miltenyi Biotec, 
California, USA) containing 0.4 ml sterile ice-cold 1x PBS. Lungs were homogenized at 4°C in 
gentleMACS Dissociator (Miltenyi Biotec, California, USA) on the RNA_02 programme. The 
tubes were pulse-centrifuged to collect contents before being transferred to a sterile 1.5 ml 
micro-centrifuge tubes and centrifuged at 13,200 r.p.m., 10 minutes, 4°C (Eppendorf, 
Hamburg, Germany). The supernatant (lung homogenate) was collected and transferred to a 
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fresh sterile 1.5 ml micro-centrifuge tube and used immediately for RNA extraction and viral 
plaque assay or stored at -80°C for protein analyses. 
 
2.11 RNA extraction and purification 
 
The RNeasy Mini kit (Qiagen, Hilden, Germany) was used in the extraction and purification of 
total RNA extracted from animal tissues. 50 μl of lung homogenate was added to 0.6 ml of RLT 
buffer containing guanidine thiocyanate (added with 0.143 mmol β-mercaptoethanol per μl of 
RLT buffer). 0.6 ml of 70% ethanol was added, mixed immediately before transferring to an 
RNeasy spin column and centrifuged at 10,000 r.p.m. for 20 seconds at room temperature. 
This was repeated until all of the mixture was centrifuged. The flow-through was discarded 
after each centrifugation. The spin columns were then washed once with 0.35 ml RW1 buffer. 
27.3 Kunitz units of DNase I (Qiagen, Hilden, Germany) in 80 μl of RDD buffer was added 
directly to each spin column membrane and incubated at room temperature for 20 minutes 
before the addition of 0.35 ml RW1 wash buffer. The spin columns were washed twice in 0.5 
ml RPE Buffer by centrifugation at 10,000 r.p.m. for 20 seconds at room temperature. RNA 
was eluted by applying 50 μl of RNase-free water directly to spin column membranes and 
centrifugation at 10,000 r.p.m. for 1 minute at room temperature. Purified total RNA was 
stored at -80°C until use.  
 
2.11.1 RNA quantification and RNA integrity 
 
A volume of 1.2 μl purified RNA was used to determine the purity and concentration using a 
ND-1000 Nanodrop Spectrophotometer. The ratio of the absorbance at 260 nm and 280 nm 
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(A260/280) was used to assess the purity of RNA. Samples were regarded as pure if A260/280 was 
approximately 2. The ratio of the absorbance at 260 and 230 nm (A260/230) was used as a 
secondary measure of RNA purity from organic compounds. Samples were regarded as pure if 
A260/230 was above 2. The integrity of RNA was determined by an agarose gel electrophoresis. 
Intact total RNA on a gel will have sharp 28S and 18S rRNA bands with the 28S rRNA band 
twice the intensity as the 18S rRNA band. A 1% agarose (1st BASE, Singapore) was casted in 1x 
TAE buffer stained with ethidium bromide (10 mg/ml) (Bio-Rad Laboratories, Inc., California, 
USA). A volume of equivalent to 500 ng of extracted total RNA was loaded per well and 
subjected to gel electrophoresis at 60 Volts for 30 minutes. The gel was visualised under a UV 
transilluminator (Figure 2-4). 
 
            1                 2               3               4               5                6                7               8 
 
 
Figure 2-4: Agarose gel electrophoresis of extracted RNA.  
Intact RNA displays 2 distinct bands on a 1% agarose gel. Upper and lower bands represent the 28S and 
18S ribosomal RNA bands respectively. 100 bp DNA ladder (Lane 1); 500 ng extracted RNA samples 
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2.12 cDNA synthesis from RNA by reverse transcription 
 
A volume equivalent to 1 μg extracted total RNA was added to 0.25 μg random primers 
(Promega, Wisconsin, USA), heated in a 0.2 ml PCR tube at 70°C for 5 minutes using a 
thermocycler (Mastercycler®, Eppendorf, Hamburg, Germany) and immediately cooled on ice 
for 5 minutes. To this, a master mix containing 1x Moloney Murine Leukemia Virus Reverse 
Transcriptase (M-MLV RT) reaction buffer (Promega, Wisconsin, USA), 0.5 mM dNTP (dATP, 
dCTP, dGTP, dTTP) mix (Promega, Wisconsin, USA), 25 units Recombinant RNasin® (Promega, 
Wisconsin, USA) Ribonuclease Inhibitor, 200 units M-MLV RT (Promega, Wisconsin, USA) and 
topped up to a final volume of 25 μl nuclease-free water (Promega, Wisconsin, USA) was 
added. The reaction was performed at 1 hour at 37°C and inactivated at 70°C for 15 minutes. 
cDNA was stored at -20°C until further use. 
 
2.13 Quantitative RT-PCR 
 
LightCycler® FastStart DNA MasterPLUS SYBR Green I (Roche Diagnostics GmbH, Roche Applied 
Science, Mannheim, Germany) reaction mix for PCR using the LightCycler® 2.0 Instrument was 
employed for the real-time PCR experiments. SYBR Green I intercalates in to the DNA double 
helix. The generatation of PCR products is detected by the increase in SYBR Green I 
fluorescence signal upon DNA-binding. During PCR, the increase in SYBR Green I fluorescence 
is proportional to the amount of double-stranded DNA generated. 
In a 0.2 ml PCR tube on ice, a 10 μl reaction volume comprising of 6 μl of PCR-grade nuclease-
free water, 2 μl of 5x SYBR Green I Master Mix, 1 μl of 10 μM forward primer and 1 μl of 10 
μM reverse primer were mixed with 1 μl of cDNA. The reaction mix was then transferred to a 
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LightCycler® Capillary, sealed with a stopper and centrifuged at 3000 rpm for 5 seconds. The 
capillary was placed in the sample carousel in the LightCycler® 2.0 Instrument Roche 
Diagnostics GmbH, Roche Applied Science, Mannheim, Germany). Cross-over threshold cycle 
(CT) numbers were used for relative quantification analysis and relative expression was 
calculated by the 2−ΔΔCT method (Livak and Schmittgen 2001). PCR parameters are shown in 
Figure 2-5 and primer sequences in Figure 2-6. 
Analysis Mode Cycles Segment  Target 
Temperature 
Hold Time Acquisition 
Mode 
Pre-Incubation 
None 1  95°C 10 min None 
Amplification 
Quantification 45 Denaturation 95°C 10 s None 
Annealing Primer 
dependent 
5 s None 




Melting Curves 1 Denaturation 95°C 0 s None 
Annealing 65°C 60 s None 
Melting 95°C 
Ramp Rate = 
20°C/s 
0 s Continuous 
Cooling 
None 1  40°C 30 s None 
Figure 2-5: PCR parameters typical for a PCR run with the LightCycler® FastStart DNA MasterPLUS SYBR 
Green I 
 







β-actin Forward ACTGGGACGACATGGAGAA 384 56°C 16 s 
Reverse TCTCAGCTGTGGTGGTGAA 
Caspase-1 Forward GAGATGGTGAAAGAGGTGAAAG 342 54°C (Melting 




IL-1β Forward GCAACTGTTCCTGAACTCAA 382 56°C 16 s 
Reverse CTCGGAGCCTGTAGTGCAG 
Caspase-4 Forward CAGATGTGCTACAGTATGATAC 96 55°C 4 s 
Reverse AGGCCTGCACAATGATGACT 
PR/8-NS1 Forward CAGCACTCTTGGTCTGGACA 360 55°C 15 s 
Reverse GGAAGAGAAGGCAATGGTGA 
Figure 2-6: Primer sequences used for real-time PCR reactions 
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2.14 Polymerase Chain Reaction (PCR) for viral NS1 gene 
 
Classical PCR was performed to probe for the presence of viral RNA by targeting the NS1 gene. 
The reagents used are listed in Figure 2-7 and the thermal cycling conditions on Figure 2-8. 
For a 25 μl reaction Volume (μl) 
10 mM dNTPs (Promega Corporation) 0.5 
PR/8-NS1 Forward primer 1.25 
PR/8-NS1 Reverse primer 1.25 
10x ThermoPol buffer 2.5 
Taq polymerase (New England BioLabs®) 0.5 
Nuclease-free water 18 
cDNA 1 
Total 25 
Figure 2-7: Reagents used in the PCR reaction targeting viral NS1 gene 
 
Segment No. of cycles Temperature Hold Time 
Initial denaturation 1 94°C  2 min 
Amplification 35   
Denaturation  94°C 30 s 
Annealing  55°C 30 s 
Extension  72°C 1 min 
Final extension 1 72°C 5 min 
Hold  4°C ∞ 
Figure 2-8: Thermal cycling conditions for PCR targeting viral NS1 gene 
 
2.15 MouseRef-8 v2.0 expression BeadChip microarray  
 
2.15.1 Illumina® TotalPrep RNA amplication 
 
A detailed description of the entire microarray procedure is found in Appendix IV. Briefly, the 
Illumina® TotalPrep RNA Amplification kit (Ambion® Inc., Texas, USA) was used to prepare 
RNA samples for microarray analysis. The total RNA sample (500 ng) used for a single array 
was prepared by pooling equal amounts of total RNA from 3 mice for each group, namely, +/+ 
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Mock-infected, -/- Mock-infected, +/+ Infected, -/- Infected. Arrays were performed in 
triplicates for each group with each array representing a biological replicate.  
The kit comprises of firstly, a reverse transcription (RT) step to synthesize first-strand cDNA, 
next second strand cDNA synthesis converted the single strand cDNA into a dsDNA template 
for transcription. cDNA was the purified using a cDNA filter cartridge system which included a 
cDNA binding step, a wash step and a final elution of cDNA. Subsquently, the synthesis of 
cRNA was performed by in vitro transcription.The cRNA generated was purified in cRNA filter 
cartridges using a cRNA binding buffer, wash buffer and 100% ethanol. The cRNA was eluted 
with nuclease-free water. 
 
2.15.2 Whole-genome gene expression direct hybridization assay 
 
Single-channel SENTRIX® BeadChip Array MouseRef-8 v2.0 Microarray for Gene Expression 
(Illumina®, Inc., California, USA) targets approximately 19,100 unique genes. About 25,600 70-
mer oligonucleotide probe sequences, representative of individual genes, of the mouse 
genome were represented on each array. The purified cRNA samples generated in the steps 
above was loaded onto the arrays for a 18-hour incubation in a rocker at 58°C. After 
hybridization, the microarray slides were washed and stained with Cy3 fluorescent dye. The 
BeadChip were subjected to additional washing and drying steps before scanning. They were 
scanned using the BeadArray Reader (Illumina®, Inc., California, USA) with the scan factor of 
0.5 and at the Cy3 channel-specific wavelength.  
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2.16 Microarray data analysis 
 
2.16.1 GeneSpring GX 11.5 
 
The probe ID, average signal value and detection p-values obtained from GenomeStudio 
(Illumina®, Inc., California, USA) as the sample probe profile and were imported into 
GeneSpring GX 11.5’s (Agilent Technologies, California, USA) ‘Illumina Single Color Guided 
Workflow to find differentially expressed genes’ for the normalisation of raw data. Two 
parameters were created for the experimental groupings, namely, Genotype and Infection. 







Probesets were then filtered based on their flag values P (present) and M (marginal). Only 
entities having the present and marginal flags in at least 1 sample are displayed as a profile 
plot (Figure 2-9). The flag values are based on detection p-values. Values below 0.6 are 
considered as Absent, between 0.6 and 0.8 are considered as Marginal and values above 0.8 
are considered as Present.  
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Figure 2-9: A profile plot displaying 23438 out of 25697 entities where 1 out of the 12 samples have 
present and marginal flags.  
The plot was generated using the normalized signal values and samples grouped by the interpretation, 
Genotype and Infection. 
 
For significance analysis, a 2-way ANOVA was performed with Benjamini-Hochberg False 
Discovery Rate (FDR) multiple testing correction. A p-value cut-off of 0.05 was considered as 
significant. The 9714 entities which satisfied the significance analysis (Figure 2-10) are passed 
on for the fold change analysis. 
 
Figure 2-10: A Venn diagram displaying 9714 of 23438 entities which satisfied the corrected p-value 
cut-off of 0.05.  
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2.16.2 GeneSpring fold change analysis 
 
Fold change analysis is used to identify genes with expression ratios or differences between a 
treatment and a control that are beyond a threshold. Fold change is the ratio between 
Condition 1 and Condition 2. It is calculated as Fold change = Condition 1 / Condition 2. Fold 
change gives the absolute ratio of normalized intensities (no log scale) between the average 
intensities of the samples grouped. A fold-change cut-off of 1.5 was used in the analysis 
following the 2-way ANOVA analysis with corrected p-value cut-off of 0.05.   
 
2.16.3 Ingenuity Pathway Analysis 
 
GeneSpring GX 11.5 software (Agilent Technologies) was employed to calculate averages and 
p-values for the replicate samples as well as to calculate fold-change ratio values. The .txt file 
generated was uploaded to Ingenuity Pathway Analysis (IPA®) (Ingenuity Systems, Inc.) for 
further analysis of the dataset. IPA® revealed functions and pathways which are associated 
with the differentially expressed genes present in the dataset. 
 
2.17 Quantification of antibody titres by micro-neutralisation assay 
 
Influenza micro-neutralisation assay is a visual assay to determine whether a serum sample 
contains antibodies that block virus infection. Two-fold dilutions of serum sample are 
prepared and mixed with virus before infecting the cells. If the serum contains antibodies that 
block viral infection, then the cells will survive. If no antiviral antibodies are present in the 
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serum, the cells will die and cytopathic effects observed. At the lower dilutions, antibodies will 
block infection, but at higher dilutions, there will be too few antibodies to have an effect. The 
neutralising titre is defined as the reciprocal of the highest dilution of serum at which the 
infectivity of 100 TCID50 of the virus for MDCK cells was completely neutralised in 50% of the 
wells. 
In a 96-well, flat bottomed polystyrene cell culture plate (NuncTM, NucleonTM Surface, 
Denmark), 2 x 104 MDCK cells were seeded per well and grown to confluency in growth 
medium. Sera from clotted blot, derived from intra-cardiac puncture of mice heart, was 
filtered through the Ultrafree®-MC 0.45 μm centrifugal filter device (Millipore, Massachusetts, 
USA) by centrifugation at 12,000 x g for 4 minutes then complement-inactivated for 30 
minutes at 56°C. The influenza A/Puerto Rico/8/34 (H1N1) was diluted in serum-free Eagle’s 
Minimum Essential Medium to 100 TCID50. 
In 210 μl of serum-free Eagle’s Minimum Essential Medium, 30 μl of serum was diluted by 8-
fold followed by subsequent 2-fold serial dilutions with 120 μl diluted sera in 120 μl medium. 
An equal volume of 65 μl of 100 TCID50 virus was added to sera diluents and incubated for 2 
hours in a humidified atmosphere containing 5% CO2 at 35 °C. Cell monolayer was rinsed twice 
with serum-free medium. 100 μl of 2 μg/ml TPCK-trypsin in serum-free Eagle’s Minimum 
Essential Medium and 50 μl of virus : serum mixture were added to cell monolayer in 
quadruplicates and incubated in a humidified atmosphere containing 5% CO2 at 35°C for 3 
days. Cells were monitored for cytopathic effects under the 10x objectives of a light 
microscope and readings were taken at 3 days post-infection. The absence of cytopathic effect 
was indicative of a neutralising effect by the antibodies present in mice sera. Geometric 
means of antibody titres were calculated. 
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2.18 Histopathological Analyses 
 
Formalin-fixed organs, namely, lungs, brain and heart, were embedded in paraffin wax and 
processed for haematoxylin and eosin stain. The details of the staining protocol are reported 
in Appendix V. Each haematoxylin and eosin-stained slide was evaluated by 2 separate 
investigators in a blinded manner. To generate the lung injury score, a total of 300 alveoli 
were counted on each slide at 400x magnification. Within each field, points were assigned 
according to predetermined criteria (Figure 2-11). All of the points for each category were 
added and weighted according to their relative importance. The injury score was calculated 
according to the following formula:  
Injury score = [(alveolar haemorrhage points/no. of fields) + 2 x (alveolar infiltrate points/no. 
of fields) + 3 x (fibrin points/no. of fields) + (alveolar septal congestion/no. of fields)]/total 
number of alveoli counted. 
 
Tissue 0 1 2 3 
Alveolar septae All septae are thin 
and delicate 
Congested 
alveolar space in 
less than 1/3 of 
the field 
Congested 
alveolar space in 
1/3 to 2/3 of the 
field 
Congested 
alveolar space in 
greater than 2/3 
of the field 
Alveolar 
haemorrhage 
No haemorrhage At least 5 
erythrocytes per 
alveolus in 1 to 5 
alveoli 
At least 5 
erythrocytes per 
alveolus in 5 to 10 
alveoli 
At least 5 
erythrocytes per 
alveolus in more 





Fibrin strands in 
less than 1/3 of 
the field 
Fibrin strands in 
1/3 to 2/3 of the 
field 
Fibrin strands in 
greater than 2/3 
of the field 
Intra-alveolar 
infiltrates 
Less than 5 intra-
alveolar cells per 
field 
5 to 10 intra-
alveolar cells per 
field 
10 to 20 intra-
alveolar cells per 
field 
More than 20 
intra-alveolar cells 
per field 
Figure 2-11: Quantitative Histopathology Scores of Lung Injury 
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2.19 Bio-Rad DC Protein Assay  
 
For the estimation of protein concentration, the Bio-Rad DC protein microplate assay was 
performed. The Bio-Rad DC protein assay (Bio-Rad Laboratories, Inc., California, USA) is a 
colorimetric assay similar to that of Lowry assay. The assay is based on the reaction of protein 
with an alkaline copper tartrate solution and Folin reagent. The two steps which lead to colour 
development involve the reaction between protein and copper in an alkaline medium, and the 
subsequent reduction of Folin reagent by the copper-treated protein. The blue colour 
development is mainly due to the amino acids tyrosine and tryptophan, as well as, cystine, 
cysteine, and histidine.  
To prepare the working reagent A’, 20 μl of reagent S was added to 1 ml of reagent A. A 
standard curve was prepared with 6 dilutions of bovine serum albumin (BSA) protein standard 
containing 0 mg/ml to 10 mg/ml each time the assay was performed. 5 μl of standards and 
samples were pipetted in triplicates into a clean microtitre plate. 25 μl of reagent A’ was 
added to each well, followed by 200 μl of reagent B. The plate was gently agitated to mix the 
reagents and bubbles were removed. After 15 minutes, absorbances were read at 750 nm 
using the Tecan® Infinite® 200 PRO microplate reader (Tecan® Trading AG, Switzerland). 
 
2.20 Western immunoblotting 
 
A detailed description of the Western blot procedure and reagents are found on Appendix VI. 
Briefly, a total of 50 μg of denatured proteins in 5x Laemeli sample buffer were loaded per 
well of a 15% polyacrylamide separating gel. The gel electrophoresis, in tris-glycine running 
buffer, was performed at constant 80 Volts (V) for 1 hour 30 minutes. 
 45  
The Mini Trans-Blot® Electrophoretic Transfer Cell system (Bio-Rad Laboratories, Inc., 
California, USA) was used for the transfer of proteins from the SDS-PAGE gel to a methanol 
activated Hybond-P polyvinylidene fluoride (PVDF) (Amersham Biosciences, GE Healthcare, 
Buckinghamshire, United Kingdom) membrane for 1 hour 20 minutes at 60 Volts with cooling. 
The blocking of non-specific binding sites was performed by immersing the membrane in 5% 
non-fat dried milk, 0.1% (v/v) Tween 20 in TBS (TBS-T) for 1 hour at room temperature on a 
shaker.  
The caspase-1 p10 antibody (1:500) (sc-514; Santa Cruz Biotechnology, Inc., California, USA) 
detects both the p10 subunit and the p45 pre-cursor caspase-1. While the IL-1β antibody 
(1:1000) (#2022; Cell Signaling Technology, Inc., Massachusetts, USA) detects endogenous 
levels of both the 31 kDa precursor and 17 kDa mature forms of IL-1β. The membrane was 
sealed in a polystyrene plastic bag with 7 ml of the diluted primary antibody in 5% skimmed 
milk in TBS-T and incubated at 4°C overnight on an orbital shaker.  
For the detection of proteins, the membrane was incubated with secondary goat anti-rabbit 
IgG, HRP-linked (1:4000) (InvitrogenTM, California, USA) antibody, diluted in 5% skimmed milk 
in TBS-T for 1 hour at room temperature on a shaker.  
Amersham ECL Plus Western blotting detection reagents (GE Healthcare, Buckinghamshire, 
United Kingdom) was used in the detection. The blots were placed, protein side up, onto an X-
ray film cassette (Amersham Biosciences Hypercassette, GE Healthcare, Buckinghamshire, 
United Kingdom) and exposed on an autoradiography film (Amersham HyperfilmTM ECL, GE 
Healthcare, Buckinghamshire, United Kingdom) in the dark.  
The blots were then immersed in stripping buffer and placed at 56°C for 15 minutes and 
blocked with 5% non-fat dried milk in TBS-T for 1 hour before probing for β-actin. β-actin was 
used as a loading control. The antibody incubation and detection steps were repeated. Mouse 
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β-actin antibody (Sigma-Aldrich®, St. Louis, USA) (1:2000) and goat anti-mouse IgG, HRP-linked 
antibody (1:10000) (InvitrogenTM, California, USA) were used. 
Densitometry of protein bands were analysed using ImageJ (Wayne Rasband, 
http://rsb.info.nih.gov/ij/).  
 
2.21 TUNEL Assay 
 
Using the in situ Cell Death Detection Kit, POD (Roche® Applied Science, Mannheim, 
Germany), immunohistochemical detection and quantification of apoptosis at single cell level 
was analysed by light microscope. Firstly, DNA strand breaks generated during apoptosis were 
labelled in the Terminal deoxynucleotidyl transferase (TdT) polymerization of labelled 
nucleotides to free 3’-OH DNA ends. Next, incorporated fluorescein was detected by anti-
fluorescein antibody Fab fragments from sheep, conjugated with horse-radish peroxidase 
(POD). After substrate reaction, stained cells can be analyzed under light microscope.  
Paraffin-embedded lung sections were dewaxed by heating at 60°C for 5 minutes and 
immersing in 2 rounds of xylene for 3 minutes each. Lung sections were rehydrated through a 
graded series of ethanol (absolute, 95%, 90%, 80%, 70%) followed by 2 rounds of 1x 
phosphate buffered saline (PBS) for 3 minutes each step. Lung sections were incubated with 
Proteinase K (Roche® Applied Science, Mannheim, Germany) for 15 minutes. A blocking step 
was included by adding 3% hydrogen peroxide in methanol to the section (or cells) and 
incubated for 10 minutes at room temperature. For the in vitro inhibitory study, adherent 
MDCK cells grown on coverslips were infected and treated and fixed by 4% paraformaldehyde 
(Appendix VIII) prior to TUNEL assay. After the blocking step, cells were permeabilised with 
0.1% Triton X-100 in sodium citrate buffer (pH 7.4) for 2 minutes on ice. 
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TUNEL reaction comprising of 50 μl of enzyme solution mixed with 450 μl Label solution was 
prepared on ice. A positive control treated with DNase I recombinant grade I (Roche® Applied 
Science, Mannheim, Germany) for 10 minutes. After rinsing twice with PBS, 50 μl of TUNEL 
reaction mixture was applied on the sample, covered with parafilm, and incubated for 1 hour 
at 37°C in a humidified atmosphere in the dark. Sections were rinsed thrice with PBS and 
signal conversion was performed by adding 50 μl of Converter-POD on sample and incubated 
for 30 minutes at at 37°C in a humidified atmosphere in the dark. 50 μl of DAB Substrate 
(Roche® Applied Science, Mannheim, Germany) was added after rinsing and incubated for 10 
minutes at room temperature. Slides were rinsed thrice, mounted under a coverslip and 
analysed under light microscope. Ten fields at 200x magnification were randomly selected, 
and the average number of TUNEL-positive cells was calculated. 
 
2.22 Bio-Plex ProTM cytokine assay   
 
Bio-Plex Pro™ Mouse Cytokine Standard Group I 23-Plex (Bio-Rad Laboratories, Inc., California, 
USA) was used for cytokine level determination from bronchoalveolar lavage fluid (BALF). 500 
μl of BALF were brought out from -80°C and thawed on ice. To these were added 25 μl of 20% 
Bovine Serum Albumin (BSA) (Sigma-Aldrich®, St. Louis, USA) + 4 μl 50x Complete Mini 
(Protease Inhibitor Cocktail, Roche, Hoffmann-La, Germany), giving a final concentration of 1% 
BSA and 1x protease inhibitor cocktail.  
Lyophilized premixed standards were reconstituted in 500 μl solution of 1x PBS + 1% BSA + 1x 
protease inhibitor cocktail, mixed and incubated on ice for 30 minutes. The low 
photomultiplier tube (PMT) standard dilution series for pre-mixed standards for an 8-point 
standard dilution set have been selected for optimized curve fitting using the 5-parameter 
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logistic (5PL) regression in Bio-Plex Manager™ software. 128 μl of the reconstituted standard 
was added to 72 μl standard diluent buffer. After mixing by pipetting, a 4-fold serial dilution 
was performed 7 times by adding 50 μl to 150 μl standard diluent buffer.  
5 μl of 10x coupled magnetic beads were diluted to 1x with assay buffer before being 
dispensed to each well of a pre-wet 96-well filter plate, to give a final volume of 50 μl. 50 μl 
room temperature-equilibrated diluted standards and samples were then dispensed into each 
well in duplicates. The plate was then incubated on a shaker at 300 r.p.m. at room 
temperature for 30 minutes.  
1x detection antibodies was prepared by diluting 2.5 μl of 10x detection antibodies with 
detection antibody diluent. The plate was washed 3 times with the vacuum manifold before 
25 μl of 1x detection antibody was dispensed per well. Plates were then incubated on a shaker 
at 300 r.p.m. at room temperature for 30 minutes. 
1x streptavidin-PE was prepared by diluting 0.5 μl of 100x streptavidin-PE. 50 μl of 1x 
streptavidin were were dispensed to each well. Plates were incubated at room temperature 
for 10 minutes After the incubation, plates were washed 3 times and 125 μl assay buffer were 
added to each well before being shaked at 1100 r.p.m. for 30 seconds and then at 300 r.p.m. 
at room temperature. Plates were read using a Bio-Plex System 200 and analysed using the 
Bio-Plex Manager software version 5.0. 
 
2.23 Infection of cell lines 
 
In a 24-well, flat bottomed polystyrene cell culture plate, 1 x 105 MDCK cells or 5 x 104 
RAW264.7 cells were seeded per well and grown in Eagle’s Minimum Essential Medium or 
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Dulbecco’s Modified Eagle’s medium, respectively, with 10% heat-inactivated FBS and 
incubated overnight in a humidified atmosphere containing 5% CO2 at 37 °C. Virus was diluted 
to plaque forming units (PFU) in 100 μl in infection medium (2 μg/ml of TPCK-trypsin (Sigma-
Aldrich®, St. Louis, USA) in serum-free medium). Cell monolayer was washed twice with 1 x 
PBS prior infection. 100 μl virus diluent were inoculated to cells and incubated at 37°C for 1 
hour for viral absorption. 400 μl serum-free medium was added to each well and incubated in 
a humidified atmosphere containing 5% CO2 at 37°C. At specified time-points, namely, 4 
hours, 8 hours, 12 hours, 24 hours and 48 hours. Cells were observed for cytopathic effect 
under light microscopy.  
 
2.24 Protein extraction from cells 
 
Protein was extracted from cells for Western blotting. Tissue culture fluid was discarded or 
stored at -80°C for virus titration. 100 μl of protein lysis buffer (Appendix VI) was added to lyse 
the cell layer. Lysate was collected in 1.5 ml micro-centrifuge tubes and subjected to rapid 
freeze-thaw action by repeated cycles of immersion into liquid nitrogen and 37°C water bath. 
Lysate was centrifuged at 3000 r.p.m. to remove cell debris. Protein concentration of the 




A pan-caspase peptide inhibitor, Z-Val-Ala-Asp-fluoromethylketone (z-VAD-FMK) (Alexis® 
Biochemicals, Lausen, Switzerland), a caspase-1 inhibitor, Z-Leu-Glu(OMe)-Val-Asp(OMe)-
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fluoromethylketone (z-LE(OMe)VD(OMe)-FMK) (Alexis® Biochemicals, Lausen, Switzerland) 
and a reversible inhibitor of p53-mediated apoptosis and p53-dependent gene transcription 
such as Cyclin G, p21/waf1 and mdm2 expression, 2-(2-Imino-4,5,6,7-tetrahydrobenzothiazol-
3-yl)-1-p-tolylethanone hydrobromide (pifithrin-α) (Sigma-Aldrich®, St. Louis, USA) were each 
reconstituted to 10 mM in dimethyl sulphoxide (DMSO) and stored in aliqouts at -20°C until 
use. 
 
2.26  MTS cell viability assay 
 
 
CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay (Promega Corporation, 
Wisconsin, USA) is a colorimetric method for determining the number of viable cells. The 
assay is composed of solutions of a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS] (U.S. Pat. No. 
5,185,450) and an electron coupling reagent phenazine methosulfate (PMS). MTS is 
bioreduced by cells into a formazan product that is soluble in tissue culture medium (Cory, 
Owen et al. 1991). The conversion of MTS into aqueous, soluble formazan is accomplished by 
dehydrogenase enzymes found in metabolically active cells. The quantity of formazan product 
as measured by the amount of 490 nm absorbance is directly proportional to the number of 
living cells in culture.  
In a 96-well, flat bottomed polystyrene cell culture plate (NuncTM, NucleonTM Surface, 
Denmark), 2 x 104 MDCK cells were seeded per well and grown to confluency in growth 
medium. Confluent cells were washed twice with 1x PBS before the addition of 10 μM, 25 μM 
or 50 μM of inhibitors in serum-free Eagle’s Minimum Essential Medium. Inhibitors added 
were made up to equal volumes with solvent DMSO. After 30 minutes of pre-treatment with 
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inhibitors, cells were infected, at multiplicity of infection of 0.5, with A/PR/8/34 (H1N1) for 24 
hours prior to MTS assay.  
The MTS/phenazine methosulfate (PMS) solution was reconstituted by transferring the 1 ml of 
PMS solution to the 20 ml of MTS solution. This mixture was stored in aliquots at -20°C. To 
measure the amount of soluble formazan produced by cellular reduction of MTS, 20 μl of the 
combined MTS/PMS solution was pipetted to each well containing 100 μl of cells in culture 
medium. After 3 hours of incubation at 37°C in a humidified, 5% CO2 atmosphere, the 
absorbance was read at 490 nm using the Tecan® Infinite® 200 PRO microplate reader. 
 
2.27 Guava ViaCount® assay (Guava Technologies®) 
 
The Guava ViaCount® assay distinguishes between viable and non-viable cells based on the 
differential permeability of DNA-binding dyes in the ViaCount® reagent. The fluorescence of 
each dye allows the quantitative assessment of both viable and non-viable cells present in a 
suspension, providing absolute cell count and viability data.  
In a 24-well plate, 1 x 105 MDCK cells were seeded per well and grown to confluency in growth 
medium. Confluent cells were washed twice with 1x PBS before the addition of 50 μM of 
inhibitors in serum-free Eagle’s Minimum Essential Medium. Inhibitors added were made up 
to equal volumes with solvent DMSO. After a 30-minute pre-treatment with inhibitors, MDCK 
cells were infected with A/PR/8/34 (H1N1) virus at a multiplicity of infection of 0.5 virus per 
cell. The cells were then incubated for 24 hours prior to the assay.  
For the counting of cells by Guava EasyCyte mini (Guava Technologies, MilliporeTM, 
Massachusetts, USA), a uniform cell suspension was needed. Cells in the tissue culture fluid 
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were pelleted by centrifugation and resuspended in 100 μl of 10% FBS in PBS. The adherent 
cell layer was detached with Guava Cell Dissociation Reagent (Guava Technologies, 
MilliporeTM, Massachusetts, USA) for 10 minutes at room temperature, quenched with 10% 
FBS in PBS and pelleted by centrifugation. Cells from the culture fluid and the adherent layer 
were pooled for each sample. As for bronchoalveolar lavage fluid cells, the harvested lavage 
was centrifuged and cell pellet resuspended in 100 μl of 10% FBS in PBS. Cell samples, 20 μl of 
each, were transferred to a round-bottom 96-well microtitre plate and 180 μl Guava ViaCount 
Reagent (Guava Technologies, MilliporeTM, Massachusetts, USA) was added to each well and 
cells were stained for 5 minutes. 
The ViaCount module in the CytoSoft software (Guava Technologies, MilliporeTM, 
Massachusetts, USA) was used to analysis the assay. The acquired data are displayed in 2 dot 
plots, they are, Viability (PM1) versus Nucleated Cells (PM2) and forward scatter (FSC) versus 
Viability (PM1). The first dot plot has a marker that acquires only events which contain a 
nucleus or DNA and thus displays live, apoptotic, and dead cells. The first dot plot also has two 
other markers, one to separate the live from dead cells (Figure 2-12; red diagonal line) and a 
second one to separate dead from apoptotic cells (Figure 2-12; purple diagonal line). The 
second dot plot has a marker to discriminate cells from debris that might have associated 
DNA. The second dot plot has a marker to discriminate cells from debris that might have 
associated DNA.  
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Figure 2-12 Example of dot plots of MDCK cells stained with ViaCount. 
Culture is at 6.49 x 106 cells/ml with 76.1% viable, 15.5% apoptotic and 8.4% dead cells. MDCK cells 
were stained with the ViaCount reagent and acquired on a Guava PCA. Live cells appear on the left side 
of the first plot and at the bottom of the second plot (to the right of the marker). Dead cells are on the 
right side of the first plot and at the top of the second plot (to the right of the marker). Apoptotic cells 
are shown in between the live and dead cell populations. This sample of cells also contains some debris 
(shown as dots to the left of the marker in the second plot).  
 
2.28 Statistical analysis 
 
Data obtained were expressed as a mean value ± standard error (SE). The two-tailed Student’s 
unpaired T-test was used to perform statistical analysis and comparison of samples. Values of 
p < 0.05 were considered to be significant.  
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2.29 Summaries of experimental procedures 
 
The following 3 schematic diagrams illustrate the experimental procedures of the 3 parts to 
this study.  
 
2.29.1 Influenza A infection of RAW264.7 murine macrophage cell line in vitro 
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2.29.3 A study on caspase inhibitors and a p53 inhibitor in vitro 
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3 RESULTS 
 
3.1 INFLUENZA A INFECTION OF RAW264.7 MURINE MACROPHAGE 
CELL-LINE IN VITRO 
 
Caspase-1 is known to be activated in macrophages and lysed by pyroptosis, a cell death 
mechanism distinct from apoptosis and oncosis/necrosis. Programmed cell death maintains 
homeostasis by removing unwanted cells and pyroptosis enables the clearance of intracellular 
bacteria such as Shigella and Salmonella. We were interested in examining (i) the response of 
host caspase-1 to an influenza A/Puerto Rico/8/34 (H1N1) virus infection of RAW264.7 murine 
macrophages; (ii) in vitro cell death induced by influenza virus in macrophages; and (iii) 
investigating if caspase-1 is activated by the influenza virus. In this section, we show that the 
influenza virus causes cell death, however, pyroptosis was not observed.  
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3.1.1 Cytopathic effect on RAW264.7 cells infected with influenza A/PR/8/34 
(H1N1) 
 




























Figure 3-1: Light microscopy images of RAW264.7 infected with A/PR/8/34 (H1N1). RAW264.7 cells 
were infected at multiplicity of infection (m.o.i.) of 5. Images were captured over 48 hours post-
infection (p.i.) at 400x magnification. Uninfected controls (Left panel); infected cells (Right panel). 
 
Morphological changes in cells caused by viral infection are called cytopathic effects (CPE). To 
observe any CPE and cell death, RAW264.7 macrophages were infected with A/PR/8/34 
(H1N1) at a multiplicity of infection of 5 and monitored over 48 hours under light microscopy, 
at 400x magnification, at 4 hours intervals. Uninfected cells were included as controls. CPE in 
infected RAW264.7 cells was first observed at 24 hours post-infection (Figure 3-1). As 
compared to the uninfected controls, infected macrophages displays increased amount of 
smaller, crinkled shaped cells with irregular shape and sizes. Cells of bigger, swollen 
morphology were also noted in the infected sample.  
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Figure 3-2: A time-course gene expression of Caspase-1 in RAW264.7 infected with influenza A/PR/8/34 
(H1N1). 
Infection at multiplicity of infection (m.o.i.) of 5 relative to uninfected controls. The fold change in 
expression of the Caspase-1 relative to the internal control gene (β-actin) at various time points 
studied. Time interval represented in hours (h). 
 
To prove the up-regulation of caspase-1 following an influenza infection, a real-time reverse 
transcription PCR was performed on the RNA extracted from infected RAW264.7 cells. 
Relative quantification for caspase-1 mRNA levels was calculated by the 2−ΔΔCT method (Livak 
and Schmittgen 2001). Gene expression of caspase-1 was normalised to the expression of β-
actin, a standard housekeeping gene. Gene expression is expressed as levels in the infected 
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There was an increasing trend in the up-regulation of caspase-1 gene expression upon 
influenza infection. An average of 2-fold increase in gene expression was observed at 8 hours 
post-infection and a peak of 3-fold increase at 12 hours post-infection (Figure 3-2). Caspase-1 
was up-regulated at mRNA levels upon influenza virus infection of RAW264.7 macrophages. 
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3.1.3 Protein expression of caspase-1 in RAW264.7 murine macrophages infected 
with influenza A/PR/8/34 (H1N1) overtime 
 
A  















Figure 3-3: Protein expression of pro-caspase-1 (p45) and active caspase-1 (p10) in RAW264.7 infected 
with influenza A/PR/8/34 (H1N1), overtime.  
RAW264.7 murine macrophages were infected with influenza at a multiplicity of infection (m.o.i.) of 5. 
Uninfected RAW264.7 cells were used as controls. (A) Western blot analysis of infected RAW264.7 at 
1h, 4h, 8h, 12h, 24h and 48h post-infection (Lanes 1 to 8 respectively). Uninfected cells harvested at 1h 
and 24h were used as controls. (B) Densitometric analysis of p10 bands which appeared at 8h, 12h, 24h 
post-infection. Average density of p10 bands from 3 experiments were normalized to their 











































*p = 0.02p = 0.29
B
Infected (MOI 5) Control 
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To show the protein expression levels of caspase-1 following influenza infection, RAW264.7 
murine macrophages were infected and cell lysate was harvested at 4 hours intervals, 
specifically 1, 4, 8, 12, 24 and 48 hours post-infection. The pro-form (p45) of caspase-1 was 
slightly increased as virus infection progressed (Figure 3-3). The cleaved p10 band was 
indicative of the active caspase-1. No active form of caspase-1 was observed prior to 8 hours 
post-infection (Figure 3-3A). Active caspase-1 was observed at 8, 12 and 24 hours post-
infection with the band at 12 hours post-infection being the most pronounced. Figure 3-3B 
shows the average density, from 3 blots, of p10 band at 8, 12 and 24 hours post-infection. The 
cleaved caspase-1 band was not observed in control uninfected cells. Active caspase-1 protein 
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Figure 3-4: A time-course gene expression of viral NS1 in RAW264.7 infected with influenza A/PR/8/34 
(H1N1).  
Infection at a multiplicity of infection (m.o.i.) of 5 relative to uninfected controls. The fold change in 
expression of the NS1 relative to the internal control gene (β-actin) at various time points studied. Time 
interval represented in hours (h). 
 
To investigate virus growth in infected RAW264.7 macrophages, gene expression of influenza 
non-structural 1 (NS1) was measured by real-time PCR overtime. There was an increasing 
trend in gene expression of viral VS1 over time. The highest level of viral mRNA was observed 
at 12 hours post-infection before tapering off at 24 hours post-infection (Figure 3-4). The 
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3.1.5 Virus titres (PFU/ml) during an infection of RAW264.7 macrophages 
 
 
Figure 3-5: Average virus titres (PFU/ml) during an influenza A/PR/8/34 (H1N1) infection of RAW264.7 
macrophages overtime.  
Virus titres were determined by plaque assay from supernatant of infected cells at the various time 
points studied. Time interval represented in hours (h). 
 
Virus replication was measured by plaque assay to determine the quantity of infectious viral 
particles in order to ascertain whether the RAW264.7 macrophages could actively support 
influenza virus replication. An increasing trend in virus titre was observed over time. Virus 
titres increased to an average titre of 1.2 x 104 PFU/ml at 24 hours post-infection, but tapered 
off at 48 hours post-infection (Figure 3-5). The peak of viral NS1 gene expression at 12 hours 
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3.1.6 Evaluation of influenza A infection of RAW264.7 murine macrophages  
 
In summary, caspase-1 was up-regulated, at mRNA and protein levels, upon infection of 
RAW264.7 murine macrophages with influenza A/PR/8/34 (H1N1) virus. The up-regulation of 
caspase-1 following influenza infection indicates that caspase-1 plays a role in influenza 
infection. There was an increasing trend in the up-regulation of gene expression of caspase-1 
with a 3-fold increase at 12 hours post-infection. This is congruent to the up-regulation of 
active caspase-1 protein observed at 8, 12 and 24 hours post-infection with the most 
pronounced band appearing at 12 hours post-infection. There is evidence to show that 
RAW264.7 macrophages can be infected with influenza A virus, and these macrophages 
exhibit cytopathic effect at 24 hours post-infection, coinciding with peak virus titres.  
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3.2 AN INVESTIGATION OF THE ROLE OF CASPASE-1 IN AN IN VIVO 
MOUSE MODEL OF INFLUENZA PNEUMONITIS 
 
The main aim of this project was to investigate the role of caspase-1 in pulmonary 
inflammation and cell death and its contribution to lung pathology following influenza virus 
infection in mice. To this end, caspase-1 knock-out were infected with influenza A/Puerto 
Rico/8/34 (H1N1) and compared to wild-type controls. 
 





Figure 3-6: Agarose gel electrophoresis of genotyping PCR.  
Upper band represents the 754 bp product of caspase-1 genomic DNA specific primers to Exon 6 and 
Exon 7. Lower band represents the 380 bp product of mutated caspase-1 DNA-specific primers of Exon 
6 and 3’ region of the neomycin cassette. Lane 1 represents the DNA ladder, while Casp1-/-, Casp1+/+ and 
Casp1+/- controls were loaded in lanes 2, 3 and 4 respectively. 
 
 
Mice were weaned 3 weeks after birth, DNA extracted from tail snips and genotyped by 
means of PCR. Three primers, namely Exon6F (5’-GAGATGGTGAAAGAGGTGAAAG-3’), 
754 bp 
380 bp  
   1           2          3          4         5          6          7         8          9         10       11 
100bp   -/-       +/+      +/-      +/+     +/+       -/-       +/-      +/-       +/+      -/-        
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Exon7R (5’-CTCTATATGGGCCTTCTTAATG-3’) and NeomR (5’-
GCCAGCTCATTCCTCCACT-3’), were used in each genotyping PCR reaction. The single 
upper band of 754 bp that appears on the gel represents the wild-type genomic DNA of 
caspase-1 (Figure 3-6; Lanes 2, 6 and 10). The single lower band of 380 bp represents the 
mutated genomic DNA with the inserted neomycin cassette (Figure 3-6; Lanes 7 and 11). 
Lanes with both the upper and lower bands represent genomic DNA from heterozygous 
caspase-1 knock-out mice (Casp1+/-) (Figure 3-6; Lanes 8 and 9).  
 
3.2.2 Mortality study of caspase-1 wild-type and knock-out mice infected with 500 
PFU of influenza A/PR/8/34 (H1N1) via the intra-tracheal route 
 
 
Figure 3-7: Percentage survival of mice infected with 500 PFU of influenza A/PR/8/34 (H1N1) virus.  
Preliminary data of mice mortality of infected wild-type and caspase-1 knock-out mice. Mock-infected 
(Mock) wild-type (+/+) mice (n = 3); Infected (INF) wild-type (n = 10); Mock-infected Casp1-/- (-/-) (n = 3); 
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A pilot investigation was performed by an intra-tracheal infection of mice with 500 PFU of 
egg-propagated influenza A/PR/8/34 (H1N1). Mice were monitored for breathing difficulties 
and weight loss. Mice were sacrificed upon losing 25% of their original weight. Mice used in 
the preliminary study were non-littermates and had an average age of 9 months. In this pilot 
study, a separate group of older mice were used initially due to the limited number of 
caspase-1 knockout mice. Weight loss was deemed as a crude indicator of mice infected with 
the influenza virus as they were shown to lose weight before succumbing to the infection.  
From this pilot study, no weight loss was observed in the mice mock-infected with phosphate-
buffered saline (PBS). There was 100% survival in the mock-infected groups of both wild-type 
and Casp1-/- mice. By day 7 post-infection, there was 90% survival in the infected wild-type 
mice group and only 60% survival in the infected Casp1-/- mice group (Figure 3-7). However, 
due to the limited number of animals, the p-value was 0.22 by Kaplan-Meier survival curve 
analysis. Hence, the difference between genotypes was not statistically significant.  
From a preliminary study, there was an indication that aged mice deficient in caspase-1 were 
more susceptible to influenza infection.  
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3.2.3 Weight loss as a primary read-out for the intra-tracheal infection of caspase-
1 knock-out and wild-type mice with 500 PFU of influenza A/PR/8/34 (H1N1) 
virus 
 
Figure 3-8: Mean percentage weight change of mice upon influenza infection with 500 PFU of 
A/PR/8/34 (H1N1).  
Mock-infected (Mock) wild-type (+/+) mice (n = 6); Infected (INF) wild-type (n = 10); Mock-infected 
Casp1-/- (-/-) (n = 6); Infected Casp1-/- (n = 10). Data expressed as mean ± SE. 
 
Wild-type and Casp1-/- mice, 8 to 10 weeks of age, were infected with 500 PFU of egg-
propagated influenza A/PR/8/34 (H1N1) virus, or mock-infected with PBS, via the intra-
tracheal route. Mice weights were monitored daily and mice were euthanized when weight 
loss reached 25% of their original weight prior influenza infection. This occurred at day 7 post-
infection. Figure 3-8 shows the trend in weight loss between the different groups namely, 
mock-infected wild-type and Casp1-/-, infected wild-type and Casp1-/- mice.  
There was a significant difference in weight loss between infected and mock-infected mice but 
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3.2.4 Real-time reverse transcription (RT)-PCR analysis of caspase-1 mRNA levels in 
lungs 
 3 d.p.i. 7 d.p.i. 
 -/- +/+ -/- +/+ 
Gene expression of Caspase-
1 in infected mice relative to 
mock-infected controls  
0.60 ± 1.45 3.22 ± 3.10 0.07 ± 1.61 4.76 ± 1.22 
p-value between infected 
genotypes 
*p < 0.01 *p < 0.01 
 
Figure 3-9: Gene expression of caspase-1 in the lungs of influenza infected caspase-1 knock-out (-/-) 
and wild-type (+/+) mice relative to its mock-infected controls.  
Mock-infected (Mock) wild-type (n = 6); Infected wild-type (n = 10); mock-infected Casp1-/- (n = 6); and 
infected Casp1-/- (n = 10) were euthanized at 3 days post-infection (d.p.i.) and 7 d.p.i. Data expressed as 
mean ± SE.  
 
To study the regulation of caspase-1 in the lungs of infected mice, relative expression of 
caspase-1 mRNA was determined by real-time RT-PCR. An average of 3.1-fold increase (*p < 
0.01) and 4.8-fold increase (*p < 0.01) in the gene expression of caspase-1 mRNA was 
observed in the lungs of wild-type mice upon infection with influenza virus, at days 3 and 7 
post-infection, respectively (Figure 3-9). The out-of-range threshold cycle numbers (CT) 
obtained from reaction of the caspase-1 knock-out (Casp1-/-) mice were indicative of the 
absence of the caspase-1 gene in these mice.  
Gene expression of caspase-1 in lungs was up-regulated upon influenza virus infection of mice 
at days 3 and 7 post-infection. 
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3.2.5 Western blot for caspase-1 in lung homogenates of mice at day 7 post-
infection 
A              1                  2                 3                4                 5                 6                  7                   8 
 p45  
                        
     _________________    ________________   ________________   __________________ 






Figure 3-10: Western blot analysis of pro-caspase-1 (p45) in lung homogenates at day 7 post-infection.  
(A) Western blots of pro-caspase-1 (p45) in lung homogenates of influenza virus infected (INF) wild-
type (+/+) (Lanes 1 & 2); and mock-infected (Mock) wild-type (Lanes 3 & 4) and infected caspase-1 
knock-out (-/-) (Lanes 5 & 6); and mock-infected Casp1-/- (Lanes 7 & 8) mice. (B) Densitometric analysis 
of pro-caspase-1, expressed in fold-change of infected lung relative to mock-infected control lung. 
Mock-infected (Mock) wild-type (+/+) (n = 6); Infected wild-type (n = 10); mock-infected Casp1-/- (-/-) (n 




















































B *p < 0.01
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To see the effect of influenza infection on Caspase-1 protein levels in the lungs, Caspase-1 was 
probed by Western blotting.  At day 7 post-infection, pro-caspase-1 (p45) protein expression 
increased, by an average of 4-fold (*p < 0.01), following an influenza virus infection in the 
lungs of wild-type mice (Figure 3-10A). Low levels of pro-caspase-1 were expressed in the 
mock-infected wild-type mice. Pro-caspase-1 protein was not observed in the lungs of Casp1-/- 
mice. The active caspase-1 (p10) protein was not detected in the Western blots.  
Caspase-1 is up-regulated at protein levels in the lungs of mice infected with influenza virus at 
day 7 post-infection.  
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3.2.6 Virus titres (PFU/ml) in lung homogenates at days 3 and 7 post-infection as 
determined by plaque assay 
 
 
Figure 3-11: Virus titres (PFU/ml) in the lungs of infected Caspase-1 knock-out and wild-type mice were 
determined by plaque assay.  
Virus titres (A) at day 3 post-infection (B) at day 7 post-infection. No plaques were observed in the 
assay of homogenates from lungs of mice mock-infected with PBS. Mock-infected (Mock) wild-type 
(+/+) (n = 6); Infected wild-type (n = 10); mock-infected Casp1-/- (-/-) (n = 6); and infected Casp1-/- (n = 
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Viral burden in the lungs following the influenza infection was determined by viral plaque 
assay. Mice lungs were harvested at days 3 and 7 post-infection and snap-frozen in liquid 
nitrogen. Frozen lungs were homogenized and virus titres were determined by plaque assay 
on MDCK cells. At day 3 post-infection, a 2.4-fold increase (p = 0.13) in the virus titres was 
observed in the infected lungs of caspase-1 knock-out mice as compared with the infected 
wild-type mice (Figure 3-11A). An average titre of 1.0 x 106 PFU/ml and 4.2 x 105 PFU/ml were 
obtained from caspase-1 knock-out and wild-type mice, respectively. No plaques were 
observed in the lungs of mock-infected mice of either genotype.  
At day 7 post-infection, a 2.1-fold increase (*p = 0.05) in the virus titres was observed in the 
infected lungs of caspase-1 knock-out mice as compared with the infected wild-type mice 
(Figure 3-11B). An average titre of 1.6 x 105 PFU/ml and 7.7 x 104 PFU/ml were obtained from 
caspase-1 knock-out and wild-type mice, respectively. No plaques were observed in the lungs 
of mock-infected mice of either genotype.  
In general, higher virus titres were observed in the lungs at day 3 post-infection as compared 
to at day 7. Virus titre was 2-fold higher in the lungs of the caspase-1-deficient mice at day 7 
post-infection relative to its wild-type counterparts.  
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Infected Casp1-/- (3 d.p.i.) 
 
 
Infected wildtype (3 d.p.i) 
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C 
 
Infected Casp1-/- (7 d.p.i.) 
 
 
Infected wildtype (7 d.p.i.) 
 
 
Figure 3-12: Gross anatomy of mice. 
(A) Mock-infected mice at day 7 post-infection. (B) Infected mice at day 3 post-infection. (C) Infected 
mice at day 7 post-infection. Insets display the dissected lung. Arrow indicating the enlarged 
spleen. 
 
From the gross anatomy of mice euthanized at days 3 and 7 post-infection, the lungs of mice 
mock-infected with 1 x PBS appeared a healthy pink (Figure 3-12A) while lungs harvested from 
mice infected with 500 PFU of influenza A/PR/8/34 (H1N1) were inflamed and swollen and 
exhibited regions of red colouration which indicated the presence of hyperaemia, edema and 
haemorrhage (Figure 3-12B and 3-12C). These were more pronounced at day 7 post-infection 
(Figure 3-12C). Infected mice also presented with enlarged spleen as seen in Figure 3-12C.  
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3.2.8 Histopathological analyses of the lung 
 
Histopathological analyses by haematoxylin and eosin staining provides an excellent visual and 
quantitative perspective to lung damage due to the influenza infection. Mice lungs were 
harvested at day 3 and 7 post-infection and fixed in 10% formalin prior to processing and 
haematoxylin and eosin staining. Each lung section was evaluated by 2 independent 
investigators in a blinded fashion. To generate the lung injury score, a total of 300 alveoli were 
counted on each slide at 400x magnification. Within each field, scores were assigned 
according to pre-determined criteria. Total scores for each category were added and weighted 
according to their relative importance. The injury score was calculated according to the 
following formula:  
Injury score = [(alveolar haemorrhage points/no. of fields) + 2 x (alveolar infiltrate points/no. 
of fields) + 3 x (fibrin points/no. of fields) + (alveolar septal congestion/no. of fields)]/total 
number of alveoli counted. 
Brain and heart sections were evaluated qualitatively. 
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Lung injury at day 3 post-infection 
 
 
Figure 3-13: Average histopathology scores of haematoxylin and eosin stained lung sections of infected 
Casp1 knock-out and wild-type mice at day 3 post-infection.  
(A) Average total lung injury score of infected (INF) caspase-1 knock-out (-/-) and wild-type (+/+) mice. 
10 mice of each genotype were infected with 500 PFU of influenza A/PR/8/34 (H1N1) via the intra-
tracheal route. (B) Average histopathological scores of alveolar septal congestion, alveolar 
haemorrhage, intra-alveolar fibrin deposition and cellular infiltration of infected caspase-1 knock-out 
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p = 0.53 
p = 0.50





















Infected wild-type   Score 18 out of 21 
 
 
Figure 3-14: Representative photomicrographs of haematoxylin and eosin stained lung sections of mice 
euthanized at day 3 post-infection (200x magnification).  
(A) Mock-infected Casp1-/- mice lung section shows only mild septal congestion and mild alveolar 
haemorrhage, representing a total score of 2 out of 21. (B) Infected wild-type mice lung section shows 
moderate septal congestion and moderate alveolar haemorrhage, mild fibrin and mild inflammatory 
cellular infiltrate, representing a total score of 9 of 21. (C) Infected Casp1-/- mice lung section showing 
moderate septal congestion, moderate alveolar haemorrhage, moderate fibrin exudates and moderate 
inflammatory cellular infiltrate, representing a score of 14 of 21. (D) Infected wild-type mice lung 
section shows moderate septal congestion, mild alveolar haemorrhage and marked fibrin exudates and 
marked inflammatory cellular infiltrate, representing a score of 18 of 21. 
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Lung injury at day 7 post-infection 
 
 
Figure 3-15: Average histopathology scores of haematoxylin and eosin stained lung sections of infected 
Casp1 knock-out and wild-type mice at day 7 post-infection.  
(A) Average total lung injury score of infected (INF) caspase-1 knock-out (-/-) and wild-type (+/+) mice. 
10 mice of each genotype were infected with 500 PFU of influenza A/PR/8/34 (H1N1). (B) Average 
histopathological scores of alveolar septal congestion, alveolar haemorrhage, intra-alveolar fibrin 
deposition and cellular infiltration of infected caspase-1 knock-out and wild-type mice lungs. Weightage 
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Mock-infected Casp1-/-  Score 4 out of 21 
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Infected wild-type  Score 14 out of 21 
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Infected wild-type mice  Score 16 out of 21 
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Figure 3-16: Representative photomicrographs of haematoxylin and eosin stained lung sections of mice 
euthanized at day 7 post-infection (200x magnification).  
(A) Mock-infected wild-type mice lung section showing only mild septal congestion, representing a 
score of 1 of 21. (B) Mock-infected Casp1-/- mice lung section showing only moderate septal congestion 
and moderate alveolar haemorrhage, representing a score of 4 of 21. (C) Infected wild-type mice lung 
section showing moderate septal congestion, mild alveolar haemorrhage, mild fibrin exudates and 
moderate inflammatory cellular infiltrate, representing a score of 10 of 21. (D) Infected wild-type mice 
lung section showing moderate septal congestion, moderate alveolar haemorrhage and moderate fibrin 
exudates and moderate inflammatory cellular infiltrate, representing a score of 14 of 21. (E) Infected 
wild-type mice lung section showing moderate septal congestion, moderate alveolar haemorrhage and 
moderate fibrin exudates and marked inflammatory cellular infiltrate representing a score of 16 of 21. 
(F) Infected wild-type mice lung section showing marked septal congestion, moderate alveolar 
haemorrhage, moderate fibrin exudates and marked inflammatory cellular infiltrate, representing a 
score of 17 of 21. (G) Infected Casp1-/- mice lung section showing moderate septal congestion, mild 
alveolar haemorrhage and moderate fibrin exudates and marked inflammatory cellular infiltrate, 
representing a score of 16 of 21. (H) Infected Casp1-/- mice lung section showing marked septal 
congestion, moderate alveolar haemorrhage and marked fibrin exudates and marked inflammatory 
cellular infiltrate, representing a score of 20 of 21. (I) Infected Casp1-/- mice lung section showing 
marked septal congestion, moderate alveolar haemorrhage, marked fibrin exudates and marked 
inflammatory cellular infiltrate, representing a score of 20 of 21. 
G 
 
Infected wild-type mice  Score 17 out of 21 
H 
 
Infected Casp1-/-  Score 20 out of 21 
I 
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As expected, lungs of infected mice had higher lung injury scores than mock-infected mice. 
Mock-infected mice of both genotypes had an average score of less than 4. The infected mice 
displayed severe lung pathology with greater severity of damage for mice sacrificed at day 7 
than at day 3 post-infection. 
At day 3 post-infection, the infected knock-out mice had, on average, a higher injury score of 
13.4 compared to 12.2 in the infected wild-type group. However, this difference between 
genotypes did not reach statistical significance (p = 0.42) (Figure 3-13). 
At day 7 post-infection, the infected knock-out mice fared significantly worse than the 
infected wild-type with an average total score of 18.8 and 15.6 respectively. This difference 
between genotypes was statistically significant (*p = 0.02) (Figure 3-15). As compared to the 
infected wild-type mice, the lungs of infected knock-out mice had injury scores 1.3 times (*p = 
0.02) higher for fibrin exudates and 1.2 times (*p = 0.05) higher for cellular infiltration.  
Representative photomicrographs of haematoxylin and eosin-stained lungs at day 3 post-
infection are shown in Figure 3-14(A) – (D). In Figure 3-14, (A) shows a mock-infected Casp1-/- 
mice lung section with only mild septal congestion and mild alveolar haemorrhage. This 
represents a total score of 2 out of 21. (B) shows an infected wild-type mice lung with 
moderate septal congestion and moderate alveolar haemorrhage, mild fibrin and mild 
inflammatory cellular infiltrate. This represents a total score of 9 of 21. (C) shows an infected 
Casp1-/- mice lung with moderate septal congestion, moderate alveolar haemorrhage, 
moderate fibrin exudates and moderate inflammatory cellular infiltrate. This represents a 
score of 14 of 21. (D) shows an infected wild-type mice lung with moderate septal congestion, 
mild alveolar haemorrhage and marked fibrin exudates and marked inflammatory cellular 
infiltrate, representing a score of 18 of 21. 
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Lung sections of mice sacrificed at day 7 post-infection are shown in Figure 3-16(A) – (I). 
Figure 3-16, (A) shows a mock-infected wild-type mice lung section with only mild septal 
congestion. This represents a score of 1 of 21. (B) shows a mock-infected Casp1-/- mice lung 
section with only moderate septal congestion and moderate alveolar haemorrhage. This 
represents a score of 4 of 21. (C) shows an infected wild-type mice lung section with moderate 
septal congestion, mild alveolar haemorrhage, mild fibrin exudates and moderate 
inflammatory cellular infiltrate. This represents a score of 10 of 21. (D) shows an infected wild-
type mice lung section showing moderate septal congestion, moderate alveolar haemorrhage 
and moderate fibrin exudates and moderate inflammatory cellular infiltrate. This represents a 
score of 14 of 21. (E) shows an infected wild-type mice lung section with moderate septal 
congestion, moderate alveolar haemorrhage and moderate fibrin exudates and marked 
inflammatory cellular infiltrate. This represents a score of 16 of 21. (F) shows an infected wild-
type mice lung section with marked septal congestion, moderate alveolar haemorrhage, 
moderate fibrin exudates and marked inflammatory cellular infiltrate. This represents a score 
of 17 of 21. (G) shows an infected Casp1-/- mice lung section with moderate septal congestion, 
mild alveolar haemorrhage and moderate fibrin exudates and marked inflammatory cellular 
infiltrate. This represents a score of 16 of 21. (H) shows an infected Casp1-/- mice lung section 
with marked septal congestion, moderate alveolar haemorrhage and marked fibrin exudates 
and marked inflammatory cellular infiltrate. This represents a score of 20 of 21. (I) shows an 
infected Casp1-/- mice lung section with marked septal congestion, moderate alveolar 
haemorrhage, marked fibrin exudates and marked inflammatory cellular infiltrate. This 
represents a score of 20 of 21. 
In the more severely injured lungs, massive inflammatory cell infiltrate were present 
throughout (**) (Figure 3-16D, H, I). There were necrotizing bronchiolar (Black arrows, Figure 
E) and alveolar walls and intra-alveolar edema (*) (Figure 3-16F) and desquamated alveolar 
epithelial cells. Lung interstitium showed congestion, edema, and an inflammatory infiltrate of 
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primarily neutrophils. Pulmonary haemorrhage with alveolar spaces containing erythrocytes 
was also evident. 
In summary, histopathologic analysis revealed that the infected Casp1-/- mice fared 
significantly worse than the infected wild-type at day 7 post-infection and that Casp1-/- mice 
exhibited increased intra-alveolar fibrin exudates, implying augmented alveolar damage as 
well as increased cellular recruitment in the lungs. 
 





Figure 3-17: Haematoxylin and Eosin stained brain section of an infected Casp1-/- mice (Case #78).  
Infected caspase-1-deficient mouse (Case #78) brain harvested at day 7 post-infection, showing focal 
lymphocytic infiltrates, (A) 200x magnification (B) 400x magnification. 2 out of 10 infected knock-out 
mice exhibited brain lymphatic infiltration. None was observed in the infected wild-type mice group. 
 





Figure 3-18: Haematoxylin and Eosin stained brain section of an infected Casp1-/- mice (Case #80).  
Infected caspase-1-deficient mouse (Case #80) brain harvested at day 7 post-infection, showing focus of 
lymphocytic infiltrates, centred around a small blood vessel (A) 200x magnification (B) 400x 
magnification. 2 out of 10 infected knock-out mice exhibited brain lymphatic infiltration. None was 
observed in the infected wild-type mice group. 
 
Interestingly, brain inflammation was observed in 2 of the 10 infected Casp1-/- mice at day 7 
post-infection. These 2 mice exhibited brain lymphocytic infiltration while none was observed 
in the infected wild-type or mock-infected control groups. Photomicrographs showing focal 
lymphocytic infiltrates of these 2 cases are shown in Figures 3-17 and 3-18 (A) – (B). 
 
3.2.10 Heart histopathological analysis 
 
Heart sections were also stained with haematoxylin and eosin and evaluated. No anomalies 
were detected in the hearts of infected and mock-infected mice of both genotypes at both 
days 3 and 7 post-infection.  
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Figure 3-19: Gel electrophoresis of viral NS1 PCR reaction from brain cDNA of infected wild-type and 
Casp1-/- mice.  
(+) indicates a positive control with NS1 PCR product generated from cDNA of an infected lung sample 
and (-) indicates a negative control derived from cDNA of a mock-infected lung sample. Top and bottom 
rows show products from the infected wild-type group (+/+) and infected Casp1 knock-out group (-/-), 
respectively. (A) Day 7 post-infection (B) Day 3 post-infection. 
360 bp 
360 bp 
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We suspect that the inflammation observed in the brain sections was most likely due to the 
influenza virus infection. Therefore, plaque assay was conducted to test for the presence of 
viable viruses in the brains of infected mice of both genotypes, especially in the Casp1-/- mice 
group in which brain inflammation was observed in 2 of the 10 infected mice. However, no 
plaques were observed in all samples. PCR was then conducted to verify the absence of virus 
in the brains at day 7 post-infection. No bands were observed in the PCR reaction targeting 
viral NS1 gene (Figure 3-19A). This confirmed the absence of virus in the brains of infected 
mice of both genotypes at day 7 post-infection. 
A PCR was then conducted on cDNA samples generated from RNA extracted at day 3 post-
infection. No viral NS1 bands observed in the day 3 post-infection samples either. Viral RNA 
was not detected in the brains of infected mice of both genotypes at day 3 post-infection 
(Figure 3-19B). 
Although brain inflammation was observed in the brains of infected caspase-1-deficient mice 
at day 7 post-infection, the presence of virus was not detected in the brains of infected mice 
of both genotypes at days 3 and 7 post-infection. 
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3.2.12 Protein expression of IL-1β in mice lungs as determined by Western blot 
 
A          1             2             3             4             5             6             7             8 







  ______________   ____________   _____________   ____________ 




   
   
 
Figure 3-20: Western blot analysis of IL-1β in lung homogenates at day 7 post-infection.  
(A) Western blots of IL-1β in lung homogenates of influenza virus infected (INF) wild-type (+/+) (Lanes 1 
& 2); and mock-infected (Mock) wild-type (Lanes 3 & 4) and infected caspase-1 knock-out (-/-) (Lanes 5 
& 6); and mock-infected Casp1-/- (Lanes 7 & 8) mice. (B) Densitometric analysis of IL-1β, expressed in 
fold-change of infected lung relative to mock-infected control lung. p31 represents the pro-IL-1β and 
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To study the functional effects of Caspase-1 deficiency, the IL-1β protein expression was 
probed by Western blotting. Pro-IL-1β protein expression increased significantly upon 
influenza infection in the lungs of both wild-type and caspase-1 knock-out mice at day 7 post-
infection. However, the difference in the increase of pro-IL-1β between genotypes was not 
significant (p = 0.13). There was a significant 3.5-fold increase (*p = 0.02) in mature cleaved IL-
1β (p17) protein expression in the lungs of infected wild-type mice as compared to the 
infected Casp1-/- mice (Figure 3-20A). Densitometric analysis of protein expression were 
normalised to the expression of β-actin loading controls and fold-change was taken as a ratio 
between infected and mock-infected samples (Figure 3-20B).  
In summary, mature cleaved IL-1β (p17) protein expression in the lungs was up-regulated 
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3.2.13 Gene expression of IL-1β in mice lungs as determined by real-time RT-PCR 
analysis 
 3 d.p.i. 7 d.p.i. 
 -/- +/+ -/- +/+ 
Fold-change of IL-1β mRNA 
levels in infected mice 
relative to mock-infected 
controls  
17.45 ± 1.73 39.40 ± 2.21 5.51 ± 1.72 8.80 ± 1.00 
p-value between infected 
genotypes 
*p < 0.01 *p < 0.01 
Figure 3-21: Real-time RT-PCR analysis of IL-1β mRNA levels, expressed in fold-change of infected group 
relative to mock-infected group.  
Mice were infected with 500 PFU of influenza A/PR/8/34 (H1N1) or mock-infected with PBS and were 
euthanized at day 3 post-infection (d.p.i.) and 7 d.p.i. Mock-infected wild-type (+/+) mice (n = 6); 
Infected (INF) wild-type (n = 10); Mock-infected Casp1-/- (-/-) (n = 6); Infected Casp1-/- (n = 10). Data 
expressed as mean ± SE. 
 
IL-1β can be transcriptionally regulated in a positive feedback manner. Relative gene 
expression of IL-1β was quantified by real-time PCR. At day 3 post-infection, IL-1β mRNA levels 
were increased significantly by 39.4-fold (*p<0.01) in wild-type mice upon influenza virus 
infection but to a lower extent of 17.5-fold (*p<0.01) in the Casp1-/- mice (Figure 3-21A). 
At day 7 post-infection, IL-1β mRNA levels were increased significantly by 8.8-fold (*p<0.01) in 
wild-type mice upon influenza virus infection but to a lower extent of 5.5-fold (*p<0.01) in the 
Casp1-/- mice (Figure 3-21B). 
Gene expression of IL-1β was up-regulated following an influenza infection of the lungs in 
both wild-type and caspase-1 knock-out mice. Infected Casp1-/- mice displayed a lower level of 
increase in IL-1β mRNA as compared to the infected wild-type group. IL-1β mRNA levels was 
more highly up-regulated due to virus infection at day 3 post-infection as compared to day 7 
post-infection. 
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Figure 3-22: Levels of neutralising antibodies against the influenza A/PR/8/34 (H1N1) in the sera of 
infected mice, collected at day 7 post-infection.  
Bars represent the geometric mean antibody titres. Mock-infected wild-type (+/+) mice (n = 6); Infected 
wild-type (n = 9); Mock-infected Casp1-/- (-/-) (n = 6); Infected Casp1-/- (n = 9). Data expressed as mean ± 
SE. 
 
Mice sera of infected and mock-infected from both genotypes, harvested at day 7 post-
infection, were subjected to a micro-neutralisation assay on MDCK cells so as to investigate 
any effect Caspase-1 deficiency may have on the adaptive immunity.  
No neutralizing antibodies were observed in the sera of mock-infected mice. A mean titre of < 
4 denoted the absence of neutralising antibodies. There was a significant increase in 
neutralising antibody titres between infected and mock-infected mice at day 7 post-infection 
(Casp1-/-, *p = 0.02; wild-type, *p = 0.03) (Figure 3-22). However, the difference in antibody 
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3.2.15 Total and differential cell counts in the bronchoalveolar lavage fluid 
 
 
Figure 3-23: Light microscopy images of BALF cytospin slides stained with Giemsa (400x magnification).  
Top left and right panels show BALF cells from infected wild-type mice at 3 days post-infection (d.p.i.) 
and 6 d.p.i., respectively. Bottom panel represents BALF collected from a mock-infected mouse. 
Macrophages (Black arrow heads); Neutrophils (White block arrows); Lymphocytes (White triangles) 
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Figure 3-24: Differential cell counts of bronchoalveolar lavage fluid (BALF) cells following an influenza 
infection.  
Wild-type (+/+) (White bars) (n = 3) and Casp1-/- (-/-) (Black bars) (n = 3) were infected (INF) and BALF 
collected at 3 and 6 days post-infection (d.p.i.). BALF cells were cytocentrifuged, stained with Giemsa 
and counted under light microscope. (A) Total cell counts enumerated by trypan blue assay. Numbers 
of neutrophils, macrophages and lymphocytes at (B) 3 d.p.i. and (C) 6 d.p.i..  
  
To examine the differences in immune cell recruitment to the lungs of infected Caspase-1 
knockout mice, bronchoalveolar lavage fluid cells were harvested at days 3 and 6 post-
infection and stained with Giemsa. Cells were counted based on visible differences in cell 
morphology observed under a light microscope at 400x magnification (Figure 3-27). Total cell 
counts were determined by trypan blue viability count.  
Cellular infiltrates into lung airway spaces increased upon influenza infection and was more 
pronounced at day 6 as compared to day 3 post-infection. There was increased cellular 
infiltration in the lung airways of the infected Casp1 knock-out mice as compared to its wild-
type (Figure 3-28A). At day 3 post-infection, there was an average of 3.4 x 106 cells in the lung 
airways of Casp1-/- and 8.6 x 105 cells in wild-type mice and at day 6 post-infection, 2.0 x 107 
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At both days 3 and 6 post-infection, neutrophils represent the main bulk of infiltrates, 
followed by macrophages. Lymphocytes were more noticeable at day 6 post-infection (Figure 
3-28 B & C). 
There was increased cellular infiltration in the lung airways of the infected Casp1 knock-out 
mice as compared to its wild-type at both days 3 and 6 post-infection. 
 
3.2.16 Protein concentrations in lung airways following an influenza infection 
 
 
Figure 3-25: Protein concentration (mg/ml) in the bronchoalveolar lavage fluids of mock-infected and 
infected mice.  
BALF was collected at 1, 3 and 6 days post-infection (d.p.i.) and protein concentration estimated by 
Lowry HS assay. Mock-infected (Mock) wild-type (+/+; White bars) mice (n = 6); Infected wild-type (n = 
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As the lung microvascular injury and protein leakage into the alveolar spaces in the infected 
cases may be reflected in increased protein concentrations in bronchoalveolar lavage fluid 
(BALF), protein concentrations in BALF were estimated by the Bio-Rad protein DC assay. 
Elevated protein concentrations were observed in mice infected with 500 PFU of influenza 
A/PR/8/34 (H1N1) virus at day 6 post-infection as compared to the mock-infected groups of 
both genotypes (*p < 0.01) (Figure 3-29). Protein concentration remains low of less than 1 
mg/ml in the lung airways of mock-infected mice and at days 1 and 3 post-infection.  
At day 6 post-infection, higher concentration of protein was observed in the BALF of infected 
Casp1-/- mice (3.5 mg/ml), as compared to the infected wild-type (2.5 mg/ml) (p = 0.06) (Figure 
3-29). There was no difference in protein concentrations between infected genotypes at days 
1 and 3 as well as in mock-infection.  
Higher level of proteins measured in BALF indicates a more severe microvascular injury and 
protein leakage in the lung airways of infected Casp1-/- mice as compared to wild-type 
counterparts at day 6 post-infection. 
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3.2.17 Cytokine expression in bronchoalveolar lavage fluid of infection mice as 























































































































































































































































































































Figure 3-26: Cytokine expression in the bronchoalveolar lavage fluid of mice at 1, 3 and 6 days post-
infection (dpi) with 500 PFU of influenza A/PR/8/34 (H1N1) as determined by Bio-Plex PROTM Cytokine 
Assay. 
Mock-infected (Mock) wild-type (+/+) (n = 4); Mock-infected Casp1-/- (-/-) (n = 4); Infected wild-type (n = 
4); Infected Casp1-/- (n = 4). (A) – (P) IL-1α; IL-1β; IL-5; IL-6; IL-9; IL-10; IL-12(p40); IL-12(p70); IL-13; GM-
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Cytokine expressions in the airways from mock-infected and infected mice were evaluated by 
Bio-Plex PROTM Cytokine Assay. BALF was harvested from infected mice of both genotypes at 
days 1, 3 and 6 post-infection and from mock-infected mice at day 6 post-infection. Of the 
cytokines analysed, statistical difference between the infected Casp1-/- and Casp1+/+ were only 
detected at day 6 post-infection in the levels of monocyte chemoattractant protein (MCP)-1 
(*p=0.01) (Figure 3-30L), macrophage inflammatory protein (MIP)-1α (*p=0.05) (Figure 3-
30M), MIP-1β (*p=0.02) (Figure 3-30N) and RANTES (regulated on activation, normal T-cell 
expressed and secreted) (*p = 0.01) (Figure 3-30O). The difference in the levels of interferon 
(IFN)-γ (p = 0.06) (Figure 3-30K) was nearly significant.  
As compared to the infected wild-type mice, elevated levels of MCP-1, MIP-1α, MIP-1β, 
RANTES and IFN-γ were detected in the lung airways of infected caspase-1-deficient mice at 
day 6 post-infection. 
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3.2.18 Protein expression of IL-1β in bronchoalveolar lavage fluid (BALF) as 
determined by Western blot 
 
A         1              2             3             4             5             6             7              8   
 p31(pro-IL-1β)  
 
p17  
(mature IL-1β)  
______________   ____________   _____________   ____________ 
     +/+  Infected           +/+  Mock           -/-  Infected           -/-  Mock 
   
   
 
Figure 3-27: Western blot analysis of IL-1β in bronchoalveolar lavage fluid (BALF) at day 6 post-
infection.  
(A) Western blots of IL-1β in BALF of influenza virus infected (INF) wild-type (+/+) (Lanes 1 & 2); and 
mock-infected (Mock) wild-type (Lanes 3 & 4) and infected caspase-1 knock-out (-/-) (Lanes 5 & 6); and 
mock-infected Casp1-/- (Lanes 7 & 8) mice. (B) Densitometric analysis of IL-1β. P31 represents the pro-
IL-1β and p17 represents the mature, cleaved IL-1β bands. 
 
To examine the levels of IL-1β in the lung airways of Caspase-1 deficient mice, BALF samples 
were subjected to Western blotting. Pro-IL-1β (p31) protein expression increased significantly 
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3-31A). However, the difference in the increase of pro-IL-1β between genotypes was not 
significant (p = 0.19). Protein expression of mature IL-1β (p17) in BALF was also significantly 
up-regulated upon infection. This increase was lower in infected Casp1-/- mice than in wild-
type mice but the difference between genotypes did not reach significance (p = 0.07) (Figure 
3-31B).  
The levels of IL-1β secreted into the airways were not significantly different between the 
infected Casp1-/- and wild-type mice. 
 
3.2.19 Guava Technologies ViaCount assay on bronchoalveolar lavage fluid 
harvested from infected mice 
 
 
Figure 3-28: Percentage of viable, mid-apoptotic, dead cells in bronchoalveolar lavage fluid as 
determined by Guava ViaCount assay.  
Wild-type (+/+) (n = 6) and Casp1-/- (-/-) (n = 6) were infected (INF) with 500 PFU of influenza A/PR/8/34 
(H1N1). Bronchoalveolar lavage fluid cells were harvested at day 6 post-infection. Data expressed as 
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The Guava Technologies ViaCount assay was used to measure the percentage of viable, mid-
apoptotic and dead cells in bronchoalveolar lavage fluid (BALF) of mice infected with influenza 
A/PR/8/34 (H1N1) (500 PFU). At day 6 post-infection, there were lower percentage of viable 
and higher percentages of dead and mid-apoptotic BALF cells in the lungs of infected Casp1-/- 
than infected wild-type. The BALF cells in the infected Casp1-/- mice had an average of 15.2% 
lower in viable cells, 4.1% higher in mid-apoptotic cells and 11% higher in dead cells as 
compared to the infected wild-type mice (Figure 3-32).  
At day 6 post-infection, lower percentage of viable and higher percentages of dead and mid-
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3.2.20 Terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) assay 
on lung sections of mice euthanized at day 7 post-infection 
 














Figure 3-29: Representative light microscope images of mice lung sections evaluated by TUNEL assay at 
day 7 post-infection.  
(A) Mock-infected Casp1-/- (B) Mock-infected wild-type (C) Infected Casp1-/- (D) Infected wild-type at 
200x magnification. 
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Figure 3-30: Average number of TUNEL-positive cells in the lung sections of infection caspase-1 knock-
out and wild-type mice.  
Wild-type (+/+) (n = 6) and Casp1-/- (-/-) (n = 6) were infected (INF) with 500 PFU of influenza A/PR/8/34 
(H1N1) and lungs were harvested at day 7 post-infection. 
 
The in situ Cell Death Detection Kit, POD (Roche®) was used to detect DNA strand breaks in 
apoptotic cells at single cell level. Lung sections of infected wild-type and Casp1-/- mice 
sacrificed at day 7 post-infection were evaluated for TUNEL-positive cells induced by influenza 
virus infection (Figure 3-33). Total averages of 23.7 and 15.3 TUNEL-positive cells were 
enumerated per field of lung section of infected Casp1-/- and wild-type mice, respectively. The 
difference was significant (*p = 0.02) (Figure 3-34).  
The caspase-1-deficient displayed a higher amount of apoptotic cells upon influenza infection 
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3.2.21 Microarray analysis of lung transcriptome of infected mice at 7 days post-
infection 
 
In defining the role of caspase-1 in signalling host gene expression, a comparison of lung 
transcriptional changes between influenza A infected Casp1-/- and wild-type mice, a gene 
expression microarray was performed on the RNA extracted from lungs of infected and mock-
infected, wild-type and Casp1-/- mice sacrificed at day 7 post-infection. RNA from 3 mice per 
experimental group were pooled and used for each array in triplicates. The parameters and 







A two-way ANOVA analysis with Benjamini Hochberg False Discovery Rate multiple correction 
was performed using the GeneSpring GX 11.5 software. A Venn diagram displaying the 9714 
entities out of 23438 satisfied corrected p-value cut-off of 0.05 is shown in Figure 3-23. 
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Figure 3-31: Venn diagram generated from a 2-way ANOVA analysis with Benjamini Hochberg False 
Discovery Rate multiple correction on GeneSpring GX 11.  
Venn diagram illustrates the overlap of the number of significant genes due to infection (Red), 
significant genes due to genotype (Green) and significant genes due to the interaction effect of 
genotype and infection (Blue). Mock-infected (Mock); Infected (INF); Wild-type (+/+); Caspase-1 knock-
out (-/-). 
  
From the two-way Analysis of Variance (ANOVA) analysis, there were 9712 significant genes 
due solely to the virus infection and 2 genes which were significant due to genotype and 
infection. These 2 genes, namely Casp1 and Casp4, were differentially expressed between the 
2 genotypes and also upon virus infection. Entities, or genes, which passed the significance 
analysis was then evaluated for fold-change. Fold-change was calculated as a ratio of 
Condition 1 is to Condition 2.  
A fold-change of ≥ 1.5 was applied to the entity lists generated by the ANOVA analysis. The 2 
genes in the union of Genotype and Infection had fold-changes of more than 1.5-fold (Venn 
diagram – Olive green). There was a 5.9-fold up-regulation in Casp1 and a 3.8-fold up-
regulation in Casp4 gene expression in the infected wild-type as compared to mock-infected 
mice. Influenza virus induced the up-regulation of Casp1 and Casp4 gene expression.  
Significant 
genes due to 
infection 
Significant genes 
due to infection 
and genotype: 
Casp1 & Casp4 
Significant 




genes due to 
genotype 
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The 9714 entities which satisfied the statistical ANOVA analysis p-value cut-off of 0.05 (Venn 
diagram – Green) were then subjected to fold-change analysis of cut-off 1.5. The pair of 
conditions selected for fold-change analysis were [-/-, Infected] versus [+/+, Infected]. There 
were 75 out of 9714 entities which satisfied the fold-change cut-off ≥ 1.5 (Figure 3-24). This 
entity list, containing genes differentially expressed between the infected genotypes, was 
then exported into the Ingenuity Pathway Analysis (IPA®) (Ingenuity Systems, Inc.) for further 
data analysis. Specifically, in the infected knock-out mice, Casp1 and Casp4 were down-





Symbol Entrez Gene Name 
1.85 NM_011073.2 up PRF1 perforin 1 (pore forming protein) 
1.79 NM_008519.1 up LTB4R leukotriene B4 receptor 
1.77 NM_008337.1 up IFNG interferon, gamma 
1.77 NM_014194.1 up KLRA7 killer cell lectin-like receptor, subfamily A, 
member 7 
1.71 NM_021443.1 up CCL8 chemokine (C-C motif) ligand 8 
1.71 NM_024253.3 up NKG7 natural killer cell group 7 sequence 
1.70 NM_008987.2 up PTX3 pentraxin 3, long 
1.63 NM_008987.2 up PTX3 pentraxin 3, long 
1.62 NM_144544.1 up 2210407C1
8RIK 
RIKEN cDNA 2210407C18 gene 
1.62 NM_144538.1 up RAB3IL1 RAB3A interacting protein (rabin3)-like 1 
1.61 NM_008337.1 up IFNG interferon, gamma 
1.60 NM_183103.1 up PRSS46 protease, serine, 46 
1.56 NM_053153.1 up KLRA18 killer cell lectin-like receptor, subfamily A, 
member 18 
1.56 NM_013652.1 up CCL4 chemokine (C-C motif) ligand 4 
1.55 NM_008768.1 up ORM1 orosomucoid 1 
1.54 NM_009852.1 up CD6 CD6 molecule 
1.54 NM_009852.1 up CD6 CD6 molecule 
1.54 NM_009985.2 up CTSW cathepsin W 
1.54 NM_017480.1 up ICOS inducible T-cell co-stimulator 
1.54 NM_010649.2 up KLRA4 killer cell lectin-like receptor, subfamily A, 
member 4 
1.53 NM_013487.1 up CD3D CD3d molecule, delta (CD3-TCR complex) 
1.52 NM_011073.2 up PRF1 perforin 1 (pore forming protein) 
1.52 NM_021309 up SH2D2A SH2 domain containing 2A 
1.51 NM_026835.1 up MS4A6D membrane-spanning 4-domains, subfamily A, 
member 6D 
1.50 NM_172947 up LSM12 LSM12 homolog (S. cerevisiae) 
     





Symbol Entrez Gene Name 
-22.68 NM_007609.1 down CASP4 caspase 4, apoptosis-related cysteine peptidase 
-3.89 NM_009807.1 down CASP1 caspase 1, apoptosis-related cysteine peptidase 
(interleukin 1, beta, convertase) 
-3.14 NM_007751.1 down COX8B cytochrome c oxidase, subunit VIIIb 
-3.01 NM_008469.1 down KRT15 keratin 15 
-2.84 NM_016958.1 down KRT14 keratin 14 
-2.32 NM_016798.2 down PDLIM3 PDZ and LIM domain 3 
-2.19 NM_010742.1 down LY6D lymphocyte antigen 6 complex, locus D 
-2.08 NM_016798.2 down PDLIM3 PDZ and LIM domain 3 
-1.98 NM_030127.1 down HTRA3 HtrA serine peptidase 3 
-1.95 NM_010742.1 down LY6D lymphocyte antigen 6 complex, locus D 
-1.93 NM_178405.2 down ATP1A2 ATPase, Na+/K+ transporting, alpha 2 polypeptide 
-1.86 NM_019718.2 down ARL3 ADP-ribosylation factor-like 3 
-1.85 NM_007436.1 down ALDH3A1 aldehyde dehydrogenase 3 family, member A1 
-1.83 NM_009675.1 down AOC3 amine oxidase, copper containing 3 (vascular 
adhesion protein 1) 
-1.82 NM_009522.1 down WNT3A wingless-type MMTV integration site family, 
member 3A 
-1.81 NM_009696.2 down APOE apolipoprotein E 
-1.74 NM_021391.2 down PPP1R1A protein phosphatase 1, regulatory (inhibitor) 
subunit 1A 
-1.74 NM_008521.1 down LTC4S leukotriene C4 synthase 
-1.73 NM_021514.2 down PFKM phosphofructokinase, muscle 
-1.73 NM_175316.2 down SLCO2B1 solute carrier organic anion transporter family, 
member 2B1 
-1.72 NM_007812.1 down CYP2A6 cytochrome P450, family 2, subfamily A, 
polypeptide 6 
-1.70 NM_207663.2 down SYNM synemin, intermediate filament protein 
-1.69 NM_007732.1 down COL17A1 collagen, type XVII, alpha 1 
-1.69 NM_010856.2 down MYH6 myosin, heavy chain 6, cardiac muscle, alpha 
-1.69 NM_007812.1 down CYP2A6 cytochrome P450, family 2, subfamily A, 
polypeptide 6 
-1.68 NM_013648.4 down RTN2 reticulon 2 
-1.65 NM_144547.1 down AMHR2 anti-Mullerian hormone receptor, type II 
-1.61 NM_009943.1 down COX6A2 cytochrome c oxidase subunit VIa polypeptide 2 
-1.61 NM_175309.3 down UPK3B uroplakin 3B 
-1.60 NM_144930.1 down AU018778 expressed sequence AU018778 
-1.59 NM_008557.1 down FXYD3 FXYD domain containing ion transport regulator 3 
-1.58 NM_027222.1 down MGC29506 plasma cell-induced ER protein 1 
-1.58 NM_016974.1 down DBP D site of albumin promoter (albumin D-box) 
binding protein 
-1.57 NM_008256.2 down HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 
(mitochondrial) 
-1.57 NM_011111.2 down SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), 
member 2 
-1.57 NM_011136.1 down POU2AF1 POU class 2 associating factor 1 
-1.57 NM_010174.1 down FABP3 fatty acid binding protein 3, muscle and heart 
(mammary-derived growth inhibitor) 
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-1.55 NM_011123.1 down PLP1 proteolipid protein 1 
-1.54 XM_484075 down RAPGEFL1 Rap guanine nucleotide exchange factor (GEF)-like 
1 
-1.54 NM_011659 down TNFRSF4 tumor necrosis factor receptor superfamily, 
member 4 
-1.53 NM_011359.1 down SFTPC surfactant protein C 
-1.53 NM_198885.2 down SCXA scleraxis homolog A (mouse) 
-1.53 NM_00108110
6.1 
down CYTL1 cytokine-like 1 
-1.53 NM_010045.1 down DARC Duffy blood group, chemokine receptor 
-1.53 NM_015744.1 down ENPP2 ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
-1.51 NM_032541.1 down HAMP hepcidin antimicrobial peptide 
-1.51 NM_175456 down ABRA actin-binding Rho activating protein 
-1.51 NM_021883.1 down TMOD1 tropomodulin 1 
-1.50 NM_016771.2 down SULT1D1 sulfotransferase family 1D, member 1 
-1.50 XM_129390.2 down FAIM3 Fas apoptotic inhibitory molecule 3 
Figure 3-32: List of 75 entities which satisfied the 2-way ANOVA analysis of corrected p-value ≤ 0.05 and 
fold-change cut-off by GeneSpring GX 11.5 
 
The genes which were differentially expressed (ANOVA p<0.05) with fold-change of at least 
1.5-fold higher or lower in the infected knock-out group compared to the infected wild-type 
group are shown in Figure 3-24. Genes which were up-regulated in the infected Casp1-/- mice 
were involved in immune and inflammatory response include chemokine (C-C motif) ligands 
CCL8 (or MCP-2) and CCL4 (or MIP-1β), IFN-γ, ICOS and cytolysis or killing such as perforin 
(PRF-1), killer cell lectin-like receptor, subfamily A, members (KLRA4, KLRA7, KLRA18) and 
natural killer cell group 7 sequence (NKG7). Gene expression of leukotriene B4 receptor 
(LTB4R) and long pentraxin (PTX3) were also up-regulated in the infected Casp1-/- mice. 
Genes which were down-regulated participate in structural integrity such as keratin (KRT14 
and KRT15), PDZ and LIM domain 3 (PDLIM3), synemin (SYMN), collagen, type XVII, alpha 1 
(COL17A1), tropomodulin-1 (TMOD1) and mitochondrial respiratory chain and energy 
transduction such as cytochrome c oxidases (subunit VIIIb COX8B) and (subunit VIa 
polypeptide 2 COX6A2), and ATPases such as ATPase, Na+/K+ transporting, alpha 2 
polypeptide (ATP1A2) and myosin, heavy chain 6, cardiac muscle, alpha (MYH6). 
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From Ingenuity Pathway Analysis, the top associated network was “Inflammatory response, 
Antimicrobial response, Cell-to-cell signalling and interaction” as depicted in Figure 3-25. 
 
Figure 3-33: Top network generated by Ingenuity Pathway Analysis from the entity list generated from 
a 2-way ANOVA analysis of p-value ≤ 0.05 and fold -change ≥ 1.5 between [ -/-, Infected] and [+/+, 
Infected].  
Genes which are up-regulated in the [-/-, Infected] relative to [+/+, Infected] group are indicated in red, 
while those which are down-regulated are in green. Values indicate fold-change = [-/-, Infected] / [+/+, 
Infected]. 
 
From the summary generated from data analysis using the Ingenuity Pathway Analysis, top 
diseases disorders include “Cancer, Inflammatory disease, Immunological disease and 
Inflammatory response” while top molecular and cellular functions include “Cellular 
movement and Cell-to-cell signalling and interaction”. Top physiological system development 
and function include “Immune cell trafficking and Cell-mediated immune response”, to 
highlight a few.  
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3.2.22 Gene expression of Casp4 in mice lungs as determined by real-time RT-PCR 
analysis 
 7 d.p.i. 
 -/- +/+ 
Fold-change of Caspase-4 mRNA levels in 
infected mice relative to mock-infected 
controls  
2.17 ± 2.18 4.41 ± 1.26 
p-value between infected genotypes *p < 0.01 
Figure 3-34: Real-time RT-PCR analysis of Casp4 levels, expressed in fold-change of infected group 
relative to mock-infected group.  
Mice were infected with 500 PFU of influenza A/PR/8/34 (H1N1) or mock-infected with PBS and were 
euthanized at (A) day 3 post-infection (B) day 7 post-infection. Mock-infected wild-type (+/+) mice (n = 
6); Infected wild-type (n = 10); Mock-infected Casp1-/- (-/-) (n = 6); Infected Casp1-/- (n = 10). Data 
expressed as mean ± SE. 
 
Real-time PCR was performed to verify the mRNA expression data obtained from the 
microarray analysis. At day 7 post-infection, caspase-4 mRNA levels were increased by 4.4-fold 
(*p = 0.01) in infected wild-type mice but to a lower extent of 2.2-fold (*p = 0.05) in the 
infected Casp1 knock-out mice relative to their mock-infected groups (Figure 3-26). There was 
a 3-fold (*p < 0.01) down-regulation in caspase-4 mRNA levels in the infected Casp1-/- mice as 
compared to its infected wild-type. 
Caspase-4 mRNA was up-regulated upon influenza virus infection but to a lesser extent in the 
infected lungs of Casp1-/- mice. This trend corresponds to the trend seen in the microarray 
analysis thus verifying the microarray data.  
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Figure 3-35: Nucleotide sequence alignment of Caspase-1 microarray probe with Caspase-4. 
The nucleotide sequence of the Caspase-1 microarray probe was aligned with Mus musculus Caspase-4 
using the Nucleotide Basic Local Alignment Search Tool (BLASTn) program. 
 
Since Casp4 showed the greatest negative fold-change instead of Casp1, we were interested 
to know the relationship between Casp1 and Casp4. Upon query of the Casp1 Illumina 
BeadChip probe sequence in the nucleotide Basic Local Alignment Search Tool (BLASTn) 
database, we found that the probe used to identify Casp1 gene expression was identical to a 
portion of the Mus musculus Caspase-4 nucleotide sequence. Lakshmanan, and Porter (2007) 
stated that both caspase-1 and caspase-4 belong to the family of “inflammatory caspases”. 
Therefore, the caspase-4 probe in the mouse could actually be detecting both caspase-4 as 
well as caspase-1. Hence, our microarray data further verifies our mice genotyping. 
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3.2.23 Evaluation of in vivo experiments 
 
Our study investigates the role of caspase-1 in pulmonary inflammation and cell death and its 
contribution to lung pathology following influenza virus infection in mice. To this end, we have 
infected wild-type and caspase-1-deficient (Casp1-/-) mice with 500 PFU of influenza A/Puerto 
Rico/8/34 (H1N1) virus via the intra-tracheal route. From a pilot study, there was an indication 
that aged mice deficient in caspase-1 were more susceptible to influenza infection. Whereas 
in 8 to 10 week-old mice, the difference in weight loss between the infected genotypes was 
not significant.  
Caspase-1 was up-regulated at mRNA and protein levels in the lungs of influenza infected 
wild-type mice. The virus titres observed at day 3 was higher than at day 7 post-infection. 
Virus titre was 2-fold higher in the lungs of the caspase-1-deficient mice at day 7 post-
infection relative to its wild-type.  
Histopathologic analysis revealed that the infected caspase-1 knock-out mice fared 
significantly worse than the infected wild-type at day 7 post-infection and that caspase-1-
deficient mice exhibited increased intra-alveolar fibrin exudates as well as increased cellular 
recruitment in the lungs. Interestingly, brain inflammation, indicating mild encephalitis, was 
detected in 2 of the 10 infected caspase-1-deficient mice that was absent in the wild-type 
counterparts at day 7 post-infection. However, the presence of virus was not detected in the 
brains of infected mice of both genotypes at days 3 and 7 post-infection. Influenza infection 
here did not induce pathology in the heart. 
Both gene and mature cleaved IL-1β (p17) protein expressions were up-regulated following an 
influenza infection of the lungs in both wild-type and caspase-1 knock-out mice but to a lower 
extent in the infected Casp1-/- mice than the infected wild-type group. IL-1β mRNA levels was 
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more highly up-regulated due to virus infection at day 3 post-infection as compared to day 7 
post-infection. Neutralising antibodies were present in the sera of infected mice at day 7 post-
infection. However, the difference in antibody titres between genotypes was not significant.  
There was increased cellular infiltration in the BALF of the infected Casp1-/- mice as compared 
to its wild-type at both days 3 and 6 post-infection, with neutrophils comprising the bulk of 
infiltrates. Furthermore, higher protein concentrations measured in BALF indicates a more 
severe microvascular injury and protein leakage in the lung airways of infected Casp1-/- mice 
as compared to wild-type counterparts at day 6 post-infection. 
Lung damage was also assessed by cell death assays. At day 6 post-infection, lower 
percentage of viable and higher percentages of dead and mid-apoptotic BALF cells were 
observed in the lungs of infected Casp1-/- than infected wild-type mice, as determined by 
Guava ViaCount assay. The infected Casp1-/- mice also displayed a higher amount of TUNEL-
positive apoptotic in lung sections as compared to their wild-type counterparts. 
There were elevated levels of MCP-1, MIP-1α, MIP-1β, RANTES and IFN-γ detected in the BALF 
infected Casp1-/- mice at day 6 post-infection as compared to wild-type mice. The levels of IL-
1β secreted into the airways at day 6 post-infection were not significantly different between 
the infected Casp1-/- and wild-type mice as shown in the Bio-Plex PROTM cytokine assay and 
Western blot on BALF. 
In the lung transcriptomic analysis, the ANOVA revealed that Caspase-1 and Caspase-4 are the 
genes which had differential expressions due to both infection and genotype effects. Caspase-
4 gene expression was up-regulated upon influenza virus infection but to a lesser extent in the 
infected lungs of Casp1-/- mice, as verified by real-time RT-PCR. The microarray analysis 
revealed that, in comparison to the infected wild-type mice, genes which were up-regulated in 
the infected Casp1-/- mice were involved in immune and inflammatory response and cytolysis 
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while those genes which were down-regulated participate in structural integrity, 
mitochondrial respiration and energy transduction.  
In conclusion, there is evidence to show that caspase-1-deficient mice are more susceptible to 
a high dose of 500 PFU of influenza A/Puerto Rico/8/34 (H1N1) virus infection. Caspase-1-
deficient mice suffered augmented lung damage. A more in-depth discussion is presented in 
Chapter 4. 
  
 119  
3.3 A STUDY ON CASPASE INHIBITORS AND A p53 INHIBITOR IN VITRO 
 
Since excessive cell death due to influenza virus infection causes lung damage, we initially 
postulated that by inhibiting cell death, by means of caspase and p53 inhibitors, may be an 
avenue in limiting lung damage. A study on cell death inhibitors was conducted to investigate 
the effect of introducing these peptides in an influenza infection of MDCK cells, in vitro.  
 
3.3.1 MTS cell viability assay 
 
 
Figure 3-36: Proportion (%) of viable, infected MDCK cells upon treatment with inhibitors, relative to 
infected DMSO control.  
p-values were derived from the comparisons between treated, infected cells and the infected cells 
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To study the effect of peptide inhibitors z-VAD-FMK, z-LEVD-FMK and pifithrin-α on cell death, 
infected MDCK cells were treated with varying amounts of inhibitors, namely at 10, 25 and 50 
μM concentrations of z-VAD-FMK, z-LEVD-FMK and pifithrin-α. Following a 24-hour infection, 
cells were assayed with 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) for cell viability. The conversion of MTS into 
aqueous, soluble formazan is accomplished by dehydrogenase enzymes found in metabolically 
active cells. The quantity of formazan product as measured by the amount of 490 nm 
absorbance is directly proportional to the number of living cells in culture.  
The largest increase in cell viability of infected MDCK cells occurred at the concentration of 50 
μM of inhibitors (Figure 3-36). The p values (p = 0.10, 0.13, 0.08) obtained in this experiment 
when comparing z-VAD-FMK, z-LEVD-FMK and pifithrin-α relative to infected dimethyl 
sulphoxide (DMSO) control were the closest to significance (p ≤ 0.05).  Hence, this 
concentration was selected for subsequent experiments. The concentration of 50 μM of z-
VAD-FMK was also used in previous literature (Coleman, Sahai et al. 2001).  
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3.3.2 Cytopathic effect in MDCK cells 24 hours post-treatment 
 














Figure 3-37: Light microscope images of MDCK cells pre-treated with 50 μM of inhibitors, z-VAD-FMK, z-
LEVD-FMK and pifithrin-α and infected with influenza A/PR/8/34 (H1N1) for 24 hours. 
 Uninfected, treated controls (Left panel) and treated, infected samples (Right panel). 
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MDCK cells were pre-treated with inhibitors for 30 minutes before a 24 hour infection at 0.5 
multiplicity of infection (m.o.i.). Cells were observed under 100x magnification of a light 
microscope at 24 hours post-treatment and infection. Cytopathic effect (CPE) was observed in 
the influenza infected samples (Figure 3-35). Visually, out of the 3 treated samples, infected 
cells treated with 50 μM z-VAD-FMK exhibited the least CPE. Cell monolayer remained intact. 
Abundant growth of MDCK was seen in the uninfected, z-VAD-FMK treated cells. Infected 
MDCK treated with 50 μM z-LEVD-FMK tend to display elongated morphology and smaller, 
light-reflective dead cells appear to clump together. CPE was pronounced and empty spaces 
present at the base of the well, denoting the detachment of adherent cell layer. As for 
pifithrin-α treated, infected cells, cell monolayer was still present, although much empty 
spaces were seen. Dead cells were seen floating in the wells.  
From visual observations of infected, treated cells, inhibitor z-VAD-FMK appeared to be the 
most promising inhibitor of cell death.  
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3.3.3 Guava ViaCount assay 
 
Figure 3-38: Proportion of viable and dead cells in infected MDCK cells treated with 50 μM of inhibitors 
for 24 hours, as determined by Guava ViaCount assay.  
Each bar represents a percentage of total cells which comprised of viable and dead cells. The averages 
of each treatment, namely z-VAD-FMK, z-LEVD-FMK or pifithrin-α were compared with the infected and 
solvent-treated (Virus-DMSO) control. P-values represent the comparisons between each treatment 
and the Virus-DMSO control. 
 
MDCK cells were pre-treated with 50 μM of z-VAD-FMK, a pan-caspase inhibitor, z-LEVD-FMK, 
a caspase-1 inhibitor and pifithrin-α, a p53 inhibitor, for 30 minutes prior to a 24-hour 
infection with influenza A/PR/8/34 (H1N1). Adherent cells were detached, pooled with the 
cells in the culture fluid and subjected to Guava ViaCount assay.  
A decrease in the percentage of dead cells was observed in the infected MDCK cells treated 
with z-VAD-FMK (p = 0.09) as compared to the solvent (DMSO)-treated, infected samples 
(Figure 3-37). Pan-caspase inhibitor z-VAD-FMK could partially inhibit cell death of infected 
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Figure 3-39: Light microscopy images of TUNEL assay on MDCK cells treated with 50 μM of inhibitors 
followed by 24 hours infection with influenza A/PR/8/34 (H1N1). 
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Figure 3-40: Average number of TUNEL-positive cells in MDCK treated with 50 μM of inhibitors followed 
by 24 hours infection with influenza A/PR/8/34 (H1N1). 
 
MDCK cells were grown to confluency on coverslips, treated with 50 μM of inhibitors and 
infected with influenza A/PR/8/34 (H1N1) at a multiplicity of infection of 0.5 for 24 hours. 
Cells were fixed in 4% paraformaldehyde. TUNEL assay was performed using the in situ Cell 
Death Detection Kit, POD (Roche® Applied Science, Mannheim, Germany) for quantification of 
apoptosis at single cell level and this was analysed by light microscopy (Figure 3-38).  
Infected MDCK cells treated with 50 μM z-VAD-FMK, a pan-caspase inhibitor, and the p53 
inhibitor, pifithrin-α, markedly decreased the average number of TUNEL-positive cells per field 
(*p < 0.01) as compared to the infected MDCK cells treated with solvent DMSO (Figure 3-39).  
Inhibitors z-VAD-FMK and pifithrin-α were able to inhibit apoptosis of infected MDCK cells at a 
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Figure 3-41: Virus titres (PFU/ml) derived from MDCK cells treated with 50 μM inhibitors and infected 
for 24 hours. 
Virus titres were determined by plaque assay on the supernatants of treated, infected cells. P-values 
were derived from the comparisons between each treatment and the Virus-DMSO control. 
 
MDCK cells were pre-treated with 50 μM of z-VAD-FMK, z-LEVD-FMK and pifithrin-α for 30 
minutes prior to a 24-hour infection with influenza A/PR/8/34 (H1N1). Virus titres were 
determined by plaque assay on the supernatant of treated and infected cells. There was no 

























 127  
3.3.6 Evaluation of cell death inhibitory study 
 
In summary, out of the 3 inhibitors used, namely, z-VAD-FMK, z-LEVD-FMK and pifithrin-α, 
inhibitor z-VAD-FMK appeared to be the most promising inhibitor of cell death through visual 
observation under the light microscope. This was confirmed by the MTS cell viability where z-
VAD-FMK, at 50 μM, showed the highest increase in cell viability of infected, treated cells. 
When cell death was assayed by the Guava Technologies ViaCount assay, pan-caspase 
inhibitor z-VAD-FMK was able to lower the amount of dead cells as compared to the infected 
solvent-treated control. From the TUNEL assay, 50 μM of z-VAD-FMK and pifithrin-α were able 
to decrease the number of TUNEL-positive (or apoptotic) cells in cells infected with influenza 
A/PR/8/34. There was no significant difference in virus titres between the inhibitors treated 
and untreated, infected DMSO controls. The inhibitors did not affect virus replication directly. 
These inhibitors are unlikely candidates for therapeutic drugs against lung damage. Inhibiting 
caspases may lead to a worse outcome since cell death could represent a means of limiting 
overt inflammation. 
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4 DISCUSSION 
 
4.1 Influenza as a significant public health concern  
 
In the past century alone, influenza viruses have already been responsible for 4 major 
pandemics, with the pandemic of 1918 causing deaths in excess of 50 million worldwide 
(Taubenberger and Morens 2006). Although the latest 2009 H1N1 pandemic caused far less 
deaths, it still posed a significant health burden to human populations (Viboud, Miller et al. 
2010). Globally, widespread outbreaks of seasonal influenza are estimated to cause 250,000 
to 500,000 deaths annually. Each year in the United States alone, on average, 5% to 20% of 
the population is infected with influenza and approximately 36,000 deaths from complications 
of influenza virus infection with 90% of these deaths in the elderly population aged more than 
65 years of age (Thompson, Shay et al. 2004).  
Influenza pneumonitis has been a considerable concern as it is associated with substantial 
morbidity and mortality. Inflammation of the lung could lead to acute lung injury (ALI) or in 
more severe cases, acute respiratory distress syndrome (ARDS) (Yokoyama, Tsushima et al. 
2010). The role of caspase-1 in converting pro-interleukin-1β into its bioactive mature form 
has been long established. In recent years, the pro-inflammatory caspase-1 has been in the 
limelight for its role in the inflammasome, a macromolecular platform which brings together 
the nucleotide-binding domain and leucine-rich-repeat-containing (NLR) family of pattern-
recognition receptors, activates caspase-1 which in turn mediates host immunity. In this 
study, we investigated the role of caspase-1 in pulmonary inflammation and cell death and its 
contribution to lung pathology following influenza A virus infection in an in vivo murine model 
so as to better understand the virus-host interaction.  
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4.2 Expression of caspase-1 and growth of virus in influenza A/PR/8/34 
(H1N1) infection of RAW264.7 macrophages 
 
We first examined the response of host caspase-1 to an influenza A/Puerto Rico/8/34 (H1N1) 
virus infection of RAW264.7 murine macrophages, in vitro. In this study, we demonstrated 
that caspase-1 was up-regulated, at mRNA and protein levels, upon infection of RAW264.7 
murine macrophages with influenza A/PR/8/34 (H1N1) virus. The up-regulation of caspase-1 
following influenza infection indicates that caspase-1 serves a role early in influenza infection. 
There was an increasing trend in the up-regulation of gene expression of caspase-1 with a 3-
fold increase at 12 hours post-infection. This is congruent to the up-regulation of active 
caspase-1 protein observed at 8, 12 and 24 hours post-infection with the most pronounced 
band appearing at 12 hours post-infection. The up-regulation of caspase-1 gene expression 
parallels previous findings that caspase-1 mRNA expression was enhanced in human 
macrophages by influenza A at 6 hours after infection, and it persisted up-regulated up to 
24 hours during viral infections of macrophages (Pirhonen, Sareneva et al. 1999). We showed 
that inactive pro-form (p45) of caspase-1 was expressed in both infected and uninfected 
RAW264.7 murine macrophages at all the time-points assessed. This constitutive expression 
of pro-caspase-1 was demonstrated also in human macrophages (Pirhonen, Sareneva et al. 
2001) and that influenza A only weakly increased the expression of procaspase-1. Influenza A 
virus induced the cleavage of pro-caspase-1 and into its mature form at 8 to 24 hours in 
RAW264.7 cells and this process was previously described at 18 hours post-infection of human 
macrophages (Pirhonen, Sareneva et al. 2001). 
As for virus growth in macrophages, we showed that RAW264.7 macrophages can be infected 
with influenza A virus. Presence of viruses often gives rise to morphological changes in the 
host cell, and detectable changes are known as cytopathic effects (CPE), which include cell 
rounding, disorientation, death, shrinking, detachment from surface (Scholtissek, Becht et al. 
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1967). We observed cytopathic effect in infected RAW264.7 cells upon infection with 
influenza A/PR/8/34 (H1N1) virus at 24 hours post-infection. Synthesis of viral RNA was 
detected by real-time PCR in the infected RAW264.7 cells and gene expression of NS1 
increased overtime with the highest levels noted at 12 hours post-infection. Progeny viruses 
were measured by means of plaque assay. Virus titres increased overtime with a peak at 24 
hours post-infection. These macrophages exhibit cytopathic effect at 24 hours post-infection, 
coinciding with peak virus titres, while the expression of caspase-1 corresponded to peak NS1 
gene expression at 12 hours post-infection. These indicate that caspase-1 may serve a role in 
influenza virus infection of macrophages and cell death. Here, we showed that RAW264.7 
murine macrophages are susceptible to influenza A infection and that caspase-1 expression in 
these macrophages was enhanced at both at gene and protein levels upon viral replication.  
 
4.3 Insights into the role of caspase-1 using a murine model of 
influenza pneumonitis 
 
Our study investigates the role of caspase-1 in pulmonary inflammation and cell death and its 
contribution to lung pathology following influenza virus infection in mice. To this end, we 
infected wild-type and caspase-1-deficient (Casp1-/-) mice with 500 PFU of influenza A/Puerto 
Rico/8/34 (H1N1) virus via the intra-tracheal route.  
 
4.3.1 Increased mortality of influenza A/PR/8/34 (H1N1) infected, aged caspase-1 
knock-out mice  
 
From a pilot study, there was an indication that aged mice deficient in caspase-1 were more 
susceptible to influenza infection. A lower survival rate of 40% was observed in the Casp1-/- 
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group at day 7 post-infection. This agrees with the findings of Thomas et al. (2009) and Allen 
et al. (2009) who both observed that infection with a high viral load of reduced survival from 
70% in wild-type animals to 40% Casp1-/- animals by day 7 post-infection. However, we did not 
observe this higher mortality rates in the experiment with younger, 8 to 10 week-old, mice. 
The difference in weight loss between the infected genotypes was not significant. Taken 
together, this could indicate that caspase-1-deficiency alone was not sufficient for mice to 
succumb to the infection but with age, caspase-1-deficiency could provide an immuno-
compromised condition leading to higher mortality. This parallels the clinical manifestation in 
humans where there is increased mortality of influenza infection in geriatric patients 
(Thompson, Shay et al. 2004). 
 
4.3.2 Weight loss as a crude read-out for influenza virus infection 
 
Weight loss is deemed as a crude indicator of morbidity and the progression of influenza virus 
infection in murine models (Belser, Szretter et al. 2009). Animals generally lose weight when 
they are ill because they have decreased appetites and feed much less, although food and 
water were provided ad libitum. As compared to the mock-infected groups, mice infected 
with 500 PFU influenza A/Puerto Rico/8/34 (H1N1) lost 25% of original weight by day 7 post-
infection. Furthermore, clinical observations such as ruffled fur coat, lethargy and laboured 
breathing were observed in infected mice from both groups, which were indicative of 
respiratory disease. These observations made during the course of monitoring the infection 
could give an indication that the mice were infected by the influenza virus. Control mice 
mock-infected with PBS lost weight during the first 2 days after infection due to the effects of 
the anaesthesia but the animals recovered to at least their original weights while the virus 
infected mice continued losing weight to 25% by days 7 post-infection where they were 
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euthanized. However, there was no significant difference in weight loss between the infected 
Casp1-/- and the infected wild-type.  
 
4.3.3 Up-regulation of caspase-1 in the lungs of infected wild-type mice 
 
Caspase-1 was up-regulated at mRNA and protein levels in the lungs of influenza infected 
wild-type mice. This implies that caspase-1 serves a function in the host response to an 
influenza virus infection. Expression of caspase-1 mRNA increased by approximately 3-folds on 
both days 3 and 7 post-infection in the infected wild-type groups as compared to its mock-
infected counterparts. This is congruent to findings by Allen et al. (2009) who demonstrated 
that influenza induced an increase in gene transcription of caspase-1 in wild-type mice at days 
3 and 7 post-infection. Caspase-1 gene expression increased to approximately the same levels 
on both days 3 and 7 post-infection. In our study, the out-of range threshold cycle numbers 
were indicative of the absence of the caspase-1 gene in the knock-out mice.  
At protein levels, pro-caspase-1 expression was increased in the lungs of wild-type mice upon 
influenza infection. Lower levels of pro-caspase-1 were detected in the mock-infected wild-
type mice. Caspase-1 protein was not observed in the lungs of Casp1-/- mice. However, the 
p10 active form of caspase-1 was not observed in the Western blots of lung homogenates at 
day 7 post-infection. This could imply that the antibody used was not sufficiently sensitive to 
detect the low level of expression of p10 or the active form may not be as stable. Caspase-1 is 
primarily activated in phagocytic cells such as macrophages (Franchi, Eigenbrod et al. 2009) 
and yet in the Western blot of RAW264.7 macrophage cell line, merely faint bands of the 
active p10 caspase-1 bands were detected. With macrophages constituting just a proportion 
of the numerous cell types present in the lungs, the expression of the p10 form may have 
been too low for detection. 
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4.3.4 Higher viral load present in the lungs caspase-1-deficient mice at day 7 post-
infection 
 
No virus was detected from the plaque assay of lung homogenates from control mock-
infected animals. This was expected because the animals were not exposed to the virus and 
were housed separately from infected mice at all times. In general, higher virus titres were 
observed in the lungs at day 3 post-infection as compared to at day 7. This is typical of an 
acute influenza virus infection where virus titres generally peak within the first 2 to 3 days of 
infection and titres start to decline thereafter (Reiss and Schulman 1980). The decline of virus 
titre is due to the activation of the host immune system upon influenza virus infection, which 
contributes to viral clearance (Baccam, Beauchemin et al. 2006). At an earlier time-point of 
day 3 post-infection, virus titres in the Casp1-/- mice was not significantly different from its 
wild-type. In contrast, at a later stage of infection, Casp1-/- mice sustained significant 2-fold 
higher viral load at day 7 post-infection. Viral clearance in the Casp1-/- mice was impaired and 
caspase-1 may be required for the control of virus replication. 
In parallel, when mice were infected with a sub-lethal dose of 10 PFU, Ichinohe et al. (2009) 
described that virus titres were similar between wild-type and Casp1-/- mice at day 5 post-
infection but Casp1-/- mice sustained a high viral load at day 10 post-infection when wild-type 
mice had completely cleared the virus. However, Thomas et al. (2009) concluded that at a 
sub-lethal viral dose, caspase-1 does not play an essential part in limiting virus production as 
equivalent virus titres at days 3 and 6 after infection were observed. Perhaps, caspase-1 could 
affect viral clearance at a later stage in infection of a sub-lethal dose while for a high viral 
dose, as seen in our study, the difference in virus titres as compared to the wild-type could be 
distinguished by day 7 post-infection. 
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4.3.5 Lower expression of IL-1β in the lungs of infected caspase-1-deficient mice as 
compared to its wild-type counterparts 
 
IL-1β was not constitutively expressed but synthesized upon stimulation, such as by influenza 
virus infection (Pirhonen, Sareneva et al. 1999). But transcriptional activation alone is not 
sufficient for efficient production of functional IL-1β protein. IL-1β is synthesized as an inactive 
precursor protein that requires cleavage by caspase-1, post-transcription, to become a 
biologically active molecule (Kuida, Lippke et al. 1995; Li, Allen et al. 1995). In our study, IL-1β 
mRNA levels was more highly up-regulated due to virus infection at day 3 post-infection as 
compared to day 7 post-infection indicating that IL-1β was more involved in the initial innate 
response to influenza. Similarly, Allen et al. (2009) reported a significant increase in the gene 
transcription of IL-1β at day 3 post-infection in infected wild-type mice. The increase in 
relative mRNA expression seen on day 3 post-infection was also greater than that at day 7 
post-infection.  
As for protein expression at day 7 post-infection, influenza virus infection induced the 
generation of pro-IL-1β in the lungs of both genotypes. In addition, higher levels of mature 
cleaved form of IL-1β were detected in the infected wild-type group as compared to the 
infected Casp1-/- group. This signifies the importance of caspase-1 in the maturation of this 
cytokine. However, bioactive IL-1β was still detected in the lungs of Casp1-/- mice. This implies 
that IL-1β, a master regulator of immune response, could be activated by caspase-1-
independent mechanisms. For instance, processing of the IL-1β precursor into an active 
cytokine is performed by the neutrophil protease proteinase-3 (Schönbeck, Mach et al. 1998; 
Coeshott, Ohnemus et al. 1999). Other proteases such as elastase, matrix metalloprotease 9 
and granzyme A also process IL-1β extracellularly (Dinarello 2009). The existence of non-
caspase-1 processing of IL-1β by neutrophil proteases is plausible given that abundant 
neutrophillic infiltration that results from influenza A/PR/8/34 (H1N1) infection. 
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4.3.6 Histopathological analyses – Caspase-1-deficient mice exhibited more severe 
lung and brain pathology 
 
Histopathologic analyses revealed that the infected caspase-1 knock-out mice fared 
significantly worse than the infected wild-type at day 7 post-infection. Casp1-/- mice exhibited 
increased intra-alveolar fibrin exudates, implying augmented alveolar damage as well as 
increased cellular recruitment in the lungs. The greater severity of lung damage is consistent 
with the findings of Thomas et al. (2009) who described increased pulmonary necrosis and 
abundant collagen deposition which formed concentric layers occluding the alveoli and 
terminal airways of Casp1-/- mice. Their experimental end-point was at day 11 post-infection. 
This was different from what was observed by Allen et al. (2009) who described that Casp1-/- 
mice demonstrated reduced airway inflammation but he surveyed the lung section at day 3 
post-infection. Although there are histologic discrepancies, these 2 studies as well as ours 
depict an essential protective role of caspase-1 in response to influenza A virus infection.  
Interestingly, brain inflammation or mild encephalitis, was detected in 2 of the 10 infected 
caspase-1-deficient mice. This was absent in the wild-type counterparts at day 7 post-
infection. However, the presence of virus was not detected in the brains of infected mice of 
both genotypes at days 3 and 7 post-infection. This could mean that the virus may have been 
cleared by day 7 post-infection or that viral load was too low of detection. Nonetheless, the 
influenza infection of Casp1-/- mice resulted in brain lymphocytic infiltration in 20% of the 
infected Casp1-/- mice and, to our knowledge, we present here the first findings of brain 
inflammation in an influenza infected Casp1-/- mice. Caspase-1 may be crucial in the control of 
virus dissemination to the brain. Encephalitis lethargicia has been associated with influenza in 
Japan (Morishima, Togashi et al. 2002) and was described as late sequelae of the 1918 
influenza infection (Ravenholt and Foege 1982). Similar to our findings, influenza RNA not 
detected in archival brain tissues from acute encephalitis lethargica cases (McCall, Henry et al. 
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2001). Nevertheless, additional work is needed to elucidate the mechanisms which may have 
led to this influenza-induced brain inflammation in caspase-1-deficient animals. In addition, 
upon evaluation of heart sections, we conclude that influenza A infection here did not induce 
heart pathology. 
 
4.3.7 Experiments on BALF – Caspase-1-deficient mice suffered from increased 
lung inflammation 
 
The experiments performed on the BALF of infected mice provide insights into the response in 
lung airways due to influenza infection. The inflammatory response to influenza can be 
measured in lungs of mice models. Determinants of pneumonia include neutrophil 
recruitment and pulmonary edema which occur both in humans as well as mice. Neutrophil 
recruitment in the lungs can be enumerated in bronchoalveolar lavage. Pulmonary edema 
could be measured from protein-rich plasma exudates by quantifying concentrations of total 
protein in bronchoalveolar lavage fluid (Mizgerd and Skerrett 2008). 
In this study, we have found an increased cellular infiltration in the lung airways of the 
infected Casp1-/- mice as compared to its wild-type at both days 3 and 6 post-infection, with 
neutrophils comprising the bulk of infiltrates. From the enumeration of cells present in 
bronchoalveolar lavage fluid, the increased cellular infiltration corresponded to the 
histopathological analysis of infected lungs. This is contrary to what Thomas et al. (2009) and 
Ichinohe et al. (2009) reported. In their studies, total leukocytes were markedly reduced in 
Casp1-/- mice compared to the wild-type. Ichinohe et al. (2009) performed a flow cytometry 
on single cell suspension obtained from lung tissue while Thomas et al. (2009) used cells from 
bronchoalveolar lavage fluid. They explained that the diminished leukocyte infiltration into 
the airways in Casp1-/- mice upon influenza infection was due to the reduced amount of pro-
inflammatory IL-1β, a cytokine responsible for the expression of adhesion factors on 
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endothelial cells to mediate the transmigration of leukocytes (Dinarello 2009) as well as a 
generally lower production of cytokines and chemokines in the Casp1-/- mice. However, this 
was not the case in our study as we showed that the secretion of other chemokines was 
increased in the lung airways of Casp1-/- mice. 
Furthermore, higher protein concentrations measured in BALF of Casp1-/- mice at day 6 post-
infection indicated a more severe microvascular injury and protein leakage due to damaged 
epithelium and endothelium in the lung airways of infected Casp1-/- mice as compared to wild-
type counterparts at day 6 post-infection. This corresponded to the increased edementous 
fluid and fibrin exudates from damaged capillaries and necrotic cells seen in the 
histopathology slides of infected Casp1-/- mice.  
In all, experimental outcomes from BALF samples of infected mice allude that the caspase-1-
deficient mice suffered from greater lung inflammation. 
 
4.3.8 Cell death assays – Increased cell death in the lungs of caspase-1 knock-out 
mice 
 
Lung damage was also assessed by cell death assays. At day 6 post-infection, lower 
percentage of viable and higher percentages of dead and mid-apoptotic BALF cells were 
observed in the lungs of infected Casp1-/- than infected wild-type mice, as determined by 
Guava ViaCount assay. The infected Casp1-/- mice also displayed a higher percentage of 
TUNEL-positive apoptotic in lung sections as compared to their wild-type counterparts. The 
augmented cell death in the lungs of infected Casp1-/- mice suggest exaggerated lung damage. 
Due to the increased ratio of neutrophil to macrophage numbers observed in the infected 
Casp1-/- mice, the increased amount of dead cells could also imply impaired clearance of cell 
debris by phagocytic macrophages. The increased neutrophil infiltration could trigger 
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downstream inflammation leading to protein leakage (Conn, McClellan et al. 1995) and the 
reduction in phagocytic macrophages could result in feedback loop of increased inflammation 
and viral replication (Kim, Lee et al. 2008).  
 
4.3.9 Cytokine expression – Chemoattractant cytokines were more prominent in 
the lung airways of infected caspase-1-deficient mice 
 
In assessing the differential cytokine expressions between the infected Casp1-/- and wild-type 
mice, elevated levels of MCP-1, MIP-1α, MIP-1β, RANTES and IFN-γ were detected in the lung 
airways of infected Casp1-/- mice at day 6 post-infection as compared to wild-type mice. MCP-
1, MIP-1α, MIP-1β and RANTES are well-known chemoattractant cytokines involved in 
inflammatory leukocyte recruitment to the site of infection (Van Reeth 2000). They could have 
influenced the enhanced cellular infiltration seen in the infected Casp1-/- mice. Although a 
lower level of IL-1β was observed in the BALF of Casp1-/- mice at day 3 post-infection from the 
Bio-Plex PROTM cytokine assay, the levels of IL-1β secreted into the airways were not 
significantly different between the infected Casp1-/- and wild-type mice at day 6 post-infection 
as shown in the Bio-Plex PROTM cytokine assay and Western blot. Thomas et al. (2009) 
previously reported a significantly lower level of IL-1β in the BALF of Casp1-/- mice than wild-
type mice 3 days after influenza infection.  
As mentioned above, we found that although the increase in gene expression and mature IL-
1β were lower in the lungs Casp1-/- mice, the level of IL-1β present in the bronchoalveolar 
lavage fluid was similar in both genotypes. This suggests that the maturation of IL-1β may 
depend on caspase-1 but the secretion of IL-1β may not be affected by caspase-1-deficiency 
or that the secretion or the activation of IL-1β by day 6 after infection may depend on non-
caspase-1 means such as by neutrophil proteases. The role of IL-1β in leukocyte recruitment 
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could be superseded with the increase in other chemoattractant cytokines, namely, MCP-1, 
MIP-1α, MIP-1β and RANTES.  
Additionally, the initial lower production of most of the cytokines assayed at day 3 post-
infection in the infected Casp1-/- mice, for instance, IL-1α, IL-1β, GM-CSF, MIP-1α and RANTES. 
These same cytokines were increased to a level higher than in the infected wild-type at day 6 
post-infection. This raises the question as to whether a mechanism exists to compensate for 
the caspase-1 deficiency and this may have overwhelmed the system and contributed to the 
increased lung injury.  
The elevation of secreted IFN-γ and MIP-1β (CCL4) in BALF of Casp1-/- mice corresponded to 
their increase in gene expressions found in the microarray. The increase in IFN-γ might be due 
to a sustained viral load which recruits leukocytes including activated T lymphocytes which 
secretes the cytokine into the lung parenchyma (Baumgarth and Kelso 1996). The increased 
amount of lymphocyte infiltration into the lung was evident from the enumeration of BALF 
cells.   
TNF-α was significantly lower in the infected Casp1-/- mice at day 3 and also lower at day 6 
post-infection. TNF-α is efficiently produced by influenza-infected macrophages (Julkunen, 
Melén et al. 2000). Therefore, this could be attributed to the lower macrophage ratios in the 
Casp1-/- mice as seen in the differential cell counts in BALF. 
In summary, elevated levels of chemoattractant cytokines MCP-1, MIP-1α, MIP-1β and 
RANTES detected in the lung airways of infected Casp1-/- mice at day 6 post-infection could 
have contributed to the enhanced leukocyte recruitment observed in the infected Casp1-/- 
mice. 
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4.3.10 Caspase-1 may not play a major role in the production of neutralising 
antibodies to influenza infection 
 
Neutralising antibodies were present in the sera of infected mice while none was detected in 
the mock-infected mice at day 7 post-infection. However, the difference in antibody titres 
between genotypes was not significant. This could suggest that caspase-1 may not be directly 
involved in the adaptive response or, any difference in antibody titres were not yet seen at 
day 7 post-infection.  
 
4.3.11 Microarray analysis – Genes differentially expressed in caspase-1-deficient 
mice point to greater severity of lung damage 
 
In the lung transcriptomic analysis performed at day 7 post-infection, the two-way ANOVA (p 
< 0.05) with fold-change ≥ 1.5 revealed  that caspase-1 and caspase-4 had differential 
expressions due to both infection and genotype effects. Caspase-4 was up-regulated upon 
influenza virus infection but to a lesser extent in the infected lungs of Casp1-/- mice, as verified 
by real-time RT-PCR using caspase-4-specific primers. From a BLASTn 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi) search of the given caspase-4 Illumina® BeadChip 
probe sequence (CCCCACATCACTTGTCCTACCGAGACAAAACAGGAGGCTCTTACTTCATC), there 
was a 100% identity with Mus musculus caspase-1 mRNA ref|NM_009807.2|. Therefore, the 
largest down-regulated gene, with fold-change of -22.7 was essentially also caspase-1. 
Nevertheless, this verifies our genotyping protocol. 
In addition, genes which were up-regulated in the infected Casp1-/- mice relative to the 
infected wild-type, were involved in immune and inflammatory response. They include 
chemokine (C-C motif) ligands CCL8 (or MCP-2) and CCL4 (or MIP-1β), IFN-γ, ICOS and cytolysis 
or killing such as perforin (PRF-1), killer cell lectin-like receptor, subfamily A, members (KLRA4, 
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KLRA7, KLRA18) and natural killer cell group 7 sequence (NKG7). Gene expression of 
leukotriene B4 receptor (LTB4R) and long pentraxin (PTX3) were also up-regulated in the 
infected Casp1-/- mice.  
CCL8 (MCP-2) and CCL4 (MIP-1β) are early response mediators which participate in the 
recruitment of multiple leukocyte subsets including NK cells, monocyte/macrophages, T cells 
and granulocytes (Charo and Ransohoff 2006). The inducible T-cell co-stimulator (ICOS) 
promotes the cytotoxic activity of natural killer cells (Ogasawara, Yoshinaga et al. 2002) and 
ICOS co-stimulation alters chemokine expression on activated T cells, which in turn controls 
the migration of T cells from secondary lymphoid tissue to the lung during influenza infection 
(Román, Miller et al. 2002). The enhanced expression of these molecules, CCL4, CCL8 and 
ICOS, could explain the increased cellular infiltration observed in the infected lungs of Casp1-/- 
mice.  
Perforin (PRF1) is a pore-forming, membrane-disrupting protein involved in inducing apoptosis 
and cell death by cytotoxic lymphocytes and natural killer cells in eliminating virus-infected 
cells via the granule exocytosis pathway (Trapani and Smyth 2002). Killer cell lectin-like 
receptors, subfamily A (KLRA or Ly49) are natural killer (NK)-cell inhibitory receptors specific 
for MHC class I molecules. Natural killer cells survey tissues for expression of MHC class I 
molecules and inhibitory receptors, by binding to target cell MHC class I ligands, prevent the 
lysis of healthy autologous cells (Yokoyama and Plougastel 2003). In the absence of otherwise 
ubiquitously expressed MHC class I molecules (‘missing self’), such as in virus infected cells, NK 
cells kill target cells. Up-regulation of KLRA or Ly49 may potentially serve to dampen the 
immune response. Leukotriene B4 receptor (LTB4R) is important for the activation and 
recruitment of inflammatory cells including neutrophils, eosinophils, monocyte/macrophages, 
and T cells to tissues in inflammatory diseases (Serhan and Prescott 2000) and was reported 
to play a role in viral clearance (Gaudreault and Gosselin 2008). While long chain pentraxin 
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(PTX3) is produced by innate immune cells and was reported to mediate antiviral activity 
including inhibition of haemagglutination, neutralization of virus infectivity and inhibition of 
viral neuraminidase (Reading, Bozza et al. 2008). Perhaps, there was a late induction or 
prolonged up-regulation of these genes which facilitates killing and clearance of infected cells 
as well as genes which aid in resolving the inflammatory response. This could have led to a 
delay in clearance of dead cells and sustained viral burden which in turn result in increase 
insult to the lungs of Casp1-/- mice at day 7 post-infection.  
Genes which were down-regulated participate in structural integrity such as keratin (KRT14 
and KRT15), PDZ and LIM domain 3 (PDLIM3), synemin (SYMN), collagen, type XVII, alpha 1 
(COL17A1), tropomodulin-1 (TMOD1) and mitochondrial respiratory chain and energy 
transduction such as cytochrome c oxidases (subunit VIIIb COX8B) and (subunit VIa 
polypeptide 2 COX6A2), and ATPases such as ATPase, Na+/K+ transporting, alpha 2 
polypeptide (ATP1A2) and myosin, heavy chain 6, cardiac muscle, alpha (MYH6). 
Cytochrome c oxidase has critical roles in cellular respiration and the enzyme participates in 
energy release (Capaldi 1990). Keratins are intermediate filament proteins which constitute 
the epithelial cell cytoskeleton (Omary, Coulombe et al. 2004) while synemin (SYMN) is an 
intermediate filament protein in skeletal and cardiac muscles (Olivé, Goldfarb et al. 2003). 
Tropomodulin (TMOD1) is involved in inhibiting polymerization and depolymerization of actin 
monomers and interacts with tropomyosin as a component of actin filament (Kostyukova 
2008). With the down-regulation these genes, the cell cytoskeleton may be unable to 
accommodate mechanical stress.  
Myosin is a motor protein that interacts with actin to generate the force for cellular 
movements. Myosin, heavy chain 6, cardiac muscle, alpha (MYH6) contains the ATPase activity 
providing energy in striated muscle contraction (Weiss and Leinwand 1996). A down-
regulation in MYH6 gene may imply a weaker cardiac muscular activity. Taken together, down-
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regulation in the expression of these genes involved in the cytoskeleton and energy 
transduction may indicate a generalized muscular weakness in the caspase-1-deficient mice 
infected with influenza A/PR/8/34 (H1N1) virus.  
Gene expression of surfactant protein C (SFTPC or SP-C) was also down-regulated in the 
infected Casp1-/- mice. Pulmonary-associated surfactant protein-C is a hydrophobic surfactant 
protein secreted by the type-II alveolar epithelial cells of the lung and maintains the stability 
of pulmonary tissue by reducing the surface tension of fluids that coat the lung. Transgenic 
mice lacking SFTPC have abnormalities in surfactant properties and develop severe lung 
disease with alveolar airspace remodelling, inflammation, and emphysema. This demonstrates 
that SP-C plays a critical role in the maintenance of alveolar homeostasis (Glasser, Detmer et 
al. 2003). In our study, the gene expression of SFTPC in the infected caspase-1-deficient mice 
was lower than that of its wild-type counterparts. The down-regulation of SP-C in the lungs of 
Casp1-/- mice suggests a more severe lung pathology which has been confirmed in the 
histopathological analyses.  
In all, the lung transcriptomic study revealed that genes differentially expressed in the 
infected Casp1-/- mice suggest a greater severity of influenza pathogenesis in the lungs of 
these mice. Nonetheless, the expression of these genes has to be validated by means of real-
time RT-PCR and protein expression verified by Western blotting.  
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CONCLUSIONS 
 
In conclusion, there is evidence to show that caspase-1-deficient mice are more susceptible to 
a high dose of 500 PFU of influenza A/Puerto Rico/8/34 (H1N1) virus infection. Caspase-1 was 
up-regulated in the lungs of infected wild-type mice. The function of caspase-1 as the 
interleukin (IL)-1β-converting enzyme (ICE) was shown by the lower expression IL-1β of in the 
lungs of infected caspase-1-deficient mice as compared to its wild-type counterparts. 
However, mature IL-1β was not totally absent in caspase-1-deficient mice. This indicates the 
existence of caspase-1-independent processing of the cytokine and non-caspase-1 
mechanisms which leads to stimulation of IL-1β. Viral clearance may be impaired in the lungs 
caspase-1-deficient mice as a higher viral load was sustained at day 7 post-infection. Caspase-
1-deficient mice exhibited more severe brain and lung pathology, particularly, increased 
cellular infiltration and intra-alveolar fibrin exudation in the lungs. To our knowledge, we 
present here the first findings of brain inflammation in an influenza infected Casp1-/- mice. 
However, further studies are required to elucidate the involvement of caspase-1 in 
aggravating influenza-induced encephalitis. Caspase-1-deficient mice suffered from increased 
lung inflammation and this is evident from the increase in cellular infiltration and protein 
leakage into the lung airways. This was supported by the increase in chemoattractant 
cytokines such as MCP-1, MIP-1α, MIP-1β and RANTES, in the lung airways of infected 
caspase-1-deficient mice. Gene expression analysis also revealed differentially expressed in 
caspase-1-deficient mice which suggest greater severity of lung damage. The augmented cell 
death observed in the lungs of caspase-1 knock-out mice was observed by TUNEL and Guava 
ViaCount cell viability assays. Caspase-1 may not play a major role in the production of 
neutralising antibodies to influenza infection. In all, caspase-1 plays a protective role in 
antiviral defense against respiratory influenza A virus infection. 
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FUTURE DIRECTIONS 
 
Proinflammatory role of caspase-1 plays an essential role in the regulation of innate immunity 
and inflammatory response. We have observed detrimental outcomes of caspase-1-deficieny 
especially in the lung immunopathology and viral clearance in response to influenza infection. 
The absence of any known single nucleotide polymorphisms (SNPs) signifies that caspase-1 is 
highly conserved. This reflects the evolutionary importance of this protein and essentiality its 
function in processing the master cytokine, IL-1β. Yet, because of the importance of this 
cytokine in initiating the immune response, other enzymes come into play in activating this 
cytokine in the absence of caspase-1. This also raises the question as to whether a mechanism 
exists to compensate the deficiency of protective caspase-1. This may lead to a dysregulation 
in immune response and as the host tries to cope with the infection, other modes of actions 
stimulated in turn may result in more damage.  
Programmed cell death is intertwined with immunity to provide an effective way to remove 
infected cells. A previous study described that caspase-1-deficient mice have delayed 
neutrophil apoptosis and a prolonged inflammatory response to lipopolysaccharide-induced 
acute lung injury (Rowe, Allen et al. 2002). Perhaps, neutrophil apoptosis was delayed in the 
caspase-1-deficient mice, hence we noticed the increased in neutrophillic pulmonary 
inflammation at day 6 post-infection. Neutrophils with short life-span helps in the killing of 
virus infected epithelial cells, undergoes apoptosis and are phagocytosed by macrophages. 
The elimination of dying, infected cells in this manner is deemed as anti-inflammatory and 
initiates a resolution of the inflammatory response. In this study, we have not studied the role 
and effect of neutrophil apoptosis and macrophage phagocytosis of infected cells. Caspase-1-
deficiency may be involved in the delay of neutrophil death and hence resulted in a prolonged 
inflammatory response to lung injury.  
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4.4 A pan-caspase inhibitor for the treatment of influenza? 
 
To complement the study of caspase-1 and other caspases in cell death aspects of the 
influenza infection, we explored the effects of manipulating of cell death by means of 
inhibitors, in vitro. 
It has been long established that influenza infection triggers apoptosis of the infected cells as 
well as in vivo (Takizawa, Matsukawa et al. 1993; Fesq, Bacher et al. 1994; Hinshaw, Olsen et 
al. 1994; Mori, Komatsu et al. 1995). Within the infected cell, the apoptotic programme is 
facilitated by activation of caspases (Takizawa, Matsukawa et al. 1993; Zhirnov, Konakova et 
al. 1999; Lin, Holland et al. 2002) with effector caspase-3 playing the most crucial role 
(Wurzer, Planz et al. 2003). In viral infections, apoptosis is usually considered to be a host 
defense mechanism. However, induction of apoptosis may also contribute to virus-induced 
cellular pathology and evidence has shown that influenza has anti-apoptotic genes, to 
overcome apoptosis and are able to replicate efficiently before apoptosis completes 
(Kurokawa, Koyama et al. 1999).  
Influenza A virus infection results in host cell death by cytolysis or apoptosis. Virus replication 
involves blocking of host cell mRNA transport into the cytoplasm and destruction of cellular 
pre-mRNAs by viral endonucleases. Epithelial cells support maintenance of viral protein 
synthesis, packing and production of new viral particles so cytolytic death occur later at 20 to 
40 hours of infection (Julkunen, Melén et al. 2000). In our study, the cytopathic effect of 
influenza A/PR/8/34 on MDCK cells was observed at 24 hours post-infection was more 
pronounced at 48 hours post-infection.  
From our study, the pan-caspase inhibitor z-VAD-FMK was the most promising inhibitor of cell 
death as it increased cell viability of infected MDCK cells. There was no significant difference 
in virus titres between the inhibitors treated and untreated, infected DMSO controls. Hence, 
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the inhibitors did not affect virus replication directly. This is consistent with the findings of 
Takizawa et al. (1999) where peptide inhibitor z-VAD-FMK suppressed a H3N2 virus-induced 
cell death but did not inhibit viral replication in MDCK cells (Takizawa, Tatematsu et al. 1999). 
However, Wurzer et al. (2003) reported that a H7N7 virus propagation was strongly impaired 
in the presence of the pan-caspase inhibitor z-VAD-FMK and a caspase-3 inhibitor z-DEVD-
FMK in Vero and A549 epithelial cells. Yet, they did not show z-VAD-FMK to be effective in 
inhibiting viral replication in MDCK cells (Wurzer, Planz et al. 2003). In another study, z-VAD-
FMK inhibited H5N1 avian virus-induced cytopathicity in porcine airway epithelial cells but not 
viral growth or release of progeny viruses (Daidoji, Koma et al. 2008). Perhaps, caspase 
inhibition affects host cell death but does not directly interferes with viral replication. 
Takizawa et al. (1999) reported that Ac-YVAD-CHO, a caspase-1-like protease inhibitor, 
showed almost no inhibitory effect on virus-induced cell death of MDCK cells. Likewise, in our 
study, the caspase-1 inhibitor z-LEVD-FMK was not able to inhibit influenza A/PR/8/34 induced 
cell death. This suggests that caspase-1 may not play a major role in influenza virus-induced 
epithelial cell death.  
Although this was a limited study, we do not discount the possibility of using the pan-caspase 
inhibitor as a therapeutic approach but perhaps in combination therapy with anti-virals such 
as neuraminidase inhibitor, oseltamivir phosphate (Tamiflu®) to tackle both virus and host 
response to the infection. z-VAD-FMK could be administered in vivo to study its effects in an 
organism. Currently, z-VAD-FMK was able to protect mice from LPS-induced acute lung injury 
(Kawasaki, Kuwano et al. 2000) and bleomycin-induced pneumopathy (Kuwano, Kunitake et 
al. 2001). Thus, there is hope for the inhibitor’s effectiveness in an influenza pneumonitis 
model. 
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To subculture MDCK cells, culture medium was discarded and the adherent cell layer was 
rinsed twice with sterile autoclaved 1x phosphate buffered saline (PBS) solution (1st BASE Pte 
Ltd, Singapore) to remove all traces of serum that contains trypsin inhibitor. Three millilitres 
(ml) of 1x Trypsin-Ethylenediaminetetraacetic acid (EDTA) in PBS, pH 7.4 (PAA Laboratories 
GmbH, Austria) solution was added to a 25-square centimetre (cm2) flask and cells were 
observed under an inverted microscope until cell layer is dispersed (usually 15 minutes at 
37°C). To quench the action of trypsin, 6 ml of complete growth medium was added to the 
flask and detached cells were aspirated by gentle pipetting. Cell suspension was centrifuged at 
500 r.p.m. then supernatant was discarded. Cell pellet was resuspended in complete growth 
medium and aliquots were added to new culture flasks. 
To subculture RAW264.7 cells, 10 ml of growth medium was added to a 75-cm2 flask and 
dislodged by scraping with a cell scraper. Aliquots of cell suspension were added to new 
culture flasks. Cells were cultured in a humidified atmosphere containing 5% CO2 at 37°C and 
growth medium changed every 3 days. 
 
Cryopreservation of cells 
 
Cells were stored frozen in liquid nitrogen for further use. The freezing medium comprised of 
10% dimethyl sulphoxide (DMSO) (Sigma-Aldrich®, St. Louis, USA), 20% FBS and medium. After 
the detachment of adherent cells from culture flasks, cell suspension containing trypsin-EDTA 
was pelleted by centrifugation at 500 r.p.m for 5 minutes. Supernatant was discarded and 
cells were washed by resuspension in growth medium. After centrifugation, cell pellets were 
resuspended in freezing medium in a drop-wise fashion. Cells were stored in 1 ml aliquots in a 
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cryogenic vial (Nalgene®, New York, USA). The vial was tightly capped and sealed with 
Parafilm® (Pechiney Plastic Packaging Company, Illinois, USA) and stored in a styrofoam box 
overnight at -80°C to allow gradual freezing. The vial was then transferred to liquid nitrogen 
for long term storage. 
 
Recovery of frozen cells 
 
Quick thawing of frozen cells was achieved by agitation of cryogenic vial in a 37°C water bath. 
After thawing, the vial was wiped with alcohol and the contents transferred dropwise into a 
tissue culture flask containing 20% heat-inactivated foetal bovine in growth medium. Cells 
were incubated overnight in a humidified atmosphere containing 5% CO2 at 37°C. On the 
following day, the adherent cell layer was washed with 1x PBS to remove floating dead cells 
and residual DMSO. Growth medium was replaced and cells left to grow to confluence which 
occurred within 5 days. 
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Appendix II: Reagents for genotyping PCR 
 
U1.5% Agarose Gel 
Disperse 1.5 g of agarose powder in 100 ml 1x Tris-Acetate buffer. Microwave to melt agarose. 
Cool molten agarose to about 50°C and add 0.5 μg of ethidium bromide (10 mg/ml stock) per 
millitre of gel. Pour gel onto casting tray and leave, for about 15 minutes, to set at room 
temperature.  
 
UTail lysis buffer UFor 100 ml 
100 mM Tris-hydrochloride (Tris-HCl) (pH 8.5) 10 ml 1 M Tris-HCl (pH 8.5) 
200 mM sodium chloride (NaCl) 4 ml 5 M NaCl 
5 mM EDTA (pH 8.0) 1 ml 0.5 M EDTA (pH 8.0) 
0.2% sodium dodecyl sulphate (SDS) 2 ml 10% (v/v) SDS 
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Appendix III: Reagents for plaque assay 
 
UAvicel® suspension UFor 250 ml of 2.4% Avicel® suspension 
Avicel® Microcrystalline Cellulose & 
carboxylmethylcellulose sodium (RC-591) 
(kind gifts from FMC BioPolymer, 
Philadelphia, USA) 
6 g  
 
Disperse the 6 g of powder in 250 ml filtered sterilized water. Mix on a shaker for 1 h. Sterilize 
Avicel® stock by autoclaving. 
 
U2x Minimum Essential MediumU  UFor 500 mlU (Store at 4°C) 
Minimum Essential Medium (GIBCO®, 
Invitrogen Corporation, California, USA) 
 
1 packet 
1 M HEPES (PAA Laboratories GmbH, Austria) 10 ml 
7.5% sodium bicarbonate 7 ml 
 
The overlay medium was prepared by mixing 250 ml 2.4% Avicel® suspension with 250 ml of 
double-strength Minimum Essential Medium.  
 
U20% Formalin fixative UFor 500 ml 
37% Formaldehyde solution 100 ml 
 
Make up to 500 ml with 1x phosphate buffered saline (PBS) 
 
U1% Crystal violet solution UFor 500 ml 
Crystal violet 5 g 
37% Formaldehyde solution 100 ml 
 
Make up to 500 ml with 1x PBS. Filter to remove particles.  
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A respresentative image of plaque assay of influenza A/PR/8/34 (H1N1) on MDCK cells and stained with 
cystal violet. A ten-fold serial dilution was performed and the dilution indicated at the top of each well. 
An inoculum of 100 μl from each diluent was added to each well in duplicate. This example shows a 
virus titre of 8.5 x 105 PFU/100μl which equates to 8.5 x 106 PFU/ml.  
 
  
 VII  
Appendix IV: Microarray procedure and data analysis 
 
Illumina® TotalPrep RNA amplication 
 
Illumina® TotalPrep RNA amplification procedure.  
(Figure adapted from Illumina® TotalPrep RNA Amplification kit manual version 0510) 
 
Illumina® TotalPrep RNA Amplification kit (Ambion® Inc., Texas, USA) was used to prepare 
RNA samples for microarray analysis. The procedure is outlined in the figure above. The total 
RNA sample (500 ng in 11 μl) used for a single array was prepared by pooling equal amounts 
of total RNA from 3 mice for each group, namely, +/+ Mock-infected, -/- Mock-infected, +/+ 
Infected, -/- Infected. Arrays were performed in triplicates for each group with each array 
representing a biological replicate. 
Reverse transcription (RT) was performed to synthesize first-strand cDNA by adding 9 μl of the 
RT Master Mix to each total RNA sample (500 ng in 11 μl) and incubating for 2 hours at 42°C.  
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For a 20 μl reaction Volume (μl) 
T7 Oligo(dT) primer 1 
10x first strand buffer 2 
dNTP mix 4 
RNase inhibitor 1 
ArrayScript enzyme 1 
Components of Reverse Transcription Master Mix. 
 
Next, second strand cDNA synthesis converted the single strand cDNA into a dsDNA template 
for transcription. For a 100 μl reaction, 80 μl of the Second Strand Master Mix was added to 
each sample, on ice. Second strand cDNA synthesis reactions were incubated for 2 hours at 
16°C.  
For a 100 μl reaction Volume (μl) 
Nuclease-free Water 63 
10X Second Strand Buffer 10  
dNTP mix 4 
DNA Polymerase 2 
RNase H 1 
Components of the Second Strand Master Mix 
 
Purification of cDNA was performed using a cDNA filter cartridge system which included a 
cDNA binding step, a wash step and a final elution of cDNA with 19 μl of 55°C nuclease-free 
water. For the synthesis of cRNA, a 25 μl IVT reaction was prepared for each sample by adding 
of 7.5 μl of IVT Master Mix to the sample and incubating for 14 hours at 37°C.  
For a 25 μl reaction Volume (μl) 
T7 10x Reaction Buffer 2.5 
T7 MegaScript® Enzyme Mix 2.5 
Biotin-NTP Mix 2.5 
Components of IVT Master Mix. 
 
The reaction was stopped by adding 75 μl of nuclease-free water. The cRNA generated was 
purified in cRNA filter cartridges using a cRNA binding buffer, wash buffer and 100% ethanol. 
The cRNA was eluted with 100 μl of 55°C nuclease-free water. 
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Whole-genome gene expression direct hybridization assay 
 
Single-channel SENTRIX® BeadChip Array MouseRef-8 v2.0 Microarray for Gene Expression 
(Illumina®, Inc., California, USA) targets approximately 19,100 unique genes. About 25,600 70-
mer oligonucleotide probe sequences, representative of individual genes, of the mouse 
genome were represented on each array. 10 μl of hybridization buffer GEX-HYB was added to 
750 ng of cRNA in 5 μl of nuclease-free water for each sample. The cRNA samples were then 
pre-heated to 65°C for 5 min, cooled to room temperature. Then, 15 μl of each sample was 
loaded onto an array. The microarray slide was positioned in a hybridization chamber loaded 
with 200 μl of humidifying buffer GEX-HCB. The microarray slides were incubated for 18 hours 
in a rocker at 58°C to allow for hybridization.  
After hybridization, the microarray slides were submerged in 250 ml of wash buffer E1BC 
solution, then transferred to a high temperature wash buffer and incubated static for 10 
minutes at 55°C. The microarray slides were then washed in the following sequence: 250 ml of 
E1BC solution for 5 minutes, 250 ml of 100% ethanol for 10 minutes, and 250 ml of E1BC 
solution for 2 minutes. The slides were incubated on a rocker with 4 ml of blocking buffer E1 
for 10 minutes. To allow the binding of Cy3 fluorescent dye to the array, 2 μl of 1 mg/ml Cy3 
coupled-streptavidin in 2 ml of E1 was then incubated with each microarray slide for 10 
minutes with rocking. Washing was carried out after Cy3-binding with E1BC solution to 
remove unbound dye and the slides were centrifuged for 4 minutes at 275 relative centrifugal 
force (rcf) to dry the slides. 
The direct hybridization gene expression arrays were scanned using the BeadArray Reader 
(Illumina®, Inc., California, USA). All slides were scanned with the scan factor of 0.5 and at the 
Cy3 channel-specific wavelength.  
 
Microarray data analysis 
 
Fluorescence emission by Cy3 was quantitatively detected using the GenomeStudio software 
(Illumina®, Inc., California, USA) and converted into a format compatible with GeneSpring GX 
11.5 (Agilent Technologies, California, USA), an advanced microarray analysis software. The 
probability of seeing a certain signal value without probe-specific target hybridization is 
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termed the detection p-value. Detection p-values were computed in GenomeStudio 
(Illumina®, Inc., California, USA) prior exporting to Genespring GX 11.5 using the Wilcoxon 
Signed Ranked Test.  
 
GeneSpring GX 11.5 
 
The probe ID, average signal value and detection p-values obtained from GenomeStudio as 
the sample probe profile and were imported into GeneSpring GX 11.5’s ‘Illumina Single Color 
Guided Workflow to find differentially expressed genes’ for the normalisation of raw data. The 
guided workflow does a thresholding of the signal values to 5. It then normalizes the data to 
75th percentile and performs baseline transformation to median of all samples.  
A box-whisker plot shows the samples on the X-axis and the log normalized expression values 
on the Y axis. 
 
Box-whisker plot showing the distribution of normalized intensity values of each sample.  
The box-whisker plot shows the median in the middle of the box, the 25th quartile and the 75th 
quartile. Entities with intensity values beyond 1.5 times the inter-quartile range are shown in red. 
 
Two parameters were created for the experimental groupings, namely, Genotype and 
Infection. The 4 experimental groups were as follows:  







Principal component analysis (PCA) was performed to check data quality. The PCA plot allows 
visualisation between groups of replicates. Ideally, replicates within a group should cluster 
together and separately from arrays in other groups.  
 
Principal Component Analysis (PCA) plot for quality control of data.  
PCA plot shows one point per array and is coloured by genotype and shaped by infection. This allows 
the visualisation of separations between groups of replicates. 
 
Probesets were then filtered based on their flag values P (present) and M (marginal). Only 
entities having the present and marginal flags in at least 1 sample are displayed as a profile 
plot. The flag values are based on detection p-values. Values below 0.6 are considered as 
Absent, between 0.6 and 0.8 are considered as Marginal and values above 0.8 are considered 
as Present.  
 XII  
 
A profile plot displaying 23438 out of 25697 entities where 1 out of the 12 samples have present and 
marginal flags.  
The plot was generated using the normalized signal values and samples grouped by the interpretation, 
Genotype and Infection. 
 
For significance analysis, a 2-way ANOVA was performed with Benjamini-Hochberg False 
Discovery Rate (FDR) multiple testing correction. A p-value cut-off of 0.05 was considered as 
significant. The entities satisfying the significance analysis (in the venn diagram below) are 
passed on for the fold change analysis. 
 
A Venn diagram displaying 9714 of 23438 entities which satisfied the corrected p-value cut-off of 0.05.  
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GeneSpring fold change analysis 
 
Fold change analysis is used to identify genes with expression ratios or differences between a 
treatment and a control that are beyond a threshold. Fold change is the ratio between 
Condition 1 and Condition 2. It is calculated as Fold change = Condition 1 / Condition 2. Fold 
change gives the absolute ratio of normalized intensities (no log scale) between the average 
intensities of the samples grouped. A fold-change cut-off of 1.5 was used in the analysis 
following the 2-way ANOVA analysis with corrected p-value cut-off of 0.05.   
 
Ingenuity Pathway Analysis 
 
GeneSpring GX 11.5 software (Agilent Technologies) was employed to calculate averages and 
p-values for the replicate samples as well as to calculate fold-change ratio values. The .txt file 
generated was uploaded to Ingenuity Pathway Analysis (IPA®) (Ingenuity Systems, Inc.) for 
further analysis of the dataset. IPA® revealed functions and pathways which are associated 
with the differentially expressed genes present in the dataset. 
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APPENDIX V: Haematoxylin and Eosin staining 
 
Formalin-fixed organs, namely, lungs, brain and heart, were processed and embedded in 
paraffin wax. Sections of 4 μm thickness were sliced. Paraffin brain, heart and lung sections 
were immersed in 2 changes of absolute xylene, 5 minutes each to deparaffinized the fixed 
tissues. Lung sections were then rehydrated in a descending series of 100%, 90% and 70% 
ethanol solutions for 2 minutes each step. Slides were rinsed in distilled water for 2 minutes. 
Slides were then placed in Harris Haematoxylin (Sigma-Aldrich®, St. Louis, USA) for 10 minutes 
and rinsed with distilled water. Differentiation was carried out by dipping of lung sections in 
0.5% acid alcohol until desired differentiation of haematoxylin was obtained. Bluing of 
differentiated lung sections was then done by immersion in saturated lithium carbonate 
(Sigma-Aldrich®, St. Louis, USA) for 2 minutes. Sections were placed in aqueous eosin (Sigma-
Aldrich®, St. Louis, USA) for 2 minutes then rinsed in distilled water for another 2 minutes. 
Finally, sections were dehydrated through an ascending series of 70%, 90% and 100% ethanol, 
each step lasting 30 seconds, before immersion in 2 changes of fresh xylene for 5 minutes 
each. Stained sections were then observed under a light microscope.  
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Appendix VI: Reagents for Western blotting 
 
UProtein lysis buffer (for cytosolic proteins) UFor 50 ml (UStore at 4°C) 
10 mM Tris-HCl (pH 7.5)  438.3 mg Tris  
150 mM NaCl  60.6 mg NaCl 
1% (v/v) Triton X-100 0.5 ml Triton X-100 
 
Add 20 μl of 50x protease inhibitor (1 tablet in 1 ml of water) (Roche complete, Mini, Protease 
Inhibitor Cocktail tablets) to 1 ml protein lysis buffer.  
Store in aliquots at -20°C upon addition of protease inhibitor 
 
UProtein 5x sample loading buffer UFor 10 ml (UStore in aliquots at -20°C) 
50 % glycerol 5 ml 
10% (w/v) sodium dodecyl sulphate 200 μl  
1M Tris-HCl pH 6.8 2.1 ml  
β-mercaptoethanol 2.56 ml  
Trace amount of bromophenol blue  
 
 
U1 M Tris buffer (pH 6.8 and 8.8) UFor 500 ml (UStore at 4°C) 
Tris base 60.5 g  
 
Make up to final volume of 500 ml after adjusting to pH 6.8 or 8.8 with hydrochloric acid 
 
U10% (w/v) ammonium persulfate (APS) stock solution 
0.1 g ammonium persulfate 
1 ml distilled water 
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USeparating GelU (15% polyacrylamide gel) UFor 10 ml 
Water (H2O) 3.2 ml 
1 M Tris buffer (pH 8.8) 3.75 ml 
30% (w/v) bis-acrylamide solution (Bio-Rad) 3.75 ml 
10% sodium dodecyl sulfate 100 μl 
10% APS 100 μl 
Temed (Invitrogen) 6 μl 
 
UStacking Gel UFor 3 ml 
Water (H2O) 2300 μl 
1 M Tris buffer (pH 6.8) 375 μl 
30% (w/v) bis-acrylamide solution (Bio-Rad) 300 μl 
10% sodium dodecyl sulfate 30 μl 
10% APS 30 μl 
Temed (Invitrogen) 5 μl 
 
U10x Running buffer  UFor 1 litre 
Tris 30 g  
Glycine 144 g  
10% (w/v) sodium dodecyl sulfate solution 100 ml  
 
Make up to a total volume of 1 litre with filtered water 
 
U10x Transfer buffer UFor 1 litre (UStore at 4°C) 
Trizma-base 30.2 g  
Glycine 144 g 
 
Make up to a total volume of 1 litre with filtered water 
Add 200 ml methanol for every 1 litre of 1x Transfer buffer before use 
 
U10x Tris-buffered saline  UFor 1 litre 
Tris 24.2 g 
NaCl 80 g 
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Make up to final volume of 1 litre after adjusting to pH 7.4 with hydrochloric acid 
Add 500 μl Tween-20 to 1 litre of 1x TBS/T 
 
UBlocking buffer (5% (w/v) skimmed milk in 
TBS-T) 
UFor 50 ml 
Skimmed milk 2 g 
TBS-T 50 ml 
 
UStripping buffer UFor 50 ml 
50 mM Tris-HCl (pH 6.8)  2.5 ml of 1 M Tris-HCl (pH 6.8) 
100 mM β-mercaptoethanol  352 μl of 14.2 M β-mercaptoethanol 
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Western blot procedure 
 
An SDS-PAGE separates proteins based on their molecular sizes. Negatively charged sodium 
dodecyl sulphate (SDS) in the sample buffer binds to heat denatured proteins. The proteins 
migrate toward the positive electrode impeded by the polymerized and cross-linked 
polyacrylamide. A 15% polyacrylamide separating gel was casted between 2 glass plates. The 
gel mixture was pipette to 1.5 centimetres (cm) below the bottom of the comb.  
Ethanol was added to the top of the gel to prevent oxygen from inhibiting polymerization. The 
gel was allowed to polymerize at room temperature for about 15 minutes. Thereafter, the 
ethanol was discarded and the stacking gel was layered over the polymerized separating gel. 
The comb was inserted and bubbles were removed. After polymerization for about 15 
minutes at room temperature, the comb was removed and the wells were flushed with water. 
Samples were constituted in 5x Laemeli sample buffer and denatured by boiling at 100°C for 5 
minutes. A total of 50 μg of proteins were loaded per well. A protein marker (Bio-Rad 
Kaleidoscope pre-stained standards, California, USA) was included for each gel. The gel 
electrophoresis, in tris-glycine running buffer, was performed at constant 80 Volts (V) for 1 
hour 30 minutes. 
The Mini Trans-Blot® Electrophoretic Transfer Cell system (Bio-Rad Laboratories, Inc., 
California, USA) was used for the transfer of proteins from the SDS-PAGE gel to a Hybond-P 
polyvinylidene fluoride (PVDF) (Amersham Biosciences, GE Healthcare, Buckinghamshire, 
United Kingdom) membrane. The membrane was first activated in 100% methanol for 10 
seconds, washed in water and equilibrated in transfer buffer for 5 minutes before blotting. 
The electroblotting cassette was assembled, carefully avoiding air bubbles between the gel 
and membrane sandwich. The transfer was carried out for 1 hour 20 minutes at 60 Volts with 
cooling.  
The blocking of non-specific binding sites was performed by immersing the membrane in 5% 
non-fat dried milk, 0.1% (v/v) Tween 20 in TBS (TBS-T) for 1 hour at room temperature on a 
shaker.  
For the detection of caspase-1, the caspase-1 p10 antibody (sc-514; Santa Cruz Biotechnology, 
Inc., California, USA) was diluted 1:500 in 5% skimmed milk in TBS-T. This antibody detects 
both the p10 subunit and the p45 pre-cursor caspase-1. As for the detection of IL-1β, the IL-1β 
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antibody (#2022; Cell Signaling Technology, Inc., Massachusetts, USA) was diluted 1:1000 in 
5% skimmed milk in TBS-T. This antibody detects endogenous levels of both the 31 kiloDaltons 
(kDa) precursor and 17 kDa mature forms of IL-1β. The membrane was sealed in a polystyrene 
plastic bag with 7 ml of the diluted primary antibody and incubated at 4°C overnight on an 
orbital shaker.  
On the following day, the blot was washed thrice in TBS-T for 5 minutes each wash at room 
temperature. Thereafter, the membrane was incubated with HRP labelled secondary 
antibody, diluted in 5% skimmed milk in TBS-T for 1 hour at room temperature on a shaker. 
Goat anti-rabbit IgG, HRP-linked (1:4000) (InvitrogenTM, California, USA) were used for the 
detection of caspase-1 and IL-1β. The blot was washed thrice for 5 minutes each wash before 
detection. 
Amersham ECL Plus Western blotting detection reagents (GE Healthcare, Buckinghamshire, 
United Kingdom) was used in the detection of immobilized specific antigens conjugated to 
horseradish peroxidase (HRP) labelled antibodies. The chemiluminescent reaction is based on 
HRP and peroxide oxidation of the Lumigen PS-3 Acridan substrates which generates 
acridinium ester intermediates. These intermediates react with peroxide to produce light 
which is detected on an autoradiography film (Amersham HyperfilmTM ECL, GE Healthcare, 
Buckinghamshire, United Kingdom).  
Excess wash buffer was drained from the membranes and placed with protein side up on a 
clingfilm. Detection solutions A and B were mixed in a ratio of 40:1 and applied over the 
protein side of the membrane and incubated for 5 minutes at room temperature. Excess 
detection reagent was drained off by holding the membrane gently in forceps and touching 
the edge against a tissue. The blots were placed, protein side up, onto an X-ray film cassette 
(Amersham Biosciences Hypercassette, GE Healthcare, Buckinghamshire, United Kingdom) 
and bubbles carefully smoothen out. The blots were exposed on an autoradiography film in 
the dark.  
The blots were then immersed in stripping buffer and placed at 56°C for 15 minutes. The blots 
were washed for 3 x 5 minutes in TBS-T and blocked with 5% non-fat dried milk in TBS-T for 1 
hour before probing for β-actin. β-actin was used as a loading control. The antibody 
incubation and detection steps were repeated. Mouse β-actin antibody (Sigma-Aldrich®, St. 
Louis, USA) (1:2000) and goat anti-mouse IgG, HRP-linked antibody (1:10000) (InvitrogenTM, 
California, USA) were used. 
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Appendix VII: Reagents for TUNEL assay 
 
Pretreatment of coverslips 
Glass coverslips (diameter 13 mm) were immersed in absolute ethanol overnight. Coverslips 
were rinsed in 2 rounds of medium. 
 
U4% paraformaldehyde fixative UFor 10 ml 
Paraformaldehyde (Sigma-Aldrich®) 4 g 
1 M sodium hydroxide (NaOH) 5 μl 
  
Add 8 ml of filtered water and heat to 70°C with intermittent agitation to dissolve. Top up to 9 
ml with filtered water. Add 1 ml of 10x PBS. 4% paraformaldehyde solution was filtered 
through a 0.22 μm syringe filter. 
 
Proteinase K, recombinant, PCR grade (Roche Diagnostics Gmb, Mannheim, Germany) 
Prepare working stock of 20 μg/ml by diluting 1 μl of 20 mg/ml stock in 1 ml of 10 mM Tris-HCl 
pH 7.5. Store undiluted enzyme at 4°C. 
 
DNase I recombinant, grade I (Roche Diagnostics Gmb, Mannheim, Germany) 
For long term storage at -20°C, dissolve lyophilized DNase I (10,000 Units/vial) in 20 mM Tris-
HCl pH 7.5, 1 mM MgCl2, 50% glycerol. 
Prepare a reaction buffer of 50 mM Tris-HCl pH 7.5, 10 mM Mg MgCl2, 1 mg/ml BSA. For a 100 
μl reaction of ~20 Units/μl, add 1 μl of DNase I to 100 μl of reaction buffer. 
 
DAB substrate (Roche Diagnostics Gmb, Mannheim, Germany) 
For 1 ml, add 100 μl of 10x DAB metal to 900 μl peroxide buffer. Keep on ice before use, do 
not allow mixture to warm to room temperature. 
